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Abstract 
Nowadays, early detection of cancer and improving survival rates mean that 
more young women diagnosed with cancer have a normal life expectancy. For 
many of them the ability to conceive after successful treatment is one of their 
prime concerns. This dissertation evaluated the adverse effects upon fertility of 
some of the most common chemotherapeutic regimens used for cancers 
affecting women of reproductive age. Serial serum anti-Müllerian hormone 
(AMH) measurements were used to assess ovarian function in female patients 
with breast cancer or lymphoma before chemotherapy and compared 
longitudinally with same age healthy volunteers. Interestingly, women 
experiencing cancer during their reproductive years had a significantly lower 
ovarian reserve than healthy women, even before the start of chemotherapy. 
Overall 35% of reproductive age women newly diagnosed with cancer still 
expressed some desire to have children, while the same was true for nearly 
50% of women aged ≤39 years. Simultaneously, only 9% of them had had a 
consultation with a fertility specialist regarding fertility preservation options or 
the impact of chemotherapy on ovarian function. Oncologists should consider 
women’s wishes regarding fertility while counselling patients prior to cancer 
therapy. Overall in the cancer group, AMH declined significantly from the pre-
chemotherapy level, remaining undetectable in 80% of patients within the first 
12 months. It confirmed devastating effects of some of the chemotherapeutic 
agents on ovarian reserve. In the breast cancer group, only 15% of women had 
detectable AMH at 12 month follow-up. In contrast, amongst patients with 
Hodgkin lymphoma, more than 60% had a detectable degree of recovery of 
AMH concentrations at 12 months of follow-up, which was even higher if only 
ABVD regimen was used in women aged ≤ 32. Nearly 90% of those women 
reported the resumption of menstruation. My study offers reliable statistics as 
well as formulae calculating the probability of return of menses that can be used 
by oncology teams during consultations prior to chemotherapy. In contrast to 
other published results, I concluded that pre-treatment serum AMH 
concentrations are not correlated with amenorrhea or post-treatment AMH 
concentrations. However, AMH in combination with age could be used to 
calculate the risk of amenorrhea at 12 months using a prediction model 
constructed as a result of my work. In light of the recent debate about the 
reliability of AMH assays, my results confirmed the intra-subject reproducibility 
of the second generation AMH assay, providing evidence that is eagerly awaited 
by clinicians working in the field of Reproductive Medicine. My study supports 
the reliability of AMH measurements at unspecified times of the menstrual cycle. 
It provides guidance and reassurance to doctors using AMH assay in clinical 
practice. 
1 
Chapter 1 
1 Introduction 
1.1 Ovarian biology and ovarian ageing 
It is widely believed that at birth, human ovaries contain a non-replaceable stock 
of oocytes, which has been estimated to comprise around 2 million oocytes 
(Wallace, 2010). Although this paradigm has been challenged by some 
evidence of oocyte renewal in mammals (Johnson et al., 2005), it remains the 
most widely accepted theory of oogenesis (Wallace, 2010). 
Oocytes are formed from primordial germ cells in the first trimester of pregnancy 
and by 16-21 weeks the first primordial follicles are present in foetal ovaries. 
The dialogue between somatic cells and oocytes plays a crucial role in their 
survival and further development (Telfer & McLaughlin, 2007). There is 
continuous recruitment of primordial follicles from the resting pool until the age 
of menopause when the number is around 1000 (Telfer & McLaughlin, 2007). It 
was found that the rate of follicular recruitment increases from birth until puberty 
when it reaches a plateau and then declines with age. Based on mathematical 
modelling, Wallace et al. suggested that the optimal recruitment rate of non-
growing follicles is 880 follicles per month at age 14.2 in women with an average 
age of menopause (Wallace, 2010). 
2 
Adult ovaries contain follicles at different stages of development. The classes of 
follicles are categorised based on their number of granulosa cells and the time 
they take to transition between stages. In vivo these have been estimated as 
follows: primordial, primary (>150 days), secondary (120 days), pre-antral, 
antral (65 days), selected (10 days) maturing (10 days) and ovulatory follicles 
(Gougeon, 1986). The majority of oocytes are arrested in prophase of the first 
meiotic division and are surrounded by granulosa cells within primordial follicles. 
The recruitment of follicles into the growing pool is inhibited by anti-Müllerian 
hormone (AMH) (Strauss Iii & Williams, 2009). 
The recruited primordial follicle undergoes mitosis within the granulosa, to form 
more layers of granulosa cells. When several layers have been laid down, the 
solid follicle forms an extracellular cavity within the granulosa, called the antrum. 
From an early antral stage, follicular development becomes dependent upon 
endocrine control, particularly FSH (follicle-stimulating hormone). At the 
beginning of each menstrual cycle, a group of small antral follicles is available 
for final selection, but normally only one is ovulated two weeks later. Only the 
ovulated oocyte has the potential to be fertilised and develop further. Remaining 
follicles become atretic and undergo apoptosis (Gougeon, 1996). 
3 
1.2 Ovarian ageing and fertility 
1.2.1 Oocyte numbers and female age 
Throughout a woman’s life, the decline in reproductive capacity so called 
ovarian aging is related to the decreasing numbers of primordial follicles in the 
ovaries. The process is mainly age dependent and influenced by genetic 
factors, but lifestyle and medical or surgical interventions also play a role. 
Some researchers have examined the age related decline in primordial follicles. 
One of the widely known models reports a bi-exponential relationship between 
follicle numbers and age, showing that loss of follicles accelerates from age 
37.5, as shown in the graph below (Faddy et al., 1992). Although, this model 
was questioned subsequently by its author and other research groups, as it 
seems unlikely that dramatic physiological changes in follicles dynamics would 
start at age of 37-38 when there is still a reasonable number of follicles 
remaining (around 25 000). Following reanalysis the differential equation model 
was proposed to be more reliable (Faddy & Gosden, 1996).  
Figure 1 Bi-exponential fall in the number of follicles (from Faddy et al., 1992).
This model is based on an assumption that the rate of decline is a function of 
the number of remaining follicles and results from its paracrine action (Faddy & 
Gosden, 1996). A recent comparison of statistical models of ovarian follicle loss 
favour the differential equation model alongside the power model suggested by 
Coxworth (Coxworth & Hawkes, 2010). In his model, he suggested that the rate 
of follicle loss due to atresia increases gradually with age rather than changing 
dramatically at a specific age. According to his model, only around 80% of 
the variation in the number of non-growing follicles could be explained by age 
alone. The author suggested that different variables (for example hormonal 
markers) could add more value to allow a more individualized assessment 
(Hansen et al., 2008). 
4 
Wallace et al. published a different mathematical model of the decline in the 
numbers of non-growing follicles from conception until menopause. According 
to his calculations based on data retrieved from histological studies, the vast 
majority of women, by the time of their 30th birthdays, have already lost 88% of 
their pre-birth pool of follicles. A decade later only 3% of the stock remains 
(Wallace WH, 2010).  
Many published studies describe genetic effects upon age at natural 
menopause. One large, prospective cohort study of the heritability of age at 
natural menopause, has shown that at least 50% of the individual factors 
accounting for age at menopause are genetic. There is a correlation between 
ages of menopause amongst daughters and mothers as well as twin sisters 
(Murabito et al., 2005).  
Other factors and its impact on menopausal age have been considered. A 
recently published meta-analysis of 11 studies has shown that smoking is a 
strong independent factor for the early age of natural menopause (Sun et al., 
2012, Nelson et al., 2013). Overall, lifestyle factors have been estimated to have 
a relatively small contribution to variation in menopausal age. Apart 
from smoking, other factors: age at menarche, parity, regularity of 
menstrual cycles, use of contraception, breastfeeding, alcohol and 
coffee consumption, diet, body mass index, and socio-economic status are 
debatable in terms of their effects on menopausal age (Kok et al., 2005; van 
Noord et al., 1997). 
5 
Possible underlying mechanism of ovarian aging has been widely 
described. Recent reports highlight an increasing incidence of DNA 
(Deoxyribonucleic acid) double-strand breaks in primordial follicles in mouse 
and human causing accelerated loss of the follicles related to age and 
presenting a marked increase from age of 36 (Couzin-Frankel,2013; 
Johnson & Keefe, 2013; Titus et al., 2013). In parallel, declining expression 
of DNA repair genes such as BRCA1, MRE11, Rad51 and ATM was 
observed. Overall, the efficiency of mechanisms to repair damaged DNA was 
found to decrease with age that negatively affected ovarian reserve and the 
functionality of the remaining follicles. 
In women with an impaired capacity to repair damaged DNA due to a 
faulty BRCA1 gene, the decline in ovarian reserve may become evident 
even at a younger age (Titus et al., 2013). 
1.2.2 Oocyte quality with female age 
It is known that not only the quantity but also the quality of oocytes declines 
with age. Statistical analysis shows that women of older age are far more 
likely to have a miscarriage, which is believed to be related to the higher 
incidence of chromosomal abnormalities in embryos (Cowchock et al., 1993).  
6 
Factors responsible for declining quality and the higher chances of 
chromosomal abnormalities in oocytes with age are still not fully understood 
One of the theories is that impaired mitochondrial function plays a significant 
role (Bentov et al., 2011). Further evidence of impaired oocyte function in older 
women comes from clinical experience where older women achieve pregnancy 
and live birth rates similar to that of young women if they receive donated eggs 
from a young donor (Nelson, 2011; Nelson et al., 2013).  
1.2.3 Uterine function and female age 
Although important, the quality and quantity of oocytes is not the only fertility 
issue in older women. There is a substantial body of evidence, mainly from 
animal studies or observational studies in humans that uterine decidua and 
placental development may become impaired with maternal age. In older 
women using oocytes donated by younger women, despite good pregnancy 
rates, the incidences of premature delivery and low birth weight in infants are 
higher (Nelson, 2011; Nelson & Lawlor, 2011). National data show that older 
women have a much higher frequency of Caesarean sections, even after 
adjusting for confounding factors such as gestational diabetes. Myometrium 
obtained at planned Caesarean section had lower contractility in older women, 
which may be one of the reasons for a higher rate of poor progress in 
labour and an increased need for surgical intervention in this age group 
(I. Demeestere, 2012;  Smith et al., 2008). 
7 
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The currently available evidence supports the idea that women are born with a 
fixed number of oocytes that declines throughout reproductive life. There is 
significant variation in the rate of follicle loss among individuals, which cannot 
be explained by lifestyle factors. None of the mathematical models can be 
reliably used for counselling of individuals about their fertility prospects based 
on age alone. Therefore, assessment of the ovarian reserve at a given time in 
a woman’s life could offer a more accurate estimate of the remaining fertile 
years for those concerned about their present and future fertility (Coxworth & 
Hawkes, 2010).  
9 
1.3 Ovarian reserve 
Ovarian reserve describes the estimated number of oocytes in a woman’s 
ovaries. As described earlier, at any given time, the majority of oocytes are 
enclosed in primordial or so-called ‘resting’ follicles while some are in the 
process of growing. A small proportion of primordial follicles is recruited to grow 
each day. The majority of growing follicles eventually become atretic, some will 
continue to grow and become responsive to follicle-stimulating hormone (FSH). 
The pool of resting follicles, is impossible to measure directly without using 
invasive methods, however, it is linked to the pool of small, growing follicles, of 
which estimation can be made more readily (McGee & Hsueh, 2000; Wallace 
WH, 2010). Indirect measures of the ovarian reserve are used as ‘ovarian 
reserve tests’.  
Several such tests are available to assess ovarian reserve including 
measurement of hormones in blood, such as FSH, luteinizing hormone (LH), 
inhibin B, estradiol (E2), AMH, antral follicle count (AFC) using transvaginal 
ultrasound, and dynamic tests (Broekmans et al., 2006) but the perfect marker 
has not yet been identified. Ideally, an ovarian reserve test (ORT) should be 
informative of not only the quantity but also the quality of oocytes. The menstrual 
cycle interplay of hormones used for assessment of ovarian reserve is 
described below. 
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1.3.1 Physiology of hypothalamo-pituitary-ovarian axis 
Early stages of follicular development are independent of gonadotropins – FSH 
and LH – however gonadotropin sensitivity develops with growth. In natural 
menstrual cycles, each month, a small cohort of antral follicles becomes 
sensitive to FSH, from which one follicle (occasionally two) becomes more 
responsive to FSH and LH and continues to grow. The outer layer of the follicle 
(theca cells) has receptors for LH and produces enzymes necessary for 
synthesis of androgens, while the inner layer (granulosa cells) has receptors for 
FSH and produces aromatase needed for conversion of androgens to 
estrogens. Thus, working together, the two cell types produce estrogens from 
androgen, via the ‘two cells, two gonadotropins’ model of steroidogenesis.  
The rise in blood levels of FSH during the early follicular phase is a response to 
increased hypothalamic gonadotropin-releasing hormone (GnRH) output 
resulting from lowering estrogen and progesterone levels. While the recruited 
antral follicle grows and secrete estradiol (E2), E2 exerts an adverse feedback 
on the pituitary gland and hypothalamus, reducing FSH production and 
preventing recruitment of more antral follicles. The selected follicle continues to 
develop until >20-25mm diameter, when an LH surge is triggered from the 
pituitary gland, which causes maturation of the oocyte from the ‘immature’ stage 
of female meiosis (Prophase I) to the ‘mature’ stage (Metaphase 2 arrest). The 
mechanism of triggering the LH surge is complex and involves increasing levels 
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of E2, associated with an increased pituitary responsiveness and sensitivity. 
After the release of the oocyte, progesterone produced from the corpus luteum 
suppresses secretion of FSH. If pregnancy occurs, human chorionic 
gonadotropin from the trophoblast continues to support progesterone 
production. If not, after 12-14 days, the progesterone level drops significantly 
resulting in menstruation. 
Superimposed upon the gonadotropin cycling, additional actions of inhibin B 
and inhibin A are also important. Inhibin B plays a role in controlling FSH 
secretion while inhibin A may have an impact on the LH surge and maintenance 
of the corpus luteum. They are known for their paracrine regulation of theca 
cells and androgen production in the ovary, while granulosa cells are affected 
by the structurally related activins (Shaw et al., 2003, Luesley & Baker, 2004). 
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1.4 Overview of ovarian reserve tests (ORTs) 
1.4.1 Follicle stimulating hormone (FSH) 
The basal level of FSH in serum, measured between day two and five of the 
menstrual cycle (where day 1 is the first day of menstruation), is the most widely 
used test of ovarian reserve in fertility clinics worldwide. The pituitary secretion 
of FSH varies substantially throughout the cycle and is under estradiol and 
inhibin feedback, so correct timing of the blood sample is important. FSH in the 
early menstrual cycle provides an indication of the tonic level of gonadotropin 
stimulation needed to drive the menstrual cycle. As a woman ages, and/or as 
her ovarian reserve declines, FSH increases early in the cycle because the 
pituitary gland has to produce more FSH in order to generate an estrogen 
response from the waning ovarian follicle population. 
Among the profound limitations of serum basal FSH as an ovarian reserve test 
are intra- and inter-cycle variations and a lack of clear cut off points for 
meaningful clinical interpretation (Bancsi et al., 2003; Johnson et al., 2006). 
Concentrations and threshold values of FSH can vary significantly between 
laboratories, depending on assay methodology (Scott & Hofmann, 1995). In 
addition, the rise in basal FSH is a relatively late indicator of decreasing follicle 
numbers, so by the time that an increased FSH level is noted, the oocyte 
number is already in decline (de Vet et al., 2002). 
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A meta-analysis on basal FSH as a prognostic marker of IVF (in vitro 
fertilisation) outcome was performed on 21 studies (Bancsi et al., 2003). The 
predictive ability of basal serum FSH for inadequate response to ovarian 
stimulation was found to be moderate while for non-pregnancy even less useful. 
The clinical application of FSH testing prior to an IVF cycle was only proved for 
a minority of patients, who had very high basal FSH concentrations. The 
burdens of this analysis were a lack of clear, uniform criteria for poor response 
and cycle cancellation in the evaluated studies. Furthermore, in the conducted 
analysis, data on clinical and ongoing pregnancies were not considered 
separately.  
A subsequent meta-analysis on FSH versus AFC (AFC is discussed further in 
section 1.4.5) in predicting IVF outcome included 32 studies on FSH. The ability 
of FSH measurements to predict response to ovarian stimulation was found to 
be inferior to AFC. Estimated summary ROC curves for the prediction of non-
pregnancy shown a poor performance for both markers (Hendriks et al., 2005). 
A more recent systematic review of ovarian reserve tests identified 37 studies 
of basal FSH that were suitable for analysis. As previously, the authors stressed 
the wide range of methods used in the studies as well as lack of standard 
definitions. For basal FSH, accuracy for the prediction of inadequate response 
to ovarian stimulation and non-pregnancy was evident at relatively high FSH 
levels that would apply only to a small group of women with normal regular 
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cycles. Considering its high false positive rate, basal FSH would not be 
considered the best marker of ovarian reserve (Broekmans et al., 2006). 
In the general population, basal FSH was not related to pregnancy outcomes. 
For women aged >30, without a history of subfertility, day 3 FSH concentrations 
does not correlate with the risk of miscarriage (van Montfrans et al., 2004). 
1.4.2 Basal estradiol (E2) 
Estradiol is a steroid hormone produced by granulosa cells by aromatization of 
androstenedione from theca cells and conversion from estrone to estradiol. 
Smaller amounts of precursors are also produced by the adrenal cortex and fat 
cells (Shaw et al., 2003, Luesley & Baker, 2004). Estradiol is involved in the 
feedback between the growing follicle and the pituitary. High concentrations of 
estradiol early in the menstrual cycle reflect the advanced follicular development 
and early selection of the dominant follicle. As the ovary ages, day 2-5 estradiol 
is frequently seen to increase transiently before levels drop at the menopause. 
In a younger woman, raised estradiol in the early follicular phase can indicate 
the presence of a functional ovarian cyst. 
Several publications have shown a correlation between high basal estradiol 
concentrations and cycle cancellation or a poor response to ovarian stimulation 
(Licciardi et al., 1995, Evers et al., 1998;). In these studies, despite normal basal 
FSH, high basal estradiol predicted a high cancellation rate and a low oocyte 
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yield. Patients fared best if they had both normal basal FSH and low estradiol 
concentrations on cycle day three. The authors concluded that serum 
measurements of day three estradiol could be useful in patients with normal 
FSH level. Another research group confirmed this finding but only for women 
above age 35 (Vázquez et al., 1998). In a study by Frattarelli et al. (2000) not 
only very high, but also very low (<20 pg/ml) concentrations of basal estradiol 
were predictive of cycle cancellation (Frattarelli et al., 2000), however, others 
did not find similar results (Phophong et al., 2000). Those studies in favour of 
basal estradiol as a predictor of the ovarian response to stimulation, even so, 
found no evidence of a relationship between pregnancy rate and basal estradiol 
concentrations (Frattarelli et al., 2000).  
The clinical usefulness of basal estradiol in predicting the ovarian reserve and 
IVF outcome was not supported in a systematic review (Broekmans et al., 
2006). Basal estradiol concentration was found to be a poor predictor of ovarian 
response due to very low predictive accuracy and lack of clear threshold levels. 
The same shortcomings were noted for prediction of non-pregnancy 
(Broekmans et al., 2006). Therefore, based on current evidence, early follicular 
phase estradiol cannot be used as a reliable predictor of response to IVF 
stimulation. 
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1.4.3 Inhibins 
Inhibins are dimeric glycoproteins, consisting of α-βA (inhibin A) and α-βB 
(inhibin B) subunits, known for their ability to suppress FSH secretion 
(Lockwood, 2004). Inhibin A is mostly produced by the corpus luteum with the 
highest serum levels detectable in the luteal phase of the menstrual cycle. 
Inhibin B is secreted by small, pre-ovulatory follicles. Its concentrations start 
rising in the early follicular phase. Inhibin B peak is corresponding with FSH’s 
decline. It then falls progressively during the rest of the follicular phase and rises 
again after the mid-cycle LH surge, remaining low for the remainder of the luteal 
phase (Groome et al., 1996). The observed changes in the serum concentration 
throughout the cycle and initial studies on patients with polycystic ovarian 
syndrome showing elevated inhibin B levels (Anderson et al., 1998) indicated 
that inhibin B might be a suitable marker of ovarian function and follicular 
reserve for a subfertile population having IVF treatment. Moreover, some 
studies suggested that serum inhibin B concentrations correspond with the 
number of small antral follicles on ultrasound scan, possibly allowing an indirect 
measurement of the size of follicle pool (Tinkanen et al., 2001). 
In a prospective comparison study on ovarian reserve tests including AFC, 
basal FSH and inhibin B, the authors found inhibin B to have a lower predictive 
value than ultrasound assessment of the number of antral follicles. However, it 
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was suggested that inhibin B measurements could potentially have some role 
as an additional test (Bancsi et al., 2002), alongside ultrasound assessment. 
Potential applications of measuring inhibin in peri-menopausaI patients with 
normal FSH were identified in a few studies. These observed that women with 
diminished ovarian reserve have low inhibin B levels before any rise in FSH 
suggested the menopausal transition. Seifer et al. (1999) in a case control study, 
assessed 109 women with a non-ovarian cause of subfertility and 47 women 
with known low ovarian reserve. Despite normal basal FSH, patients with low 
serum concentrations of inhibin B, had a smaller number of oocytes retrieved in 
IVF cycle (Seifer et al., 1999). A systematic review of ovarian reserve tests 
revealed the poor predictive performance of inhibin B in relation to response to 
ovarian stimulation and chances for pregnancy (Broekmans et al., 2006).  
Most authors of the analysed studies discussed the fact that the test for inhibin 
B is technically challenging and not readily available. A lack of international 
standardisation has resulted in contradictory data on inhibin B. A further 
disadvantage of the inhibin B test is its strict cycle-dependency, leading to a lack 
of time-flexibility that is challenging for any diagnostic test. 
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1.4.4 Anti-Müllerian Hormone (AMH) 
Recently, AMH measurement in blood, as a novel method of assessing the 
ovarian reserve, has rapidly become popular amongst fertility specialists. AMH, 
also known as Müllerian-inhibiting substance (MIS), is a dimeric glycoprotein, 
similar in structure to inhibin and activin, from the transforming growth factor-β 
(TGF-β) family (Pepinsky et al., 1988). In humans, the gene for AMH is on 
chromosome 19p13 (Cohenhaguenauer et al., 1987) while that for its receptor 
is on chromosome 12 (Josso et al., 2003). 
The ovaries are the only source of AMH in women (La Marca et al., 2005a). The 
AMH concentration in serum correlates with the number of antral follicles on 
ultrasound scan (Mendez Lozano et al., 2006) and the woman’s age (de Vet et 
al., 2002). The first, direct confirmation of the association between serum Anti-
Müllerian hormone concentrations and the number of remaining primordial 
follicles was demonstrated in mice (Kevenaar et al., 2006). The results clearly 
indicated that the serum concentration reflected the size of the follicle pool, 
confirming the value of AMH as a test of ovarian reserve in mice. Recently, one 
study confirmed the same relationship between AMH and the size of follicle pool 
in women. Serum AMH concentrations, prior to oophorectomy for benign 
causes, were correlated with the histological findings after surgery (Hansen et 
al., 2011). 
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Anti-Müllerian hormone is produced by granulosa cells of the ovarian follicles 
with expression initiated in small growing primary follicles and declining in the 
antral stages as follicles gain FSH dependence or become atretic (Baarends et 
al., 1995; Shaw et al., 2003, Durlinger et al., 2002; Weenen et al., 2004). Using 
immunohistochemistry, AMH can be detected most strongly in pre-antral and 
small antral follicles, while some weak signals have been observed in primary 
follicles while none was detected in primordial follicles (Weenen et al., 2004).  
AMH plays a role in both folliculogenesis and steroidogenesis. It is believed to 
act as a feedback mechanism that inhibits the transition from resting primordial 
follicles into growing follicles (Durlinger et al., 1999). MIS plays a role in the 
recruitment of FSH-sensitive follicles in the antral stage and reducing follicle 
sensitivity to FSH (Durlinger et al., 2001; Hirobe et al., 1994; Ueno et al., 1989). 
Nevertheless, in human ovaries, the auto- and paracrine actions of AMH are still 
not fully understood and further studies are needed to determine its mechanism 
of action. 
The AMH signalling pathway is typical for the TGF family. In females, AMH 
receptors are present in ovaries, endometrium and breast tissue (Josso et al., 
2003). In general, AMH action has a repressing effect on the targeted genes. 
AMHR-II (AMH receptor) binds with AMH ligand before forming a complex with 
type I receptor (ALK 2, 3 and 6). The phosphorylated and activated complex 
binds to cytoplasmic effectors, (Smad 1, 5, 8). Cofactors, coactivators and 
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corepressors for AMH transduction and its relationship with other hormonal 
pathways still needs further study in humans (Josso et al., 2005). 
In granulosa cells of human antral follicles, gene expression of AMH was found 
to be positively correlated with expression of FSH and androgen receptors. 
AMH’s impact on follicular estrogen production has been suggested by a 
number of authors (Andersen & Byskov, 2006; Dewailly et al., 2014). 
Additionally a statistically significant association was confirmed between AMH 
gene expression and levels of testosterone and progesterone in surrounding 
follicular fluid (Jeppesen et al., 2013). AMH concentrations were low or 
undetectable in follicles undergoing atresia (Weenen et al., 2004). This is 
suggestive of multilevel actions of AMH on follicular selection and development, 
but more studies are needed to explain fully the impact of AMH on follicular 
growth and recruitment in humans. 
In clinical setting, the serum concentration of AMH seems relatively independent 
of the menstrual cycle (Hehenkamp et al., 2006; La Marca et al., 2006b; 
Tsepelidis et al., 2007). Although some studies have reported inter- and intra-
cycle fluctuations in MIS concentrations (Cook et al., 2000; Streuli et al., 2009). 
A recently published small study on 12 women aged between 29 and 43 referred 
to an IVF unit due to primary or secondary infertility, presented repeated 
measurements of their endocrine profiles throughout the menstrual cycle 
(Hadlow et al., 2013). AMH levels were found to be statistically higher in the 
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mid-follicular and pre-ovulatory phase and declined in the luteal phase, which 
was similar to previous reports in 2008-2010. The observed changes in AMH 
concentrations were more prominent in younger women, while only minimal 
changes were observed in the older population, which the authors explained by 
changes related to ovarian aging (Sowers et al., 2010; Wunder et al., 2008a). 
At present, the general consensus is that cyclic fluctuations are too small to 
affect AMH-guided clinical decisions in the IVF setting (La Marca et al., 2009) 
and AMH measurement at unspecified times in the menstrual cycle is clinically 
acceptable (Anderson et al., 2012). This statement is supported by results from 
other studies which demonstrated the predictive value of AMH, measured on 
any day of the follicular or luteal phase, in terms of the response to ovarian 
stimulation (La Marca et al., 2007; Nelson et al., 2009). 
Interestingly, AMH was previously found to be an accurate measure of ovarian 
function even amongst women with irregular menstrual cycles (La Marca et al., 
2006a), taking oral contraception (Somunkiran et al., 2007) or undergoing 
pituitary down-regulation using a GnRH super-agonist for up to 8 weeks 
(Mohamed et al., 2006), which suggested that serum AMH levels may be 
unaffected by gonadotrophic status. However, studies published more recently 
offer opposing evidence. A significant reduction in AMH concentration has been 
noted in breast cancer patients using GnRH super-agonists (Anderson et al., 
2006b). A group of researchers investigating early maturing girls during GnRH 
agonist therapy presented similar findings. After 3 months of treatment, they 
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found that levels of AMH were around 50% lower than before commencing 
therapy (Hagen et al., 2012a). One possible interpretation is that this reflected 
the declining number of growing follicles during pituitary suppression. 
A large Danish study of 228 users and 504 non-users of oral combined 
hormonal contraception showed that, after adjusting for age, AMH was 29.8% 
lower in users compared to non-users. It was noted that for every year of use of 
hormonal contraception there had been a decline in AMH level of 2.3% (Bentzen 
et al., 2012). The recovery of ovarian function and a possible subsequent 
increase in AMH levels after discontinuing combined contraception has not yet 
been evaluated in large prospective studies. However, a small study which 
included 25 women using combined oral contraception reported an increase in 
AMH concentrations in two following cycles in women who stopped taking 
hormonal contraception (van den Berg et al., 2010). 
As mentioned earlier, AMH is produced mainly by small pre-antral and antral 
follicles - the latter are sensitive to gonadotropins and their number is reduced 
in women who have suppressed pituitary function. Pituitary suppression may 
affect the overall quantity of AMH produced by this population of follicles and, 
therefore, the serum levels of AMH. However, it remains unclear which size of 
follicles contributes most to the serum AMH levels. Intra-follicular levels of AMH, 
the population of follicles (e.g. a large group of small pre-antral follicles versus 
a small group of follicles selected for dominance), the quantity of granulosa cells 
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in a given size of follicles or its volume, it all affect serum AMH concentrations. 
One of the recently published studies, based on in vivo modelling, suggested 
that the follicles contributing the most to serum concentrations are those of size 
5-8 mm (60% of overall serum AMH levels). This was concluded from 
measurements of intra-follicular levels of AMH and the overall quantity of 
granulosa cells in a range of sizes of follicles as well as overall volume, after 
examining ovarian tissue of 157 women aged 1 to 39, who underwent 
oophorectomy for fertility preservation prior to gonadotoxic treatment. Despite 
more intense AMH gene expression in smaller follicles <5 mm and higher intra-
follicular concentrations of AMH, larger follicles (5-8 mm) were believed to have 
a higher overall content of AMH due to more granulosa cells and a greater 
volume. The smaller follicles accounted for only 25% of the serum AMH 
concentration (Jeppesen et al., 2013).  
To conclude, the impact of gonadotropins on serum AMH levels is possible. 
Serum AMH measurements obtained under pituitary suppression would reflect 
the size of the pre-antral follicle pool which is considered to be a more accurate 
reflection of the true ovarian reserve. However, calculation of reference ranges 
of AMH was performed without any additional hormonal suppression. AMH as 
a marker of the ovarian reserve would be still useful if obtained on hormonal 
contraception or while taking GnRH analogues, but the results require 
interpretation in that context.  
24 
Measurements of FSH and inhibin B are strictly cycle dependent and need to 
be done on a specific day of the menstrual cycle, usually between day 2 and 5. 
The ability to assess ovarian reserve at any time of the menstrual cycle and in 
non-menstruating women makes AMH testing more convenient compared with 
other ovarian reserve tests. This particular characteristic could have clinical 
value in women having irregular cycles due to gonadotoxic treatment or severe 
illness (Anderson et al., 2012). 
1.4.4.1 Serum Anti-Müllerian hormone (AMH) and its accuracy in 
predicting responses to fertility treatment 
One valuable clinical application of ovarian reserve testing is its ability to predict 
ovarian response to stimulation with gonadotropic drugs. 
Seifer et al. (2002) published one of the first studies that demonstrated the 
relationship between serum AMH concentrations and response to ovarian 
stimulation (Seifer et al., 2002). A number of authors have shown that AMH has 
greater association with the number of collected oocytes than day three FSH, 
Inhibin B or estradiol in all age groups ( Shaw et al., 2003, Fiçiciog et al., 2006; 
Riggs et al., 2008). A statistically significant difference between serum AMH 
levels in ‘poor’ compared to ‘good’ responders was found by others (Tremellen 
et al., 2005) confirming AMH’s value as a quantitative marker of ovarian 
function. 
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AMH measured at non-selected time of the menstrual cycle was found to be 
predictive of the ovarian response, numbers of oocytes retrieved and dose of 
FSH required for ovarian stimulation (La Marca et al., 2007, Elgindy et al., 2008). 
Similarly, Nelson et al (2009), in a prospective cohort study of 538 patients, 
measured AMH on an unspecified day of the menstrual cycle, showing the 
relationship between serum AMH concentrations and response to ovarian 
stimulation. This study confirmed the clinical usefulness of AMH in IVF settings 
(Nelson et al., 2009). 
1.4.4.2 AMH as a predictor of hyperstimulation, poor response and 
cycle cancellation 
AMH measurements were also found to be useful in predicting the extremes of 
ovarian response to gonadotropin stimulation. McIlveen et al., (2007) found that 
low serum AMH concentrations were associated with poor response to ovarian 
stimulation and a higher risk of cycle cancellation. (McIlveen et al., 2007). 
In another study, AMH was superior to FSH in predicting poor response to 
ovarian stimulation (Nardo et al., 2009). Other researchers suggested that AMH 
levels 1.26 ng/ml were highly predictive of poor ovarian response, but 
confirmation of findings by AFC improved the reliability of ovarian reserve 
testing ( McIlveen et al., 2007, Gnoth et al., 2008). 
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AMH measurements may be helpful in predicting hyperstimulation syndrome 
which is a potentially life-threatening condition resulting from use of exogenous 
gonadotropins (Tremellen et al., 2005; Nakhuda et al., 2007; Lee et al., 2008, 
Salmassi et al., 2015). 
In one of the studies, serum AMH concentrations were as effective as estradiol 
concentration on the day of human chorionic gonadotropin (HCG) administration 
in identifying women who would develop ovarian hyperstimulation syndrome 
(Lee et al., 2008). 
Later, a meta-analysis including nine studies on AMH and five studies on AFC 
showed that both tests had good predictive value for excessive response to 
stimulation in IVF cycles. AMH was shown to have 82% sensitivity and 76% 
specificity and shared the same clinical value as AFC. The authors were able to 
demonstrate that at a certain cut off points, the probability of an excessive 
response was 70% (Broer et al., 2011a).  
The following meta-analysis tested the prediction of excessive response to 
ovarian stimulation if individual patient data, such as age, duration of infertility, 
or body mass index (BMI) were included. It showed that the predictive 
performance of AMH was not altered by patients’ age, BMI or duration of 
infertility. The accuracy of AMH remained good in all subgroups. Moreover, the 
authors concluded that a combination of AFC and AMH had high predictive 
accuracy, even without taking age into consideration (Broer et al., 2013). 
Although, this analysis was performed on old data, acquired before 2009 when 
two different assays have been in clinical use. Different threshold levels of AMH 
have been reported by several authors, resulting in conflicting evidence. 
Problems identified have included differences in the assays applied and 
methods used for identifying thresholds, as well as different units of 
measurement. All this has led to the application of many different cut off points 
for AMH predictive testing (Nelson & La Marca, 2011). Newer studies have 
confirmed that AMH is a good predictor of hyper-response in normo-ovulatory 
women undergoing stimulation with clomiphene citrate and gonadotropin, but 
not in women with PCOS (polycystic ovary syndrome) (Kim et al., 2013). 
1.4.4.3 AMH as a predictor of pregnancy and non-pregnancy 
A number of studies have suggested a predictive value of serum AMH 
concentrations for occurrence of pregnancy (Hazout et al., 2004; Nelson et al., 
2007; Elgindy et al., 2008; Wunder et al., 2008b, Iliodromiti et al., 2014) and live 
birth (Nelson et al., 2007) while others have found contrasting results 
(Fiçiciog et al., 2006; McIlveen et al., 2007, Gnoth et al., 2008). 
A meta-analysis of 13 studies demonstrated the poor predictive ability of serum 
AMH measurements in predicting the chances of pregnancy in IVF cycle (Broer 
et al., 2009). It is likely that the positive association found by some researchers 
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is a consequence of the cycle performance and oocyte yield per se rather than 
a direct relationship with oocyte or embryo quality. 
A research group from Sweden recently explored this point in a prospective 
longitudinal study including 892 patients undergoing intracytoplasmic sperm 
injection (ICSI). They found that pre-treatment AMH levels were associated with 
embryo scores, pregnancy and live birth rates, even after adjusting for age and 
oocyte yield (Brodin et al., 2013). However, another group published opposing 
results on the predictive ability of AMH measurements in assessing the chances 
of pregnancy in the young, healthy population (Hagen et al., 2012b). This 
research group prospectively assessed 186 couples (women aged 19-35) and 
followed them up until pregnancy or till 6 months. It was found that AMH levels 
were not predictive of achieving natural pregnancy in young women with no 
previous history of infertility (Hagen et al., 2012b).  
Another group led by Olemdo et al. (2013) investigated AMH levels in 145 
women undergoing ICSI. After adjusting for confounding factors, they found that 
AMH < 3 pmol/L was associated with chances for pregnancy of around 31%, 
while AMH > 15 pmol/L was associated with chances of up to 35% (Brugo 
Olmedo et al., 2013). Overall, patients with lower AMH concentrations had fewer 
follicles, lower fertilization rates and generated fewer embryos (Lekamge et al., 
2007). 
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In summary, serum AMH measurement appears to indicate the size of the 
ovarian follicle pool and as such is a useful marker of ovarian reserve. Its ability 
to predict pregnancy seems to be a reflection of the quantitative measurement 
of oocyte numbers and its predictive accuracy is poor (IIiodromiti et al., 2014). 
It remains debatable whether the quality of oocytes or live birth could be 
predicted by a single serum AMH measurement because the achievement of 
pregnancy and live birth is always multi-factorial. 
1.4.4.4 Anti-Müllerian Hormone (AMH) with age 
Unlike other markers, AMH was found to be reliable in the assessment of 
ovarian aging. A considerable literature has been published on the relationship 
between AMH and ovarian ageing (Lee et al., 1996; van Rooij et al., 2004, Broer 
et al., 2011; Hagen et al., 2010, Nelson & La Marca, 2011, Freeman et al., 2012, 
Kelsey et al., 2012,Tehrani et al., 2013, Nair et al., 2015, Dolleman et al., 2015). 
The results indicated that serum AMH levels decline throughout reproductive 
life, even in young women (age 20-35) with normo-ovulatory cycles. This is in 
contrast to FSH, E2 or inhibin B, which remain relatively static in young women 
(de Vet et al., 2002). 
Initially, small studies showed a linear decline of AMH with age (Sowers et al., 
2008), however, a non-linear decline was demonstrated by others (de Vet et al., 
2002). More recently validated mathematical models have provided a 
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normogram of AMH with age (Nelson & La Marca, 2011). Nelson et al., have 
suggested that the best model to describe AMH’s decline with age is a quadratic 
equation. Their dataset was derived from around 4500 subfertile women 
(Nelson & La Marca, 2011). 
 
Figure 2 Normogram of AMH with age (from Nelson & La Marca., 2011).  
A large cross sectional study of 926 healthy volunteers between the ages of 0 
and 69 determined age-related changes in AMH levels. The peak of serum AMH 
concentration was in the early 20s. From the age of 25, the decline in AMH was 
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observed with levels of AMH being undetectable at an age of 46.7 (Hagen et 
al., 2010).  
The mathematical model from combined histological data examined the 
relationship between serum AMH concentrations and changes in the primordial 
follicle pool. The falling concentration of AMH in adult women was consistent 
with the progressive loss of primordial follicles (Kelsey et al., 2012).  
 
 
Figure 3 Concentrations of serum AMH in women at different ages (from Kesley 
et al., 2012). 
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AMH levels start increasing from birth, with a quite distinctive rise in the first few 
months of life, then continue to increase until reaching a peak in the mid-20s. 
Following that, there is a steady decline in AMH concentrations until becoming 
undetectable around five years before menopause (Hagen et al., 2010). A slight 
decrease in AMH concentration, observed around puberty, coincides with the 
time of maximal follicular recruitment (Nelson et al., 2013). 
Relative to other endocrine markers, a decrease in serum AMH concentration 
is observed much earlier on the approach to menopause ( Lee et al., 1996; van 
Rooij et al., 2004, Broer et al., 2011;). This is helpful in clinical applications since 
other markers remain relatively static until close to the menopause. 
A growing body of evidence suggests the usefulness of AMH as a predictor of 
menopause. A prospective longitudinal study of 257 women aged 21-46, 
followed up for 11 years, and has shown that AMH is highly predictive of age at 
menopause. This study was able to provide an age-specific AMH normogram 
for prediction of age at menopause. In contrast, in another study, the use of AFC 
and FSH failed to provide a better correlation than age alone (Broer et al., 2011). 
Another prospective longitudinal study followed up 401 women in their late 
reproductive years for 14 years. It confirmed that AMH was a good predictor of 
time to menopause if measured in women at an age of around 40 (Freeman et 
al., 2012). Another large study on 1015 women with follow-up for at most 10 
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years presented a prediction model for age at menopause that was accurate in 
92% of women (Tehrani et al., 2013). 
1.4.4.5 AMH testing in clinical practice 
The first documented development of an AMH assay was by Hudson et 
al.(1990) followed by Long et al. (2000) and Al-Qahtani et al. (2005a) until the 
currently used monoclonal antibodies 12H and 7A were patented by Groome et 
al. (2006). 
The first assays showed variability in AMH levels depending on the storage and 
freeze-thaw characteristics of the tested samples. The DSL Active AMH assay 
and generation II assay were greatly improved versions mainly because they 
used a pair of monoclonal antibodies directed to epitopes in the mature region 
of the AMH molecule. The 12H antibody recognizes the mature region of the 
AMH molecule directly while the 7A antibody initially binds to a pro-region, but 
after a longer period of observation, then binds to the mature region. The mature 
region of the AMH molecule is more stable against proteolysis than the pro-
region. Previous antibodies were directed to epitopes in the pro-region, which 
may have explained the discrepancy in AMH results related to AMH proteolysis 
in blood samples exposed to prolonged transport and different storage 
conditions (Kumar et al., 2010). 
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Before the second generation assay, the two available assays (DSL and 
Immunotech) used different antibodies and different standards, creating 
uncertainty about cut off points and reference ranges for AMH results. Several 
authors tried to find correlations between the two assays, suggesting initially 
4.6-fold lower results with DSL (Fréour et al., 2007). More recently others 
confirmed the reliability of both assays and similar reference values ( Streuli et 
al., 2009, Lee et al., 2011;). Additionally different reporting of results either in 
ng/ml or pmol/L has added to the lack of uniformity in reference ranges for these 
commercially available assays.  
The second generation assay available from 2010 is standardised against the 
Immunotech calibration material, traceable to an independent reference 
material in Paris. Calibrators are prepared using a bovine serum (Kumar et al., 
2010). An international standard is yet to be established by the National Institute 
for Biological Standards and Control (Nelson & La Marca, 2011). Second 
generation assay calibrators and controls are provided separately from the AMH 
ELISA plate and should be stored at -20 °C (as opposed to 2-8 °C for DSL 
Active AMH ELISA) (Kumar et al., 2010).  
The methodology of the first DSL assay carried a risk of interference by 
heterophile antibodies in the serum samples, which was corrected by the use of 
filters in second generation assay (Kumar et al., 2010). This has practical 
importance in patients with cancers treated with monoclonal antibodies (such 
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as Herceptin and Avastin) or using animal serum-based medications where 
AMH results could have been potentially affected by an ‘HAMA response’ 
(allergic reaction to mouse antibodies). In such situations, AMH results should 
be read with caution. 
The lack of manufacturer’s recommendations for transferring and handling 
samples from distant laboratories prompted me to perform a pilot study prior to 
deciding on the final protocol. Based on those results, I instructed research 
nurses and the laboratory team on sample handling and the need for strict 
adherence to the study protocol. Any samples received in MFS Laboratory more 
than 48 hours from venepuncture have been not included in the analysis and 
repeat blood samples were obtained where possible. 
A recently published pioneer study by Fleming et al., (2013) indicated that 
prolonged storage of whole blood at room temperature may increase the AMH 
measurement due to a direct effect of blood cells. His results indicated that 
storage of whole blood at room temperature up to 44 hours from venepuncture 
may lead to an increase in measured AMH levels by 12% which is within the 
normal variation of the assay and is considered to be acceptable. However, the 
authors strongly recommended the separation of serum from whole blood within 
24 hours of venepuncture (Fleming et al., 2013a). Despite this, there remains 
today no universally agreed protocol for sample handling between the patient 
and the AMH assay laboratory. Given the challenges of the assay itself, it is 
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generally run commercially in a few specialised laboratories and transport of 
samples is, therefore, a routine necessity.  
Interestingly, a recently published study reporting results from 10 laboratories in 
an external assurance scheme using the second generation II assay showed 
good reproducibility for each laboratory but the significant variability between 
laboratories. A large coefficient of reproducibility of 38.8% between Laboratories 
was reported. Individual laboratories had different average bias values relative 
to the consensus value ranging from -24.0% to +22.7%. The interpretation of 
these results is difficult, but it emphasises the fact that the technical aspects of 
performing each assay as well as the handling and storage of the kit and blood 
samples should be clearly documented in publications. It has been 
recommended that the same laboratory should be used to manage patients in 
an individual clinic in order to avoid confusion, especially with repeated results 
(Wallace et al., 2011). It is evident that the AMH assay is still under 
development.  
1.4.5 Ultrasound scan (USS) tests of ovarian reserve 
The ovaries of women of reproductive age contain populations of follicles at 
different stages of development. These are: resting reserve of primordial 
follicles, growing pre-antral follicles, small antral follicles (1-5 mm) which are 
‘selectable’ and larger antral follicles (5-12 mm), which are FSH dependent. The 
number of antral follicles, known as the antral follicle count (AFC), is believed to 
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reflect the pool of resting follicles in each ovary. This association has been 
confirmed by Gougeon et al. (1984) and repeated by others (Gougeon, 1984; 
Pellicer et al., 1998). 
Hansen et al. (2011) tested the ovarian reserve using three-dimensional 
ultrasonography prior to oophorectomy to ascertain the population of follicles 
ready to be recruited during the early follicular phase of the menstrual cycle and 
confirmed the same on histological slices post-surgery (Hansen et al., 2011).  
1.4.6 Antral follicle count 
The method by which antral follicles are counted in the early follicular phase 
varies among studies. Some measure the number of follicles of diameter 2-10 
mm (Chang et al., 1998; Scheffer et al., 2003), others 2-5 mm (Jarvela et al., 
2003) or 2-6 mm (Haadsma et al., 2007) using two- (Scheffer et al., 2003) or 
three-dimensional ultrasound (Jayaprakasan et al., 2007). The diversity of 
methods used, inter-cycle and inter-observer differences might have an impact 
on the performance of AFC as a diagnostic test. 
So far the use of 2D or 3D ultrasound does not seem to have a significant impact 
on AFC when used in predicting IVF outcomes (Jayaprakasan et al., 2007). 
Another method called Sono-Automatic Volume Calculation (Sono AVC) 
provides automated measurements and has given promising initial results 
(Sherbahn & Deutch, 2009). 
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There have been attempts to detect early signs of ovarian aging using basal 
FSH, inhibin B, estradiol and ovarian volume compared with AFC. In the study 
by Scheffer et al. (2003) the number of 2–10 mm antral follicles appeared to 
have better correlation with age than other markers of ovarian reserve (Scheffer 
et al., 2003). 
The performance of AFC as an ovarian reserve test has been assessed in a 
number of meta-analyses. In one meta-analysis comparing AFC and FSH, the
superiority of the counting of antral follicles over basal gonadotropin 
measurements was clearly demonstrated (Hendriks et al., 2005). A further 
comparative meta-analysis of AFC and ovarian volume also showed superior 
performance of AFC in predicting poor response compared to ovarian volume. 
However, for the prediction of cases of non-pregnancy, both tests were 
inadequate (Hendriks et al., 2007).  
A systematic review of ovarian reserve tests classified AFC as a reliable 
predictor of response to ovarian stimulation (at low threshold levels), while its 
prediction of non-pregnancy was very poor (Broekmans et al., 2006). AFC was 
shown to be an equally good predictor of hyper-response to ovarian stimulation 
as AMH (Broer et al., 2011a). 
In the systematic review of ultrasound tests of ovarian reserve, it was concluded 
that AFC, using a cut-off point of fewer than four, had high specificity in 
predicting non-pregnancy but low sensitivity. It would lead to a high rate of false 
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negative results if used routinely in clinical practice. In the same study, a meta-
analysis of AFC revealed that women with AFC of four or more had only a 2.5% 
risk of cycle cancellation. The authors concluded that it might be a good test to 
identify those patients with a low risk of inadequate response (Gibreel et al., 
2009).  
1.4.6.1 Ovarian volume 
Two of the first systematic reviews on ovarian reserve tests, found that ovarian 
volume had poor clinical value as a routine marker of ovarian reserve for both 
poor response to stimulation and non-pregnancy in an IVF cycle (Broekmans et 
al., 2006; Hendriks et al., 2007). 
However, a more recent analysis of ovarian volume (assessed using 2D USS) 
showed high specificity in predicting non-pregnancy and cycle cancelation at a 
very low volume of 3ml³ (Maheshwari et al., 2009). The authors discussed 
issues of reproducibility of the test, including inter-observer and inter-cycle 
variability, which seemed to be a greater problem than for AFC (Jayaprakasan 
et al., 2008). There was insufficient data available to assess outcomes such as 
pregnancy and live birth. 
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1.4.6.2 Ovarian stromal blood flow 
In a meta-analysis of measurement of ovarian stromal blood flow using 
transvaginal Doppler ultrasound, six relevant studies were identified. The 
analysis of three selected studies with same cut off values of 3 cm3 indicated 
promising results with a relatively high specificity for the cancellation of the 
treatment cycle and non-pregnancy in the prediction of IVF outcome. However, 
this analysis needed a larger number of patients and live birth rate as an 
outcome measure in order to have clinical meaning (Maheshwari et al., 2009). 
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1.5 Cancer in young women- selection of patients 
1.5.1 Introduction 
The treatment of cancer is well known to cause a range of serious side effects. 
Like some other tissues, ovaries, seem to be particularly sensitive and readily 
damaged by certain treatment regimens, causing loss of ovarian reserve. 
Persistent amenorrhoea is an obvious indicator of an effect upon ovarian 
function. However, the recovery of menses does not imply that the ovary has 
recovered completely (Partridge et al., 2010b). Occult loss of oocytes as a result 
of chemotherapy means that ovarian reserve testing in reproductive age women 
with cancer would be particularly valuable.  
The extent of chemotherapy-induced follicle loss would at least partially depend 
on how large the ovarian reserve is before treatment begins. Ideally, testing prior 
to chemotherapy could give women the opportunity to discuss fertility 
preservation options, in light of knowledge about their own ovarian reserve 
(Anderson & Cameron, 2011). Secondly, depending on the type of 
chemotherapy and dosage of each agent, the estimated degree of damage 
could be discussed individually. With increasing numbers of women living longer 
after cancer therapy, the remaining fertility potential and risk of early menopause 
become more important. In the next section, I provide a brief overview of risk 
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factors, incidence rates and the most commonly used chemotherapy protocols 
in breast cancer and lymphoma sufferers.  
1.5.2 Breast cancer 
The most common cancer in women, breast cancer, accounts for around 30% 
of all cancers. The Office for National Statistics reported that 41,259 new cases 
were diagnosed in England in 2010, and an increase of 1.8% from 2009 was 
noted (ONS, 2012a). Overall survival rates have been improving with screening 
and more aggressive treatment. The current death rate is 24 in 100,000 and 
has fallen significantly over the last 40 years. For women diagnosed with breast 
cancer, the five-year survival estimate is around 85% (ONS, 2012a). There is 
an increasing number of new cases in younger women, with overall 18% of 
breast cancer cases being diagnosed in women aged 49 and below (NCIN, 
2011). Those statistics provide evidence for the growing number of young 
women, who as a result of their diagnosis, will be experiencing chemotherapy-
related health issues. In the USA, it is estimated that around 15% of women 
diagnosed with breast cancer are of reproductive age (Oktay, 2005). Assuming 
that a similar percentage would be applicable in the UK, around six thousand 
young women each year face the risk of early menopause and infertility due to 
breast cancer therapy. 
The risk of developing breast cancer in women is age-related. According to 
statistics provided by NHS Cancer screening programme, the estimated risk of 
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developing breast cancer is ‘1 in 2,000 at age 29, 1 in 215 at age 39, 1 in 50 at 
age 49 and 1 in 13 at age 69 (PHE, 2013). 
Early menarche, late menopause and full term pregnancy at an older age 
increase the risk of breast cancer, while high parity and an extended duration of 
breastfeeding up to 24 months have a protective effect (Cancer, 2002; Ewertz 
et al., 1990). The use of exogenous estrogen in the form of oral contraceptives 
or hormone replacement therapy (HRT) is also a well-known risk for developing 
breast cancer. Women taking HRT (current users) have a 66% higher risk of 
developing breast cancer versus non-users. If HRT is stopped, within 5 years, 
the risk reduces to that of non-users (Beral, 2003). 
Genetic and family breast cancer susceptibility have been widely investigated. 
It is known that carrying the gene mutation BRCA1 and BRCA2 gives a 45-65% 
chance of developing breast cancer, and overall 10-fold increased risk 
compared with normal controls (Antoniou et al., 2003). However, overall the 
BRCA mutation accounts for only around 2% of all breast cancer cases. Other 
known gene mutations include TP53, PTEN, STK11/LKB1, ATM) (Turnbull & 
Rahman, 2008, Cancer, 2001). 
Additional risk factors include high BMI, daily alcohol intake (10g of alcohol daily 
increases the risk by 15-20%), exposure to ionising radiation, and night shift 
work (most likely due to reduced levels of melatonin which has an anti-
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carcinogenic effect) (Megdal et al., 2005; Parkin, 2011; Parkin & Boyd, 2011; 
Parkin & Darby, 2011). 
The most common type of breast cancer is ductal breast carcinoma (70-80% of 
all breast cancer cases). Invasive lobular breast cancer is diagnosed in 10-15% 
of all cases. Rare types of breast cancer include inflammatory breast cancer 
4%, Paget’s disease (1-2%). Other less common types include medullary (5%), 
mucinous (2%), tubular breast cancer (1%) and metaplastic breast cancer 
(Vogel, 2008). Important biological characteristics affecting clinical decisions 
are the presence of estrogen and progesterone receptors, and low or high 
proliferation measured by Ki-67 and HER-2. Based on those characteristics 
breast cancer can be then divided into: 
 Triple negative (around 15% of all) with negative estrogen, progesterone,
and HER-2 receptors, more frequent in the younger population.
 HER-2 positive (around 10% of all) - strongly positive HER-2 by
immunochemistry/immunofluorescence testing, estrogen receptor negative,
more common in the younger population.
 Luminal A (around 15% of all) - strongly positive estrogen and progesterone
receptors, low proliferation, negative Her-2.
 Luminal B (around 60%) low level estrogen and progesterone receptors but
high Ki-67 and HER-2 positive (Kim et al., 2011).
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Figure 4 Incidence and mortality rates for breast cancer. UK (source Office for 
National Statistics) 
Breast cancer treatment usually includes adjuvant therapy after primary surgery 
for early and locally advanced breast cancer (stage I, II and III). In case of 
advanced metastatic cancer endocrine therapy; single agent chemotherapy and 
biological therapy are most commonly chosen (NICE, 2009a). The overall 
decision about treatment is based on the stage of cancer its biological 
characteristics, hormone receptor status of tumour, patient’s age, menopausal 
status as well as patient’s choice (NICE, 2009b). 
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The aim of surgery is to remove the tumour from breast tissue and lymph nodes. 
It additionally helps to obtain more information on the tumour’s biological 
characteristics. Adjuvant treatment includes radiotherapy, chemotherapy, 
endocrine therapy or therapy with monoclonal antibodies (Trastuzumab). 
Hormonal therapy includes treatment with aromatase inhibitors or Tamoxifen 
(NICE, 2006). There is emerging evidence from RCTs and meta-analysis 
showing that aromatase inhibitors improve clinical outcomes as compared with 
Tamoxifen, mainly assessed as the disease-free interval in postmenopausal 
breast cancer survivors (Burstein et al., 2010; NICE, 2006; Xu et al., 2011).  
Aromatase inhibitors act by inhibiting the conversion of androgen to estrogen 
which reduces the levels of circulating estradiol and its negative feedback on 
the hypothalamic-pituitary axis. In pre-menopausal women, this can increase 
FSH/LH production leading to follicular growth and ovulation. Most women 
above the age of 40 would develop amenorrhea following chemotherapy. 
However, it is uncertain whether the suppression of ovaries is permanent. Some 
observational studies have reported an increased risk of return of ovarian 
function in peri-menopausal women with breast cancer taking aromatase 
inhibitors compared with non-users (Burstein et al., 2006; Smith et al., 2006). 
This subsequently carries risks related to increased estrogen levels and the 
possibility of pregnancy. Therefore, a marker which could reliably confirm the 
permanent suppression of ovarian function and assure the safety of aromatase 
inhibitors in such patients is sought after by oncologists (Henry et al., 2014). 
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Chemotherapy regimens used for breast cancer include CMF 
(cyclophosphamide, methotrexate, fluorouracil); Epirubicin followed by CMF; 
AC (anthracycline and cyclophosphamide), which can be used for women with 
lymph node negative disease. Other regimens used are FEC (fluorouracil, 
epirubicin and cyclophosphamide) with docetaxel in case of node positive 
cancer and FAC (fluorouracil, adriamycin=doxorubicin and cyclophosphamide). 
The decision about chemotherapy regimen used is based mainly on the 
biological profile of the tumour, its spread to lymph nodes, the risk of recurrence 
and patients underlying medical conditions. NICE recommends multi-agent 
therapy with the usage of antracyclines (epirubicin or doxorubicin) (NICE, 
2013b). 
Cyclophosphamide is effective, and one of the most widely used agent against 
breast cancer but its use is associated with a high risk of ovarian damage. 
Depending on the combination of drugs included in the regimen and the number 
of cycles of chemotherapy administered, it may have a variable damaging effect 
on ovarian tissue. The risk of amenorrhoea after 6 cycles of CMF or four cycles 
with AC is estimated at 33%, while six cycles of FEC or FAC increases the risk 
to 50-60% (Kim et al., 2012). Some new drugs used in HER-2 positive patients 
such as trastuzumab (humanised monoclonal antibody) have not yet been 
assessed in longitudinal studies and, therefore, the long term effects on ovaries 
are uncertain. 
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1.5.3 Lymphoma 
Hodgkin lymphoma is the third most common cancer in people aged 15-29. In 
women, the peak of disease is around age 20-24 and later in life at age 70-74. 
Overall, the incidence in females is 2.4 per 100,000 and has remained stable 
from the mid-1970s. Although there has been a significant fall in the number of 
deaths from Hodgkin lymphoma, from 1.1 to 0.3 per 100,000 in the UK 
according to Office for National Statistics and The National Cancer Intelligence 
Network (NCIN, 2009; ONS, 2011; ONS, 2012). Based on histology, the types 
of lymphoma are divided into several subtypes with Classical Lymphoma being 
the most common and represented by nodular sclerosis type (around 50% of all 
cases), mixed cellularity, lymphocyte rich and lymphocyte depleted types 
(Adami, 2008). 
Patients with early stages of Hodgkin lymphoma receive four courses of ABVD 
(adriamycin, bleomycin, vinblastine, dacarbazine) which is estimated give <10% 
chance of premature ovarian insufficiency. For more advanced stages of the 
disease, further courses of ABVD or BEACOPP (bleomycin, etoposide, 
doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisolone) 
can be used. BEACOPP’s risk of inducing early menopause is 50% in women 
exposed before the age of 30 (Kim et al., 2012). ChlvPP (chlorambucil, 
vinblastine, procarbazine and prednisolone). the combination is used in elderly 
patients not suitable for ABVD (Weekes et al., 2002). Another protocol, Stanford 
49 
V (mustine, doxorubicine, vincristine, vinblastine, bleomycin, etoposide and 
steroids) was found to be inferior to ABVD in terms of survival in a 10 year follow-
up clinical trial (Chisesi et al., 2011) 
Non-Hodgkin Lymphoma is the fifth most common cancer in UK. Although its 
incidence is higher in older people, increasing from the age of 50-54. Around 
3.8% are diagnosed at age 20-34 and 6.8% between 35 and 44. In women, the 
incidence in the last 10-15 years has increased by 11% (NCIN, 2009; ONS, 
2012b). The survival rate for women under the age of 49 is estimated at 80-85% 
(Kim et al., 2012). 
The regimen commonly used in this group is CHOP (cyclophosphamide, 
doxorubicin, vincristine, and prednisolone) which has been associated with a 
5% risk of premature ovarian insufficiency (Kim et al., 2012). 
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1.6 Effect of cancer and chemotherapy on ovarian function: 
possible mechanisms 
The impact of cancer and its treatment on ovarian biology and function is not 
fully understood in humans, and some of the studies give opposing theories. 
Here, I present an overview of the literature on the mechanism of 
chemotherapy-induced follicle damage, the impacts of different types and 
dosages of chemotherapy, as well as the range of effects in different age 
groups. 
1.6.1 Ovarian reserve before chemotherapy 
In order to understand the impact of cancer therapy upon female reproductive 
function, it is important to assess whether there is any association between the 
occurrence of a disease, or an effect of severe illness (e.g. cancer) on ovarian 
reserve prior to any treatment being commenced. There are several 
publications comparing AMH in cancer patients and the infertile population, 
however the latter may not be a suitable control group because infertility may 
be associated with a reduced follicle pool (Knopman et al., 2009; Quintero et 
al., 2010). Even if cases of male factor infertility were analysed, it couldnot be 
excluded that, on average, levels of AMH may be lower in the infertile 
population.   
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Others have tried to assess the ovarian reserve by checking the regularity of 
menstrual cycles, a method which is known to be unreliable (Bath et al., 2003; 
Larsen et al., 2003).  
Two recently published studies compare AMH in cancer patients and healthy 
volunteers. A study of 108 breast cancer patients, pre-chemotherapy, versus 99 
volunteers, reported no statistical difference in AMH concentrations between the 
groups. However, the groups were not age matched (the breast cancer group 
was significantly older) and volunteers with a previous history of polycystic 
ovarian syndrome (PCOS, known to be associated with raised AMH) or infertility 
were not excluded. Moreover, information about the type of contraception used 
was not taken into consideration (Su et al., 2013).  
Another recently published study from the FERTIPROTEKT Network in Hodgkin 
and non-Hodgkin lymphoma patients reported significantly lower levels of AMH 
in blood when compared with age-matched healthy volunteers, having a normal 
BMI and regular menstrual cycles. However, nearly 60% of volunteers were 
using oral contraception which could perhaps have affected the results 
(Lawrenz et al., 2012). Interestingly, when the same authors compared the 
number of retrieved oocytes for breast cancer and lymphoma patient groups 
(even those with normal results of ovarian reserve tests) following ovarian 
stimulation for fertility preservation, the lymphoma patients had significantly 
lower results. The authors hypothesised that reduced ovarian reserve may have 
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been related to high cytokine levels which are believed to be the reason for 
poorer quality sperm in male patients with lymphoma (Agarwal & Said, 2004).  
1.6.2 Mechanism of chemotherapy-induced ovarian damage 
The gonadotoxic influence of chemotherapy on ovaries includes effects on both 
somatic and germ cells as well as vascular damage. The degree of follicular 
apoptosis and cortical fibrosis may vary with different types and dosages of 
chemotherapy. Also, effects upon the pool of primordial follicles may not be the 
same as on other classes of follicles e.g. maturing follicles which contain 
dividing granulosa cells. The latter would be the prime target of 
chemotherapeutic agents as they directly affect actively dividing cells (Meirow 
et al., 2010).  
Overall, the prevailing view is that the number of germ cells is negatively 
affected by chemotherapy. As the destroyed germ cells cannot be regenerated, 
the damage is irreversible (Demeestere et al., 2012). A counter view was 
proposed in 2005 by Johnson et al. (2005) supporting the theory of neo-
oogenesis. While controversial, there have been some recent publications in 
support. However, neo-oogenesis is considered unlikely to impact significantly 
upon chemotherapy-induced damage (Johnson et al., 2005).  
Among the first publications studying the chemotherapy-induced ovarian 
damage, Ataya & Moghissi (1989) examined cyclophosphamide effects in rats 
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and concluded that the main action of chemotherapy is through direct effects on 
rapidly dividing cells with mitotic activity. The main effects observed were in the 
structure and function of proliferating granulosa cells, oocyte fertilization, and 
cleavage. They believed that surviving primordial follicles and oocytes had 
escaped the damaging effects and may be functioning normally after treatment 
is finished (Ataya & Moghissi, 1989). 
In the 1990s, an Italian group performed studies on the human ovarian tissue. 
They recruited 12 reproductive age women with Hodgkin disease and 
performed ovarian biopsies before and after chemotherapy with alkylating 
agents. Using electron microscopy they observed a reduction in the overall 
number of primordial follicles in all biopsied samples, as well as cellular features 
suggestive of early atresia in some of the surviving oocytes and follicle cells. 
This was interpreted to mean that chemotherapy not only immediately affected 
quantity but may also influence the quality of surviving follicles by starting early 
atretic changes which could potentially have a long term effect (Familiari et al., 
1993).  
However, Meirow et al. (2007) examined the changes in cryopreserved ovarian 
tissue in young women exposed to non-sterilising doses of chemotherapy and 
presented another idea. They provided evidence of disturbed blood supply to 
ovaries caused by obliteration of small blood vessels resulting in focal fibrosis 
of the ovarian cortex and loss of primordial follicles. They hypothesised that the 
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endothelial injury might cause long term effects resulting from fibrosis and 
follicle disappearance with subsequent abnormal neovascularisation (Meirow et 
al., 2007). 
A more recent study from a different group supported Meirow’s work on the 
vascular damage (Ben-Aharon et al., 2012, Ben-Aharon et al., 2015). Following 
animal studies, Ben-Aharon et al. (2012) recruited 20 premenopausal women 
at a mean age of 34, undergoing adjuvant or neoadjuvant treatment with 
anthracycline or taxane for non-metastatic breast cancer. Shortly following 
chemotherapy, Doppler-flow velocity index and size of the ovaries were 
measured. The results revealed significantly reduced blood flow and a decrease 
in size of ovaries in those patients. A more pronounced decrease was observed 
with sequential chemotherapy. Serum AMH measured at the same time 
revealed a drastic reduction, suggesting rapid changes in granulosa cells (Ben-
Aharon et al., 2012, Ben-Aharon et al., 2015). 
Proliferating granulosa cells may be a target for most chemotherapeutic agents, 
and loss of support from granulosa cells may lead to the death of oocytes 
(Morgan et al., 2012). Thus, if the activated, growing follicles are destroyed, the 
inhibiting effect of hormones such as AMH, produced by growing follicles and 
feeding back on follicular recruitment, is reduced. Therefore, a higher number 
of primordial follicles becomes recruited and then atretic at an increased rate 
which accelerates the loss of the ovarian reserve (Durlinger et al., 2002). This 
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is called the follicular burn-out hypothesis and states that ovaries undergo 
premature ‘burn-out’ due to an increased rate of recruitment and atresia of 
primordial follicles. If this were correct, the ratio between the number of 
primary/secondary follicles and primordial follicles would be increased. It has 
been observed in animal studies. However, there is a lack of human studies to 
confirm the same mechanism (Meirow et al., 2010). 
A number of other studies, in both humans and animals, have been reported, 
but none has a definitive answer to describe the mechanism of chemotherapy-
induced ovarian damage fully. It is possible that several mechanisms, which 
could be drug-specific or regimen-specific, take place at the time of exposure 
and may continue thereafter. Some of the damage may only become evident 
later. A constant dialogue between somatic cells and germ cells, which is 
necessary to regulate the growth and maturation of both, may be interrupted, 
and its re-establishment after profound changes due to chemotherapy exposure 
may be defective. 
It has been hypothesised that, based on mechanism of action and current 
studies, some agents such as doxorubicin and cyclophosphamide act more on 
dividing granulosa cells while others such as Cisplatin or Topoisomerase 
enzymes target the oocyte directly (Morgan et al., 2012). 
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Table 1 Summary of literature that examines the direct action of chemotherapy 
on the ovary (from Morgan et al., 2012). 
Chemotherapeutic 
agent 
Author Species Affected cell 
type 
Affected follicle 
class 
Doxorubicin Perez et al. 
(1997) 
Mouse Oocyte 
Jurisicova et al. 
(2006) 
Mouse Oocyte 
Ben-Aharon et 
al. (2010) 
Mouse Granulosa cells Secondary 
Bar-Joseph et 
al. (2010) 
Mouse Oocytes 
Soleimani et al. 
(2011) 
Human, 
Mouse 
Oocyte, granulosa 
cells, stroma, 
blood vessels 
Primordial, pre-
antral 
Cisplatin Gonfloni et al. 
(2009) 
Mouse Oocyte Primordial, 
primary 
Cisplatin/paclitaxel Yucebilgin et al. 
(2004) 
Rat Primordial 
Irinotecan Utsunomiya et 
al. (2008) 
Mouse Granulosa cells Pre-antral, 
antral, pre-
ovulatory 
Cyclophosphamide Zhao et al. 
(2010) 
Rat Granulosa cells 
Desmeules and 
Devine (2006) 
Mouse Oocyte and 
granulosa cells 
Primordial, 
primary 
Petrillo et al. 
(2011) 
Mouse, 
rat 
Mainly Oocyte Primordial, 
primary 
Oktem and 
Oktay (2007a) 
Human Oocyte Primordial 
Raz et al. 
(2002) 
Human Granulosa cells 
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1.6.3 Types of chemotherapy and effects on ovarian function 
The most commonly used types of chemotherapeutic drugs affect cell divisions 
and DNA synthesis. These types include: alkylating antineoplastic agents 
(mechlorethamine, cyclophosphamide, chlorambucil, ifosfamide); platinum 
derivatives (cisplatin, carboplatin, oxaliplatin), anti-metabolites (azathioprine 
and mercaptopurine); vinca alkaloids (vincristine, vinblastine); taxanes 
(paclitaxel, docetaxel); topoisomerase (irinotecan, topotecan, teniposide and 
etoposide); anthracycline (doxorubicin, epirubicin). Some of these agents and 
certain regimens seem to have a greater impact upon ovarian reserve than 
others. Most damage to the ovary is believed to be caused by alkylating agents. 
Cisplatin (and other platinum agents) is classified as a drug with a high impact 
but less than cyclophosphamide. Intermediate risk is associated with taxanes. 
The risk decreases further with vinca alkaloids, and the lowest risk of ovarian 
toxicity is associated with antimetabolites ( Meirow et al., 2010, Demeestere et 
al., 2012) .The anthracycline group has been previously classified as ‘low risk’, 
but recently that has been questioned (Letourneau et al., 2012) as it seems to 
have a higher impact on ovarian reserve than initially suggested. Although, the 
dosages, types, and regimens of chemotherapy continue to change.  
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1.6.4 Dosage of chemotherapy and its effect on ovarian function 
The effect of chemotherapy upon the ovary has been proven to be dose 
dependent. Meirow et al. (1999) in experiments on mice, showed that single 
increased doses of cyclophosphamide caused the loss of increasing numbers 
of primordial follicles in each subject. Follicular destruction was found to be 
proportional to the dose of cyclophospamide and was evident in all cases even 
at the lowest dose of 20 mg/kg. A dose of 75 mg/kg caused loss of 54% of 
primordial follicles (in humans the average dose of cyclophosphamide would be 
40-50 mg/kg given in divided doses). The relationship between the dose of 
chemotherapy and the reduction in the number of primordial follicles best fits an 
exponential curve. The authors highlighted the fact that even if the ovulation rate 
and pregnancy rate were not affected by chemotherapy in young animals in the 
short-term, damage to primordial follicles was still observed to increase the risk 
of early ovarian failure and a narrowed period of time to conceive (Meirow et al., 
1999). 
Those findings are consistent with some observational studies in humans, 
reporting a high risk of early menopause in women exposed to chemotherapy, 
even when regular menstrual cycles and ovulation have resumed post-
treatment. It shows that the initial recurrence of regular cycles and ability to 
conceive can give false reassurance to patients and their oncologists. Long term 
follow-ups show that young women still experience ovarian side-effects and a 
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narrowed window of opportunity to conceive as well as an increased risk of early 
menopause (Rose & Davis, 1997). 
1.6.5 Age and chemotherapy effects 
As mentioned earlier, women who regain spontaneous menstrual cycles 
following chemotherapy have usually suffered some degree of reduction in 
ovarian reserve and are therefore at risk of premature menopause (Bath et al., 
2003; Larsen et al., 2003b; Partridge et al., 2010b). The effect is age dependent. 
Meirow et al. 2010 highlighted that ovarian damage happens to women of all 
ages exposed to cytotoxic drugs but is manifested sooner in older women as 
they already have reduced ovarian reserve at the time of commencing the 
treatment (Meirow et al., 2010).  
In a retrospective survey of 1041 American women who were diagnosed with 
cancer at an age of 18-40 years, 3-10% of them reported symptoms of acute 
ovarian failure (defined as amenorrhea for 12 months which started at/post 
treatment). The percentage of cancer survivors experiencing acute ovarian 
failure increased with age and, for example, was found to be 6% at age 20 years 
and 30% at age 35 years at diagnosis in patients with Hodgkin lymphoma (p< 
0.001). For breast cancer patients, the incidence was 32% at 35 years and 55% 
at the age of 40 at diagnosis (p< 0.001). When infertility (defined as inability to 
conceive for 12 months or more) was studied, in the Hodgkin disease group, 
57% of patients at age 35 had difficulty conceiving even if their menses returned 
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within 12 months of cancer treatment. Similarly, within the breast cancer group 
the incidence of subfertility was 32% at age 35 and 80% at age 40. Interestingly, 
within the group of women whose menses returned within 12 months from the 
time of chemotherapy, younger women had a higher probability of early 
menopause than older women closer to menopause (Letourneau et al., 2012). 
Overall, those results were consistent with some previous reports and raised 
the issue of a narrowed window of opportunity to conceive even in very young 
women undergoing chemotherapy.
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Table 2 Estimates of the chemotherapy induced risk of early menopause (from 
Meirow et al., 2010). 
Breast cancer Treatment Age Ovarian 
failure 
(Lower et al., 1999) Various regimens Pre-
menopause 
45% 
<35y 28% 
(Bines et al., 1996)  Various regimens Pre-
menopause 
68% 
(Goodwin et al., 1999) CMF 43.7y 65% 
(Meirow, 1999) <44y 50% 
(Burstein & Winer, 2000) CMF 30y 19% 
30-39y 30-40% 
CAF <30y 0% 
30-39y 10-25% 
AC <30y 0% 
30-39y 13% 
(Petrek et al., 2006) Various regimens <35 15% 
35-39 39-55% 
>39 >55%
Hodgkin disease Treatment Age Ovarian 
failure 
(Howell & Shalet, 1998) Aggressive 
treatment 
38-57% 
(Meirow, 1999) Relapse post 1st 
treatment 
32% 
(Bokemeyer et al., 1994) Infradiaphragmatic 
radiotherapy 
50% 
(Brusamolino et al., 
2000) 
‘ovarian sparing 
protocol.' 
<25y 0% 
<45y 30% 
(Behringer et al., 2005) Dose escalated 
BEACOPP 
30y 51% 
>30y 95% 
AC –cyclophosphamide, CAF- cyclophosphamide doxorubicin and fluorouracil, 
CMF- cyclophosphamide, methotrexate and fluorouracil. 
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1.6.6 Radiotherapy and obstetric outcomes in cancer patients 
It has been shown that obstetric complications are more common in cancer 
survivors. This depends on the type and dosage of treatment, but overall 
chances of miscarriage, preterm delivery, and neonatal low birth weight are 
higher in cancer survivors (Meirow et al., 2010). 
Chemotherapy does not seem to have a significant, long-lasting effect upon 
uterine function, however when accompanied by total body radiation or 
radiotherapy to the pelvis, impact on both ovarian and uterine tissue is evident 
(Meirow et al., 2010). 
The occurrence of premature ovarian failure following total body irradiation and 
abdominal/pelvis radiation were 90% and 97% respectively in long-term follow-
up studies. Similarly to chemotherapy, the degree of damage depended on the 
patients’ age and the cumulative dose of radiotherapy (Meirow et al., 2010). 
Ideally, the gonads should be shielded from the radiation field, but this is not 
always possible. Based on mathematical models it has been estimated that the 
pool of non-growing follicles is halved by a radiation dose of 2Gy (Wallace et 
al., 2003). 
The damaging effect of radiotherapy on uterine function results in a lower 
implantation rate, higher number of premature deliveries and miscarriages, 
(which is assumed to be a result of abnormal vascularisation,) decrease in 
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uterine size and thinning of the endometrium following high dose ionizing 
radiation (Meirow et al., 2010). In patients who received direct pelvic 
radiotherapy, increased risks of preeclampsia, foetal malposition and post-
partum haemorrhage have been observed (Demeestere et al., 2012). The same 
has been observed in women with history of childhood cancer exposed to 
abdominal radiotherapy, where association with a higher rate of preterm 
deliveries and low birth rates in offspring was found (Reulen et al., 2009). The 
same was not found in in girls and young omen exposed to chemotherapy only. 
(Reulen et al., 2009) 
Interestingly, only a very few papers report on the impact of radio/chemotherapy 
on the hypothalamus and pituitary gland in relation to fertility. One of the cohort 
retrospective studies examined fertility outcomes in 3,619 female Childhood 
Cancer Survivors and compared them with participants’ siblings. Based on a 
multivariable regression model including race, smoking status, marital status, 
education, and age at diagnosis; hypothalamic/pituitary exposure to doses of 
radiotherapy >22 Gy was found to be associated with reduced fertility in the 
cancer group (Green et al., 2011).  
1.6.7 Teratogenic impact of chemotherapy on future pregnancy 
There is no evidence of increased chromosomal abnormalities in children born 
from mothers previously exposed to chemo- and radiotherapy (Winther et al., 
2004). However, many authors stressed that the time between the end of 
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chemotherapy and the start of pregnancy is crucial in preventing potential 
teratogenic effects. It is estimated that a break of at least 6 months after the last 
dose of chemotherapy should be recommended to avoid the potentially 
dangerous exposure of maturing oocytes to chemotherapy (Meirow et al., 
2010). Understandably, a longer period of 1 to 5 years is recommended in order 
to avoid the risk of recurrence of the malignant condition during pregnancy.  
Animal studies suggest that exposure to chemotherapy just before conception 
or during early pregnancy increases fetal malformations and miscarriages. 
Consequently, it is considered important to avoid cryopreservation of oocytes 
immediately after a first course of chemotherapy, even if it was not offered 
earlier, because the impact on future offspring could be significant (Meirow et 
al., 2010). 
1.6.8 Long term clinical impacts of chemotherapy-induced loss of 
ovarian function 
Apart from infertility, there are a number of other clinical consequences of 
premature menopause (before age 40) or early menopause (age 40-45) 
(Nelson, 2009). The terms premature ovarian failure, primary gonadal 
dysfunction or primary ovarian insufficiency (POI) are often use to describe 
secondary amenorrhoea as an effect of a significant reduction in the primordial 
follicle pool in young women aged < 40. Most commonly primary ovarian 
insufficiency is used to describe amenorrhea for more than 4 months and two 
readings of FSH at menopausal levels in women below 40. 
Nevertheless, intermittent ovarian function can still occur in half of women 
diagnosed with POI (Goswami & Conway, 2005) and about 5-10% of women 
still conceive after a diagnosis of primary ovarian insufficiency (Anderson & 
Cameron, 2011; Nelson, 2009). POI differs from menopause which is 
considered more definitive.  In patients with cancer, the situation is more 
complex, and assessment is difficult. Secondary amenorrhoea can be 
permanent and may start immediately at the time of gonadotoxic treatment in 
patients with already diminished ovarian reserve. In younger patients, usually 
having a larger stock of follicles, menses may stop as an effect of 
chemotherapy-induced loss of growing follicles but then resume as some of 
the surviving primordial follicles start to grow and mature. Chemotherapy-
related amenorrhea (CRA), describes acuter and sometimes temporary 
changes which take place within the first few months after starting 
chemotherapy rather than the long term consequences, however it has 
also been considered as a marker of ovarian function (Anderson & Cameron, 
2011; Petrek et al., 2006). The understanding of those terms and their 
definitions seems to vary among infertility experts and oncologists (Anderson 
& Cameron, 2011). 
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1.6.9 Consequences of induced premature menopause 
The consequences of premature menopause relate to the loss of circulating 
follicle-derived hormones, and include low bone density, earlier onset of 
osteoporosis and bone fractures, increased risk of cardiovascular morbidity and 
mortality, higher rates of depression and anxiety and psychosexual dysfunction 
(Daan et al., 2015). Other common complaints include vasomotor symptoms, 
vaginal dryness and dyspareunia (Rocca et al., 2009; Shuster, 2010). 
One of the commonly used methods of assessing the association between early 
menopause and health problems is to compare women who underwent 
oophorectomy for benign causes with the general population of women who had 
a natural menopause. In one such population based cohort studies, an 
increased mortality was observed in women who underwent total abdominal 
hysterectomy and bilateral oophorectomy for benign causes before the age of 
45 and who had not received estrogen replacement therapy as compared with 
the general population (Rocca et al., 2006). 
Another study looked into the potential effects of estrogen decline on 
cognitive function in women who had ovaries removed for reasons other than 
cancer. It reported impaired performance and a lower score in Mini Mental 
State examination and Wechsler Memory Scale in women post-
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oophorectomy as compared to age- and education-matched controls. Post-
surgery results in women with estrogen levels dropping more than 50% at 3 
and 6 months follow-ups, the changes in visual and logical memory loss were 
more pronounced (Farrag et al., 2002).  
In conclusion, the effects of chemotherapy on future fertility are age-, agent- and 
dose-dependent. Different combinations of agents used, and repeated 
treatments make the classification of the degree of gonadotoxicity difficult. 
The mechanisms of acute injury to ovaries and the long term impact on ovarian 
function are complex and may vary significantly among different agents. There 
is a lack of clear guidance for counselling women having gonadotoxic treatment. 
It is the time that well-designed longitudinal prospective studies with end points 
that include pregnancy and premature menopause should be undertaken. 
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1.7  Fertility preservation options 
There are a number of choices for fertility preservation in young women with 
cancer. Some oncologists decide not to refer for a preservation discussion with 
a fertility specialist and are guided by their own experience and beliefs (Quinn 
et al., 2009). Not all oncologists may have up to date knowledge on the timing, 
funding and treatment options and their side effects, as there has been 
significant progress in this field recently (Gilbert et al., 2011).  
Patients’ expectations, however, may be different. In a large web-based survey 
conducted in the United States amongst young female survivors of early stage 
breast cancer, over 50% of respondents stated that their ‘fertility concerns’; were 
not addressed properly at the time of cancer diagnosis and treatment. More than 
70% of them expressed concerns about future fertility (Partridge et al., 2004). 
In the UK, a study conducted by the University of Sheffield at a Teenage Cancer 
Trust meeting showed that only 40% of females diagnosed with cancer as a 
teenager were happy with the fertility information and fertility preservation 
options that they had received (Yeomanson et al., 2013). In the UK, the most 
established method of fertility preservation for women is embryo freezing while 
a newer option is vitrification of oocytes. Cryopreservation of ovarian tissue is 
still performed only in research settings in selected centres, due to regulations 
and a lack of funding, therefore not allowing easy accessible across the UK 
(Ajala et al., 2010; NICE, 2013a). The decision regarding an appropriate fertility 
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preservation method is ideally guided by the type of cancer, timing of 
chemotherapy/radiotherapy, age of the patient, relationship status and the 
patient’s wishes (Donnez & Dolmans, 2011) .  
Embryo cryopreservation is a widely used technique in IVF centres and it is the 
most commonly offered fertility preservation option in the UK. This method 
requires a male partner willing to consent to embryo storage and its use in the 
future. However, the psychological and emotional impact of the life-threatening 
illness on a relationship at the time of diagnosis, and a few years delay until 
embryos are actually used with a view to establishing pregnancy may cause 
difficulty in obtaining or maintaining the partner’s consent. There have been high 
profile cases where the male partner had withdrawn consent when the couple 
separated, not allowing their ex-partner to use the cryopreserved embryos, 
which had been her last chance of pregnancy with her own biological offspring 
(English, 2004). Cryopreserving mature oocytes could solve this problem. 
However, the quoted pregnancy rates vary greatly in centres worldwide.  
Since delay with commencing cancer treatment needs to be avoided, many 
centres offer a short stimulation protocol for oocyte collection for fertility 
preservation. In this situation, stimulation uses a GnRH antagonist as opposed 
to so-called long protocols requiring time consuming down-regulation with 
GnRH agonist. If the patient is referred immediately after diagnosis and 
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happens to be in the early follicular stage of the menstrual cycle, short protocol 
could result in oocyte collection within 10-14 days. 
In cases of estrogen receptor positive breast cancer, stimulation with high doses 
of FSH and LH, leading estrogen levels to increase, may cause concern 
amongst oncologists. There is no evidence of a negative effect of transiently 
high estrogen levels, just before chemotherapy is commenced, in terms of long-
term mortality and the response to chemotherapy in estrogen receptor positive 
breast cancer patients (Anderson & Wallace, 2011). However, there is also a 
lack of trials confirming its safety. Some research groups have therefore used 
modified ovarian stimulation protocols in such cases, adding Letrozole or 
Tamoxifen alongside FSH for the duration of the stimulation cycle, although this 
has raised issues of safety and impact on the development of embryos (Oktay 
et al., 2005). Health professionals may find it difficult to quote success rates and 
safety of such modified protocols during their discussions with patients (Kim et 
al., 2011). National statistics on pregnancy rates, specific for women with 
cancers who underwent fertility preservation, are not available. Some authors 
question its efficacy. Additionally, some women who generate frozen embryos 
may never wish to use them due to natural conception or ongoing illness, and 
some may die from their cancer (Anderson & Wallace, 2011; Kim et al., 2011). 
Cryopreservation of oocytes could avoid the creation of unused embryos, which 
may raise ethical concerns. The success of oocyte cryopreservation for young 
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women is becoming closer to that with fresh oocytes as stated in the American 
Society for Reproductive Medicine Guidelines for Practice, ‘Mature oocyte 
cryopreservation’ (ASRM, 2013). Using vitrification instead of slow freezing has 
improved success rates. However, the method is technically challenging and 
requires a skilled embryologist. It is estimated that over 900 babies have been 
born worldwide from frozen oocytes (mainly using slow-freezing) and there has 
been no increase in chromosomal abnormalities or birth defects reported as 
compared with natural conception (Noyes et al., 2009). Oocyte cryopreservation 
still requires ovarian stimulation and some research groups have proposed that 
cryopreservation of immature oocytes at the germinal vesicle (GV) stage may 
be an appropriate alternative for women with estrogen receptor positive breast 
cancer or where any delay of cancer therapy is not recommended. It may also 
be considered in women at a high risk of ovarian hyperstimulation syndrome 
(Kim et al., 2011). However, this approach is still experimental because it 
requires maturation of oocytes in vitro, which is associated with lower success 
rates than the use of mature oocytes (Donnez & Dolmans, 2011). 
A further option for fertility preservation that helps to avoid delays in cancer 
treatment is cryopreservation of ovarian tissue. This approach is still considered 
to be experimental in the UK and requires registration with the Human Tissue 
Authority. In Denmark and Belgium, the method is more commonly used, and 
satellite centres transport laparoscopically retrieved samples of ovarian cortex 
for cryopreservation in a central certified laboratory. Subsequent re-implantation 
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of cortical ovarian tissues into the pelvic cavity (orthotopic site), once patients 
were recovered from their cancer, has been reported to result in 15 live births 
(Donnez & Dolmans, 2011). 
In the Donnez research group, ovarian function was restored within 3-6 months 
after surgery in all cases of orthotopic re-implantation of the cryopreserved 
ovarian cortex. This therapy could therefore potentially reverse the symptoms 
of premature menopause, however, such grafts usually last for only short 
periods of time (2 years maximum). Re-implanting additional slices of ovarian 
cortex requires repeated surgery. So far, the method was found to be successful 
only in women below the age of 30, in whom a substantial ovarian reserve would 
be expected (Donnez & Dolmans, 2011). Interestingly, in Denmark, in reported 
series of 18 patients undergoing ovarian cortex orthotransplant, all of the 
recruited women resumed production of sex hormones. Authors declare that on 
average it took 20-25 weeks to develop first pre-ovulatory follicle (Andersen et 
al., 2012).  
An important disadvantage of this option is that re-implantation of ovarian tissue 
may reintroduce malignant cells. It has been reported that malignant cells are 
present in ovaries of patients with leukaemia but seems less likely in cases of 
lymphoma and breast cancer (Donnez & Dolmans, 2011). A review on the risk 
of re-implantation of malignant cells suggested that performing the procedure in 
patients in complete remission could minimise the risk. Based on current 
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literature, guidance on the risk of ovarian metastasis in all common cancers 
classified Hodgkin lymphoma and stage I-III ductal breast cancer as low risk, 
while leukaemia, Burkitt lymphoma and neuroblastoma were categorised as 
high risk (Dolmans et al., 2013). For this reason, alternative methods are being 
developed such as the re-implantation of isolated follicles within an artificial 
ovary or scaffold (Amorim et al., 2009) or maturation of oocytes from primordial 
follicles from cryopreserved ovarian tissue (Hovatta, 2004). 
A systematic literature review of studies examining the presence of malignant 
cells in cryopreserve human ovarian tissue was conducted in 2013. Based on 
42 included papers, ovarian tissue from overall 422 women have been 
examined using different methods: histology, immunochemistry, PCR or 
transplantation of tissue to animals. In around 7% of cases, some evidence or 
suspicion of the presence of malignant cells has been reported. The impractical 
observation made by authors was that transplantation of a representative tissue 
to a suitable host animal for a period of 5 months is the most reliable method of 
testing for presence of malignant cells (Rosendahl et al., 2013). Other methods 
were not as reliable as the one using host animals. 
Another option of fertility preservation comprises the use of GnRH agonists 
alongside chemotherapy, to suppress ovarian follicular activity. The 
suppressing effect of GnRH -agonists on the hypothalamic-pituitary-gonadal 
axis, slowing rate of folliculogenesis with potential protective effect on ovarian 
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tissue was initially suggested based on observational studies in women 
receiving chemotherapy for breast cancer (Blumenfeld et al., 2008; Recchia F, 
2006). Although, the exact mechanism of the potential protective action of 
GnRH agonists in humans remains uncertain. Imai et al., (2007) reported 
positive results while using GnRH - agonist against doxorubicin in in-vitro 
studies on granulosa cells obtained from patients undergoing egg collection for 
IVF (Imai et al., 2007). The effect was restricted to cells with GnRH receptors 
only. Others have suggested that GnRH agonists may reduce the blood flow to 
ovarian tissue and, therefore, minimise exposure to gonadotoxic drugs (Morgan 
et al., 2012).  
A meta-analysis of 11 prospective studies on co-treatment with GnRHa showed 
some improved ovarian function after treatment, but subanalysis of 3 
randomised trials failed to show any statistical difference (Kim et al., 2010). 
Additionally, two recently published, multicentre randomised trials have given 
opposing results, and it still remains uncertain if GnRH agonist treatment has 
any protective effect. The ZORO study did not provide evidence for any 
protective action of goserelin in hormone-insensitive breast cancer patients 
below the age of 46 receiving adjuvant chemotherapy (Gerber et al., 2011). The 
end point of the study was a recurrence of menses 6 months after the end of 
chemotherapy. However, this has been considered too short a follow-up. 
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In contrast, PROMIS-GIM6 showed a reduced incidence of early menopause 
by 17% in premenopausal women with breast cancer taking triptorelin during 
adjuvant or neoadjuvant chemotherapy (Del Mastro et al., 2011). The outcome 
was measured as the resumption of menses by 12-months follow-up and FSH 
levels. One could argue against the validity of such an assessment since a true 
measure of ovarian reserve would be long-term follow-up including pregnancy 
rates and age at menopause in all participants, and objective tests of ovarian 
reserve by AFC and AMH.  
The last published Cochrane review suggests considering GnRH agonist use in 
form of intramuscular or subcutaneous injections in reproductive age women 
undergoing chemotherapy despite a lack of evidence for improvement in 
pregnancy rates (Chen et al., 2011). Overall, GnRH agonist is currently an 
option for women who have declined or are unsuitable for other forms of fertility 
preservation and wish to use GnRHa (Kim et al., 2012) 
In summary, there are options for fertility preservation available for women prior 
to gonadotoxic treatment. The success rates and safety for cancer patients have 
been widely investigated, and provide hope for the future. None of the options 
is perfect, but women should be allowed to make an informed decision based 
on an individualised assessment, using ovarian reserve tests, and discussion 
with a fertility specialist.  
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1.8 Background to the research: Which is the most 
appropriate ovarian reserve test for cancer patients and 
selection of participants? 
Following a literature review of the available ovarian reserve tests, I selected 
serum AMH measurements as the most suited for my project. AMH is a useful 
test of ‘reproductive capacity’ in women pre- and post-chemotherapy (Anderson 
& Cameron, 2011). Recent studies have shown that amongst several ovarian 
reserve markers currently available, serum AMH measurement is of high clinical 
value (La Marca et al., 2009). The AMH concentration is relatively independent 
of the menstrual cycle and more accurate amongst women with irregular 
menstrual cycles in comparison to other markers such as FSH, E2, inhibin B 
(Cook et al., 2000b). In all the published comparisons, the performance of other 
endocrine ovarian reserve tests was never better than AMH (Broekmans et al., 
2006). 
A non-endocrine ovarian reserve test considered equally reliable is transvaginal 
ultrasound assessment of AFC. However, for a multicentre study, ultrasound 
assessment was found to be less suitable in view of inter-observer variation. If 
AFC were selected as the ovarian reserve test for this study, the same 
ultrasonographers using the same USS equipment to specific standards should 
ideally have performed it. This would, therefore, involve, for some patients, 
travelling to a distant clinic. Additionally, there is a lack of international standards 
as to which size range of follicles should be classed as antral follicles for AFC. 
Transvaginal ultrasound offered no advantage, as compared to serum AMH 
measurements, in research setting where only the ovarian reserve was to be 
tested.  
In some young women newly diagnosed with cancer, a requirement 
for transvaginal ultrasound could also cause additional stress and would 
require an additional appointment in this difficult time when they try to come 
to terms with their diagnosis. Additionally due to religious beliefs or 
previous traumatic experiences, some women may not be willing to have a 
transvaginal ultrasound for research purposes. Therefore, although a 
comparison of both AFC and AMH would have been interesting and 
valuable in my selected patient group, I decided to use only AMH, a test 
that can be done on a blood sample taken at any time. In the future, it could 
readily be included as part of the pre-chemotherapy work-up and post-
chemotherapy follow-up blood tests, carried out in all cancer patients. 
In contrast, a transvaginal ultrasound is not a routine procedure for this 
patient group and could present logistical and compliance challenges. 
Based on incidence rates from World Cancer report 2008, young women 
most commonly would be diagnosed with breast cancer, melanoma, cervical 
cancer, Hodgkin and non-Hodgkin lymphoma and colorectal cancer (Boyle 
& Levin, 2008).
In patients with early stages of melanoma, treatment would be localized 
without any systemic therapy. Treatment of cervical and colorectal cancer 
may include extensive pelvic/abdominal surgery and radiotherapy which 
would make it difficult to distinguish the impact of chemotherapy from the rest 
of treatment. Therefore, in this study, I have concentrated on two main 
groups: breast cancer and lymphoma. As study design is observational and I 
am using a new assay in previously not validated group of patients, 
following discussion with my Supervisors, I have decided to allow 
participation of women with other haematological condition (malignancy) 
or other cancer (e.g. colorectal) if patients self-referred. Due to small 
numbers, they are not included in the main statistical analysis and may be 
described only as case reports which could potentially provide interesting 
initial observations for other researchers working in the same field.
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1.9 Research questions and objectives 
In the next chapter, I present a literature review of ovarian reserve tests 
(including AMH) in female cancer patients, in order to identify currently available 
evidence and optimal practice for the assessment of ovarian function in women 
with severe illness undergoing gonadotoxic treatment. 
As an initial step of my experiment, I conducted a small pilot study to assess 
how different blood sample handling and storage may impact the AMH results. 
It was an important step in setting up multicentre study which required transport 
of samples from various hospitals. 
The objectives of my prospective study were, firstly, to compare baseline 
ovarian reserve using AMH in volunteer women and female cancer patients in 
their reproductive years. This part of the study aimed to determine whether there 
was evidence of an impact of severe illness on ovarian reserve, prior to 
chemotherapy. In this study, I aimed to ensure that AMH levels were analysed 
in full knowledge of women’s menstrual cycle stages, contraception, BMI, 
smoking habits, parity and past medical history. 
For the main part of the study, I assessed the effects of different types, dosages 
and durations of chemotherapy regimens on the ovarian reserve using AMH 
measurements as a marker, in young women receiving treatment for breast 
cancer or lymphoma. The effects of chemotherapy on the ovarian reserve in 
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cancer patients and healthy volunteers of similar ages were compared over a 
one year period. At the same time, I analysed young cancer patients’ views of 
pregnancy at the time of cancer diagnosis, at 6, 9 and 12 months using a 
medical questionnaire. Additional information was obtained directly from PIs 
and research nurses about each patient’s referral to Reproductive Medicine 
Consultant for discussion about fertility preservation options. It showed how 
patient’s wishes for pregnancy changes (if) from the time of diagnosis till 12 
month follow-up and how many female adult patients are currently referred to 
specialist for discussion about fertility preservation in the UK. In a volunteer 
group, I aimed to analyse AMH levels in relation to women’s menstrual cycles, 
contraception used, BMI, smoking habits and past medical history. I tested the 
reliability of second generation assay using a new methodology including a pre-
dilution step. 
The longitudinal design of this study, which will include a 5-year follow-up, has 
allowed me to assess the accuracy of a pre-chemotherapy serum AMH 
measurement in predicting future reproductive capacity (end points: pregnancy, 
live birth, early menopause) in cancer patients. Such a study has not previously 
been reported. If such a link is established, serum AMH, as a reliable test of 
ovarian function, could provide important information for the work-up and 
counselling of young women before chemotherapy. Due to the time frame of a 
research degree, the 5-year follow-up was not included in this dissertation. 
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FLOW CHART OF STUDY KEY ACTIVITIES 
Registration for Research Degree at University of Warwick 
Writing literature review and attendance on the following courses 
Understanding research and critical appraisal 
Epidemiology and Statistics module – Warwick Medical School 
SPSS (PASW) Statistics 17- University of Warwick - IT Services 
Subfertility and Reproductive Endocrinology course RCOG 
How to write a literature review – research skills module for PhD student 
Chief investigator course-Warwick Medical School Clinical Trial Units 
Protocol writing, collaboration with PIs (13 sites) and training of research 
nurses, opinion from patient group and experts: Professors Adam Balen, 
Richard Anderson and Nigel Stallard 
Ethical approval, support from Breast Cancer Research Study Group and 
inclusion into NHS portfolio 
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Laboratory training in sample handling and AMH immunoassay. Pilot study on 
stability of AMH assay 
R&D approvals on all sites, confirmation of local protocol and forms, 
establishing local procedures, building team contacts and setting up oncology 
clinics for this research. 
Recruitment of patients and volunteers across all sites and coordination of 
timely arrival of samples, distribution of results letters to healthy volunteers. 
Processing samples and AMH assay, analysis of medical questionnaires, data 
entry and matching control group, ensuring recruitment and sample collection 
remained on track at each setting, assisting as required by patients or PIs. 
Follow up of patient details and treatments. Arranging regular delivery of 
forms, packages to each clinic. Assuring properly timed continuation of blood 
sampling, questionnaires and patient information, as subjects reach 12 months 
from recruitment. Continually monitoring that recruitment is on track with 
appropriate size sub-groups (breast cancer and lymphoma patients), and age-
matched control samples. 
Attendance at course Theses and Dissertations- Microsoft Word, Statistical 
analysis and presentation of results at BFS, ASRM, ESHRE meetings 
Thesis submission, commencement of final stage of study (5 year follow-up) 
prior to publication of study results. 
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Chapter 2 
2 Literature review on ovarian reserve tests (ORT) in 
reproductive age women with cancer 
2.1  Introduction 
The increasing chances of survival of young women with cancer emphasise 
questions about their quality of life following successful treatment. Fertility, or 
prospects of it, are considered to be a very important aspect of quality of life 
amongst young cancer survivors (Ganz, 2000). 
Assessment of remaining ovarian function after chemotherapy is not 
straightforward. Chemotherapy-induced ovarian follicle loss depends on several 
factors including the type of chemotherapy, its dosage, duration, and the age of 
the patients, i.e. how large their ovarian reserve is before treatment begins 
(Lower et al., 1999; Meirow & Nugent, 2001). 
A number of studies have used the recurrence of menses at 6 or 12 month 
follow-ups after chemotherapy as an end point for re-initiation of fertility ( Lower 
et al., 1999, Behringer et al., 2005; Berliere et al., 2008). However, it is known 
today that this may not be the best measure of ovarian function because the 
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time for recovery from gonadotoxic therapy may be longer than 6-12 months 
and women who regain menses still may be at risk of premature menopause 
(Reh et al., 2008). 
Ovarian reserve tests could provide more tailored and detailed information for 
the individual patient. However, a number of questions remain outstanding. 
Which test, or a combination of tests, is suitable for measuring changes in 
ovarian reserve, in reproductive age women before and after chemotherapy? 
Do those tests correlate with clinical outcomes: live birth, infertility, early 
menopause? Could ORT be used as a guide as to whether or not patients offer 
fertility preservation treatment?  
This systematic review of literature of ovarian reserve testing in young women 
undergoing chemotherapy seeks to answer those questions. 
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2.2 Objectives 
My aim was to provide a review of all studies measuring ovarian reserve by 
methods that included AMH, in women exposed to gonadotoxic agents and to 
assess the validity of the findings. I sought to identify a single ovarian reserve 
test or a combination of tests which may be used reliably before, during and 
after chemotherapy, to identify women at high risk of early menopause and 
chemotherapy induced infertility. 
2.3 Methodology 
2.3.1 Protocol 
I used a prospective protocol following the widely recommended approach to a 
systematic review (PRISMA-http://www.prisma-statement.org). No pre-existing 
systematic literature review on ORT in the young female population affected by 
cancer was identified at the time of my initial analysis. The current guidelines 
and other reviews have been searched to assess their currency and to identify 
new research questions. I cross-checked systematic reviews on ovarian reserve 
tests in general and subfertile populations to identify if any data analysis on 
subgroups of cancer patients had been performed, which helped to identify one 
literature review. No existing review protocol on ovarian reserve tests in 
reproductive age women with malignancy was found. 
2.3.2 Eligibility criteria 
Given the rarity of the condition, databases were searched using PICOS 
questions (http://www.prisma-statement.org) without any additional restrictions 
(e.g. language), and with any length of follow-up. The search included all 
published studies until January 2010 without any language restriction. 
Subsequently, a further literature search has been performed prior to 
submission of this thesis, which included studies published between January 
2010 and January 2014. 
The following PICOS question set was used: 
P  (population/patient) - reproductive age women with malignancy 
I  (intervention) - cancer therapy: chemotherapy 
C  (comparison) - healthy volunteers 
O (outcome) - change in ovarian reserve prior and past 
chemotherapy, subfertility, early menopause 
S (study design) - prospective study design, cohort study or case control 
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2.3.3 Information sources and study selection 
The online search included studies of commonly used ovarian reserve tests 
(FSH, LH, estradiol, inhibin B, AMH, AFC, ovarian volume) in young female 
cancer patients treated with chemotherapy. Following advice from the Academic 
Support Librarian, Samantha Johnson, the databases were searched using 
relevant text words, Medical Subject Headings (MeSH) including all 
subheadings and their word variants. Terms representing the concept (ovarian 
reserve tests OR ovarian function OR ovarian reserve markers OR ‘specific 
ovarian reserve marker’) and (AMH OR Anti-Mullerian hormone) AND (cancer 
OR neoplasm OR malignancy) AND (chemotherapy OR drug therapy) AND 
(female) and humans were used to search Medline (2000 to 2014), Embase 
(2000 to 2014) and the Cochrane Library Database (2000 to 2014). Studies 
evaluating ovarian reserve tests in childhood cancer survivors were not 
included.  
2.3.4 Data collection process, data items 
Information was extracted from each selected study on the population and test 
characteristics including the time was taken to perform the tests. Methodological 
quality and accuracy of the results were assessed by two independent 
reviewers, myself and Dr Honest Honest (Consultant Obstetrician and 
Gynaecologist at Good Hope Hospital). We defined quality as the confidence 
that the study design, conduct and analysis minimized bias in the estimation of 
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test accuracy. We considered a study to be of good quality if it reported a 
prospective design, consecutive patient enrolment, an adequate test description 
and information on a priori estimation of the sample size. All variables for which 
papers were examined are included in a proforma ‘Data extraction’ form 
(Appendix 1). 
2.3.5 Risk of bias 
Understandably, most studies assessing the impact of chemotherapy upon 
fertility have an observational character such as case control, cohort or case 
series. With that in mind, the following criteria for assessment of the risk of bias 
in individual studies have been selected: 
 selection bias – assessing whether the same selection criteria have been used 
for all participants (patients and control group) 
 the loss to follow-up –assessing whether the loss to follow-up differs between 
the exposed and the unexposed the group 
information bias – assessing whether the same quality and extent of information 
is available from the exposed and the unexposed groups  
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2.3.6 Statistical analysis 
Due to the large heterogeneity of studies measuring ovarian reserve in young 
women with cancer, I was unable to perform quantitative synthesis of the 
results. Instead, I have provided a descriptive summary of the selected studies. 
2.4 Results 
2.4.1 Study selection 
I screened 42 papers, 35 full text articles were assessed for eligibility, and finally 
15 studies were included in qualitative synthesis (Figure 5). 
Excluded studies were excluded for the following reasons: not-systematic 
review (Letourneau et al., 2013), studies including a predominantly peri-
menopausal age group were fertility potential could not be readily assessed 
(Meng et al., 2013), or co-treatment with a GnRH agonist (Franco et al., 2012; 
Giuseppe et al., 2007; Park et al., 2010; Su et al., 2013), one review article on 
fertility conservation (Lawrenz et al., 2011), studies describing childhood cancer 
(Bath et al., 2003; Larsen et al., 2003b; Beek et al., 2007, Lie Fong et al., 2009; 
Brougham et al., 2012; Gracia et al., 2012; El-Shalakany et al., 2013; Nielsen 
et al., 2013), gynaecological cancers (Iwase et al., 2012), a small study (N=6) 
which included patients on hormonal therapy (Dieudonne et al., 2011), and 
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studies assessing only baseline AMH prior to any gonadotoxic therapy (Lawrenz 
et al., 2012; Su et al., 2013) 
Figure 5 Identification of literature for systematic review of ORTs in reproductive 
age women with malignancy treated with chemotherapy. 
Systematic reviews
References identified from search strategy: N 
= 0
Primary studies identified from search 
strategies and screened: N 46  
 duplicates removed N 42 
References excluded on the basis 
of reviewing title and abstract 
only: N 7
Full copy of papers ordered for more 
detailed evaluation and assessment of 
eligibility: N = 35
Papers excluded on the basis of 
reviewing full paper. N 20
Studies included in qualitative synthesis: N 15 
Total citations identified from electronic searches MEDLINE, EMBASE, Cochrane database to capture primary articles on 
all tests of ovarian reserve in reproductive age women undergoing cancer treatment with chemotherapy and/or 
radiotherapy
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Table 3 Study characteristics: number of cancer patients, mean age, cancer 
type and inclusion/exclusion criteria are presented. 
References N Mean 
age 
Cancer type Inclusion Exclusion 
Anders et al. 
2008 
44 40 years Breast Ca >2 menses in
180days,
Operable cancer
Pregnancy, 
Contraception, 
Ovarian tumour 
Anderson et al. 
2006 
42 
+14
41 years Breast Ca Regular menses 
or normal FSH, 
Operable cancer 
Metastases 
Anderson et al. 
2011 
42 42 years Breast Ca Regular menses 
or normal FSH, 
Operable cancer 
Hormonal 
contraception 
Anderson et al. 
2013 
59 42 years Breast Ca Regular menses 
or normal FSH, 
Operable cancer 
Previous 
chemotherapy, 
oophorectomy 
Behringer et al. 
2012 
562 32 years Hodgkin lymphoma Age less than 40, 
remission >1 year 
Other trial 
medications 
Decanter et al. 
2010 
30 24 Hodgkin, non-Hodgkin 
lymphoma 
Not specified Removal of ovary 
for 
cryopreservation 
Dhillon et al. 46 26 Any type of cancer 11-35 year old
with presence of
uterus
Pregnancy/post 
partum, lactation, 
chemotherapy 
Di Paola et al. 
2013 
63 31 Haematological 
malignancy 
Remission> 1 
year 
Oophorectomy/ 
hysterectomy, 
amenorrhea  
Henry et al. 
2014 
27 
(26) 
41 Breast Ca Menstruating 
women with 
breast Ca 
Oophorectomy/ 
hysterectomy, 
treatment with 
radiotherapy/ 
GnRHa 
Lie Fong et al. 
2008 
25 29 years Haematological Described for 
volunteers only 
Described for 
volunteers only 
Lutchman-
Singh et al. 
2007 
22 Range 
22-42
Breast Ca Pre-menopausal 
women with 
breast Ca 
Tamoxifen or 
GnRH agonist use 
Partridge et al. 
2010 
20 36 Breast Ca Menstruating 
women post-
chemotherapy 
Recurrence of Ca 
Use of tamoxifen 
Rosendahl et 
al.2009 
17 30 Any type of cancer Age 18-35 prior to 
chemotherapy 
Not specified 
Su et al. 2010 127 45.3 
years 
Breast Ca Premenopausal 
women with 
breast Ca 
Hysterectomy/ 
oophorectomy 
Yu et al. 2010 26 Range 
27-40
Breast Ca Premenopausal 
Women with 
breast Ca 
Not specified 
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Table 4 Type of ovarian reserve test used in the study and time of follow-ups. 
Study Type of ORT ORT 
before 
treatment 
ORT after 
treatment 
Time of ORT since 
cancer therapy  
Anders et al. 
2008 
FSH, inhibin B, 
E2, AMH 
Yes Yes 3-7 weeks, 6 months
and 12months
Anderson et al. 
2006 
FSH, LH, E2, 
inh B, AMH 
AFC 
Yes Yes 3, 6, 9 and 12 months 
Anderson et al. 
2011 
FSH, LH, E2, 
inh B, AMH 
AFC 
Yes Yes At 2, 3, 4, 5 years 
Anderson et al. 
2013 
FSH, inhibin B, 
AMH 
Yes Yes At 1 and 2 years from 
start of chemotherapy 
Behringer et al. 
2012 
FSH, LH, 
inhibin B, AMH 
No Yes 12- 46 months
Decanter et al. 
2010 
AMH Yes Yes 3, 6, 9, 12 months form 
start of chemotherapy 
Dhillon et al. FSH, LH, E2, 
inh B, AMH 
AFC 
Yes Yes Up to 12 months from 
chemotherapy 
Di Paola et al. 
2013 
FSH, AMH AFC No Yes 1 to >11 years form 
chemotherapy 
Henry et al. 
2014 
FSH, E2, inh B, 
AMH, 
Yes Yes Up to 15 months post 
completion of 
chemotherapy 
Lie Fong et al. 
2008 
FSH, E2, inh B, 
AMH, AFC 
Yes Yes Between 1 and 11 years 
Lutchman-
Singh et al. 
2007 
FSH, E2, inh B, 
AFC, AMH, 
dynamic tests of 
OR 
Yes Yes Immediately after 
completion of 
chemotherapy 
Partridge et al. 
2010 
FSH, E2, inhB 
AMH, AFC 
No Yes >1 year post-
chemotherapy
Rosendahl et 
al.2009 
FSH, E2, inhB 
AMH, AFC 
Yes Yes Up to 5-12 moths from 
treatment dose 
Su et al. 2010 FSH, E2, inhibin 
B, AMH 
No Yes Median 2.1 years from 
chemotherapy 
Yu et al. 2010 FSH, E2, AMH Yes Yes Up to 52 weeks 
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Table 5 Study design, control group, description of chemotherapy and outcome 
measures. 
References Study design Control group Chemotherapy 
regimen/dose 
provided 
Outcomes 
measure 
Anders et al. 
2008 
Prospective 
observational 
No Yes/no Changes in levels of 
ORTs 
Anderson et al. 
2006 
Prospective 
observational 
No Yes/Yes Changes in levels of 
ORTs 
Anderson et al. 
2011 
Prospective 
longitudinal 
Yes, women 
with breast Ca, 
no 
chemotherapy 
Yes/Yes Changes in levels of 
ORTs 
Amenorrhea 
Anderson et al. 
2013 
Prospective 
longitudinal 
No Yes/Yes Changes in levels of 
ORTs 
Amenorrhea 
Behringer et al. 
2012 
Cross sectional No Yes/Yes Differences in ORTs 
between 3 
chemotherapy 
groups 
Decanter et al. 
2010 
Prospective 
longitudinal 
No Yes/Yes Differences in ORTs 
between 2 
chemotherapy 
groups 
Dhillon et al. Prospective 
longitudinal 
No Yes/No Changes in levels of 
ORTs 
Di Paola et al. 
2013 
Cross sectional Yes Yes/yes Comparison of ORT 
with controls  
Henry et al. 
2014 
Prospective 
observational 
No No/no Changes in levels of 
ORTs 
Lie Fong et al. 
2008 
Retrospective 
(cohort) 
42 healthy 
volunteers with 
proven fertility 
No details Changes in levels of 
ORTs, 
Amenorrhea 
Lutchman-
Singh et al 2007 
Longitudinal, 
n=8, Cross-
sectional n=14 
Healthy 
volunteers with 
proven fertility 
Yes/Yes Changes in levels 
comparison with 
healthy volunteers 
Partridge et al. 
2010 
Cross sectional Yes Yes/ Comparison of 
ORTs with healthy 
volunteers 
Rosendahl et 
al.2009 
Prospective 
observational 
No Yes/Yes Changes in levels of 
ORTs, 
Su et al. 2010 Case control 
study 
Yes Yes/Yes Menses/no menses 
Comparison of 
AMH, in 2 groups 
Yu et al. 2010 Prospective 
cohort 
Yes, 
subfertilite 
(male factor) 
No/no Changes in levels of 
ORTs, 
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2.4.2 Overview of the selected studies 
In the study by Lie Fong et al. (2008), historical serum samples obtained prior 
to and post-chemotherapy from young women diagnosed with any 
haematological malignancy were thawed to analyse FSH, LH, E2, inhibin and 
AMH levels. The patient group consists of ten patients who received treatment 
with alkylating agents, three who had different chemotherapy regimens and 12 
who received total body irradiation. The control and cancer patient groups had 
AMH levels tested using two different assays. The methods of handling serum 
samples were not described although this is a currently known factor affecting 
AMH measurements. The timing of follow-up samples was between 1 and 11 
years. The research group concluded that all patients who underwent total body 
irradiation had undetectable AMH and developed premature ovarian failure. In 
the remaining group of 13 patients treated with chemotherapy alone, AMH 
levels as well as AFC were lower compared to a group of healthy volunteers 
with regular menstrual cycles and proven fertility. Considering the small sample 
size, and use of a ‘correction factor’ to compare AMH levels in both groups, the 
heterogeneity of haematological conditions, and the wide window within which 
follow-up samples were measured, then the precision of the results and their 
reproducibility could be questioned (Lie Fong et al., 2008). 
Gonadal function sub-analysis within the German Hodgkin Study Group HD13 
and HD15 Trial is one of the biggest studies describing differences in hormone 
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levels between Hodgkin lymphoma survivors receiving different chemotherapy 
regimens. Although a significant proportion of women was on GnRH analogues 
during chemotherapy and also, hormone levels were tested at any time between 
12 and 46 months follow-up, the results are still worth taking into consideration. 
In the enrolled group of Hodgkin lymphoma survivors, 562 were female. The 
study results showed differences in AMH levels between women who received 
only ABVD and women on the BEACOPP protocol. In the group of women who 
received BEACOPP, AMH levels were undetectable regardless of age. In 
contrast, women on ABVD and aged less than 30 years had higher AMH levels 
(>2 µg/L) as compared with women above 30 years old. The data lacks a 
longitudinal analysis and comparison with healthy volunteers and/or with 
hormone levels prior to treatment. The large number of patients studied gave 
definitive confirmation of the reduced gonadotoxicity of the ABVD regimen as 
compared to other regimens (Behringer et al., 2013a).  
Similarly, Decanter et al. (2010) measured AMH levels in a very young group of 
women (mean age 24), treated with ABVD and non-ABVD regimens for 
lymphoma. Serum AMH levels were measured prior to and up to 1 year after 
treatment. In the ABVD group n=17, AMH was found to be significantly higher 
than in the non-ABVD group n= 13 at 3, 6, 9 and 12 months of follow-up. 
Although the study was conducted on a small group of patients without specified 
inclusion criteria, it highlights the value of AMH measurements and once more 
confirms the lower gonadotoxicity of ABVD regimen (Decanter et al., 2010). 
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Di Paola et al. (2013) conducted a study of ovarian reserve tests amongst 
haematological cancer survivors compared with healthy volunteers. The study 
included 63 patients with various haematological conditions at remission 
between 1 and >11 years. It showed that ORTs results (FSH, AMH, AFC) were 
significantly different in the cancer group and healthy controls. Although the 
sample size is much higher than most of the studies presented earlier, concerns 
may be raised regarding the wide range of times when AMH was tested in 
relation to chemotherapy. Moreover some patients underwent total body 
irradiation which may have affected the AMH results (Di Paola et al., 2013) . 
Dillon et al. (2013) evaluated ovarian reserve markers including FSH, LH, E2 
inhibin B and AMH in a heterogeneous population comprising 46 women with 
different types of cancers including breast cancer, brain tumour, sarcoma and 
haematological malignancies. Patients receiving different types of 
chemotherapy were followed up every 3 months. The rate of post-
chemotherapy recovery of ovarian function was based on the estimated monthly 
recovery of AMH in two groups of patients with pre-chemotherapy AMH of ≤2 
ng/ml and ≥ 2 ng/ml. The research group concluded that the rate of recovery of 
AMH post-chemotherapy was associated with pre-chemotherapy levels of 
AMH. Those findings, if proven in a large well designed study, could provide a 
basis for AMH measurements during consultations about fertility preservation, 
although the heterogeneity of the population makes clinical application of results 
of this particular study difficult (Dillon et al., 2013). 
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Rosendahl et al. (2010) provided interesting data, in line with the above findings. 
The authors investigated 17 women with breast Ca or haematological 
malignancy before, during and up to 1 year after chemotherapy. It was shown 
that higher pre-treatment serum concentrations of AMH were predictive of 
higher post-treatment levels. It was also one of the first studies providing a 
description of acute hormonal changes during chemotherapy. The study 
provided interesting theories on the impact of chemotherapeutic agents on 
granulosa cells in the first week post chemotherapy, however, longitudinal data 
analysis of this study may be affected by the fact that most of the patients 
underwent unilateral oophorectomy prior to or after chemotherapy which itself 
lowered the ovarian reserve (Rosendahl et al., 2009). 
In patients with breast cancer, there is more substantial evidence for the 
usefulness of ovarian reserve tests, especially AMH. In his pioneer study, 
Anderson et al. (2006) included women with operable breast cancer aged 28-
52. The ORTs were performed before and 3, 6, 9 and 12 months after
chemotherapy. Amongst the recruited women, 42 received one of the four 
chemotherapy regimens (the remaining 14 had GnRH and/or Tamoxifen only). 
In the chemotherapy group, AMH fell rapidly during chemotherapy and 
remained low while inhibin B levels dropped only by around 50%. E2 levels were 
relatively well maintained while gonadotropins were significantly raised. AFC 
fell, but the changes remained modest. The authors concluded that their data 
confirmed the value of AMH as a marker of ovarian aging induced by 
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chemotherapy and its usefulness in assessing the degree of gonadotoxicity 
caused by different chemotherapeutic agents (Anderson et al., 2006a). 
In the study by Anders et al. (2008), a similar group of patients was recruited. 
Forty four menstruating women with operable breast Ca were examined prior 
commencement of chemotherapy; 32 of them had post-chemotherapy levels 
checked, with only 21 at final 12 month follow-up. The limitations of this study 
included the small samples size, large loss at follow-ups and heterogeneity of 
chemotherapy regimens. In summary, the study illustrated that pre-
chemotherapy concentrations of AMH and inhibin B are lower in women who 
subsequently develop chemotherapy-induced amenorrhea. The authors 
suggested that AMH could be used as a marker to assess individual risks of 
amenorrhea for patients undergoing chemotherapy (Anders et al., 2008).  
Yu et al. (2010) evaluated ovarian reserve markers in 26 women aged <40 with 
breast Ca prior to chemotherapy and follow-up for up to 52 weeks post 
chemotherapy. In contrast to the results provided by Anders et al. 2008 and 
Anderson et al. 2006, this research group did not find a correlation between pre-
chemotherapy AMH levels and the risk of chemotherapy-related amenorrhea 
(CRA) at the final 52 weeks follow-up. Both groups, women with CRA and 
menstruating women, had similar AMH levels prior to chemotherapy. Levels of 
E2 and FSH had plateaued at final follow-up while AMH levels remained lower 
as compared to pre-chemotherapy levels (Yu et al., 2010). 
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Su et al. (2010) enrolled women ~2 years post chemotherapy for breast Ca and 
measured AMH, FSH and inhibin B. The results were compared with an age-
matched control group. Overall, the treatment group was found to have lower 
AMH (p=00.4) and inhibin B (p<0.01) than healthy volunteers. Women who were 
still menstruating following chemotherapy were found to have higher AMH 
(p=0.03) than those who developed CRA. The researcher group postulated the 
use of AMH and inhibin B to predict post-chemotherapy ovarian function (Su et 
al., 2010). 
In a small study by Lutchman Singh et al. (2007), 8 patients (age 22-24) with 
breast Ca were recruited prior to chemotherapy and had FSH, E2, inhibin B, 
AFC/ovarian volume and AMH tested at baseline. Immediately following 
completion of chemotherapy, the ORTs were repeated. Although, AMH was 
found to be lower post-chemotherapy, the results did not reach statistical 
significance. Similarly, the differences in levels of the remaining biochemical 
markers did not reach statistical significance. The second cross-sectional arm 
of the study included healthy controls. FSH, AMH and inhibin B were found to 
be significantly different between women post-chemotherapy and the volunteer 
group. Additionally, the research group postulated use of dynamic ovarian 
reserve testing because baseline markers were found to be significantly 
different between post-chemotherapy patients and healthy controls (p<0.05) 
(Lutchman Singh et al., 2007).  
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In a study by Partridge et al. (2010), ovarian reserve markers including FSH, 
E2, inhibin B, AMH, AFC were evaluated in 20 breast cancer survivors and 
compared with 20 healthy volunteers. The inclusion criterion in the breast 
cancer group were that women were still menstruating post-chemotherapy (at 
least one menstrual bleeding since chemotherapy). The results confirmed a 
statistically significant difference in levels of biochemical markers of ovarian 
reserve and AFC between the two groups. It confirms that women who regain 
menstrual cycles post-chemotherapy may still have a diminished ovarian 
reserve. In this study, AMH and AFC were found to be the most sensitive 
markers of reduced ovarian reserve in the cancer population (p<0.0004) 
(Partridge et al., 2010a). 
Henry et al. (2014) examined ORTs in 27 women aged 25-50 with newly 
diagnosed breast cancer. Prior to chemotherapy, 19 out of 26 patients had 
detectable AMH. Additionally, 1 patient underwent bilateral oophorectomy and 
was excluded from follow-ups. Only 13% of patients had detectable AMH post-
chemotherapy. The authors concluded that older age and undetectable pre-
treatment levels of AMH are predictive of premature ovarian failure at 18 months 
of follow-up (Henry et al., 2014). 
In a prospective longitudinal study, Anderson and Cameron (2011) 
prospectively assessed ovarian function in women with breast cancer before, 
and 2, 3 and 5 years after chemotherapy. Pre-chemotherapy concentrations of 
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AMH were higher in women still menstruating at 5 year follow-up as compared 
to women reporting amenorrhea (2.5 ± 0.4 vs 0.7 ± 0.1 ng/ml, p< 0.0001). All 
participants with AMH less than 1.9 ng/ml prior to chemotherapy reported 
amenorrhea at final follow-up. A multivariate logistic regression model 
assessing the value of age and other ovarian reserve markers in the prediction 
of ongoing menses post-chemotherapy showed that only AMH was a 
statistically significant predictor (Anderson & Cameron, 2011). 
In his next study Anderson et al. (2013) prospectively examined AMH in women 
with breast cancer and followed them up for 2 years. The authors compared 
mean AMH in women with the return of menses (9 patients) versus women with 
no menses (30 patients) at their 2 year follow-up. Women with menses at follow-
up had statistically higher mean AMH pre-chemotherapy as compared to 
women with no menses. It is worth noting that all women had undetectable AMH 
at 1 year of follow-up (Anderson et al., 2013). 
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Figure 6 Methodological quality of studies included in the systematic review of 
ORTs in women treated with chemo/radiotherapy.- 
2.5 Discussion 
2.5.1 Summary of main findings 
There were only a limited number of studies, mainly small cross sectional and 
observational studies, assessing ovarian function in pre-menopausal women 
with malignancy undergoing gonadotoxic treatment. In all studies, ethical 
aspects and the rarity of the condition/exposure restricted the design and data 
collection. Overall, the selection criteria for the cancer populations were wide 
and not clearly specified in most of the studies. Chemotherapy regimens were 
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Clinical outcome
(menopause/pregnancy)
Sample size calculation
Prospective design
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Methodological quality of studies 
No or unclear Yes
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poorly described in some of the studies (e.g. no information about the 
cumulative dose of chemotherapy used or its duration, repeated courses of 
chemotherapy). The quality of the various studies was also affected by poor 
reporting in the respective methods’ sections. I found no agreed test(s) of 
ovarian reserve that could be used as a gold standard in the cancer population. 
Although AMH is the most widely recommended test, the timing of testing in 
relation to chemotherapy varied amongst the selected studies. 
None of the manuscripts correlated their ORT results prospectively with tangible 
outcomes such as premature menopause, pregnancy or live birth rates. The 
control groups varied in the studies and included healthy volunteers with proven 
fertility, cancer patients not receiving chemotherapy, or patients seeking fertility 
treatment for male factor infertility. Additionally there was no agreed time interval 
for when to assess or test the ovarian reserve in the context of cancer therapy. 
In summary, the results showed that there is no single widely agreed test of 
ovarian reserve or combination of tests in reproductive age women undergoing 
chemotherapy/radiotherapy, which might be used as a gold standard and 
producing results that would be reliable in predicting early menopause and 
chances of pregnancy. In this review, an accurate comparison of ovarian 
reserve tests and assessment of their accuracy for pregnancy or live birth 
prediction in cancer patients was not possible due to lack of data. Moreover, the 
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lack of consecutive recruitment and wide inclusion criteria make clinical 
interpretation and application of such results difficult.  
2.5.2 Limitations 
The clinical applications of such tests have been rare, and most of the published 
studies were pioneering. Published studies vary significantly in design and 
population selection which makes a synthesis of the results difficult. The ORT 
were measured within a wide window of follow-up periods (from weeks to 11 
years post-chemotherapy).  
2.5.3 Conclusion 
To date, the clinical application of ORTs has been rare. However, young women 
with cancer should be individually counselled about their treatment’s 
gonadotoxicity, the risk of early menopause and reduced ovarian reserve. Given 
the disparate evaluation of ORT in young women with cancers, it is timely that 
a rigorous prospective longitudinal study evaluating the different tests be carried 
out so that an accurate test or a combination of tests could be used in clinical 
practice.  
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Chapter 3 
3 Methodology 
3.1 Introduction 
In this chapter, I provide details of protocol development, followed by approvals 
and participants’ recruitment procedures. Next, the methodology used for assay 
of AMH in serum is described in detail together with the techniques used to 
assure quality in handling blood samples. Finally, the methods of data and 
record management are presented, and the statistical methods that were 
applied following expert advice from professional statisticians, Professor Nigel 
Stallard and Dr Nick Parsons, of Warwick Medical School.  
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3.2 Protocol development 
The protocol was developed following a review of the literature and having 
solicited expert opinion from a range of stakeholders, including patients.  
Stakeholders included Haematology and Oncology Consultants, especially Dr 
Fiona Clark based at University Hospitals Birmingham NHS Foundation Trust 
and Professor Chris Poole based at University Hospitals Coventry and 
Warwickshire NHS Trust (UHCW). We discussed the impact of the study on 
patients’ care, especially in the context of minimizing any form of intervention at 
the difficult time of cancer diagnosis. We planned follow-up blood samples 
according to the ‘routine’ follow-ups for cancer patients and decided that it would 
be best to avoid patients being asked to travel for additional tests (e.g. 
transvaginal ultrasound).  
As the study was funded by a private IVF clinic, we had to make sure that our 
project was not seen as an advertisement for fertility preservation services. 
Additionally, the study design was observational, and we aimed to assess 
current practice in the UK without increasing any fertility preservation 
interventions through participation in our study. 
I discussed with my Supervisors if I should be directly approaching and 
recruiting patients into the study. Due to the relative rarity of malignant 
conditions in young women, we agreed that it would be more practical and 
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would allow more patients to be recruited if I had support from research nurses 
at multiple sites. Therefore, I asked for support from the UK Clinical Research 
Network (UKCRN). In order to include my study into the UKCRN portfolio, I 
needed support from the Breast Cancer Studies Group first. I was invited to 
attend their meeting in London (meeting protocol CSG/BC 10/41) where the 
following particular issues were discussed.  
 The need to limit the number of different chemotherapy regimens, where
possible, to allow subgroup analysis of the data.
 The control group should consist of healthy volunteers, as distinct from
patients with fertility problems.
 Restricting the study to mainly breast cancer and lymphoma would
improve statistical analysis and reduce heterogeneity. In the final version
protocol, I included mainly breast cancer and lymphoma patients,
however the participation of patients with other malignancies (e.g. other
haematological conditions) was allowed due to the pioneering character
of the study in the UK. Rare cases of other cancers and the impact on
fertility of their treatment could be reported as case studies/case series
which could provide initial information for future research in this field.
I conducted multiple presentations about the research project for oncology 
nurses.  The nurses raised some additional points (e.g. not repeating the same 
question about number of pregnancies with each medical questionnaire at 6, 9 
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and 12 month follow-ups because patients undergoing chemotherapy may find 
it inappropriate to be asked sensitive questions repeatedly). Therefore, I 
requested an amendment so that the question about pregnancy was asked at 
the time of recruitment and at 12 month follow-up only.  
Further changes to the study design were a result of discussions at my 
upgrading meeting (as per University regulations, the initial registration of 
research degree students is for a masters degree). Professor Janet Dunn, who 
was the expert present at my upgrade, suggested that for the longitudinal 
observational design of the study, the most appropriate ratio of patients to 
controls would be 1:2. Therefore, I contacted the R&D Department and the 
research nurses at UHCW, requesting additional support with recruitment of 
volunteers, to increase the numbers and improve age matching between cases 
and controls. 
The stakeholders agreed that there was a need for more studies in the field of 
oncofertility in order to improve information counselling prior to chemotherapy 
and to assess the risk of infertility and early menopause post chemotherapy. 
Most of the clinicians (Principal Investigators) thought that women generally 
wished for more accurate and detailed information tailored for themselves as 
individuals prior to chemotherapy.  
The majority of the cancer patients who were consulted prior to the study 
recruitment stage said that having an additional blood sample taken before and 
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after chemotherapy to check hormone levels would not be too invasive or 
interruptive at this difficult and busy time of cancer diagnosis. However, some 
of them felt that travelling to an IVF unit for transvaginal ultrasound scanning of 
the ovaries for research purposes only, would not be appropriate.  
 An independent peer review was obtained from Professor Richard Anderson, 
University of Edinburgh, an expert in the field of oncofertility. One of the main 
points he discussed was supporting the decision not to exclude women with 
endocrine pathology (I was planning to exclude women with e.g. thyroid 
problems), but instead obtaining information on any medical conditions via 
questionnaire.  
All of the above was discussed during meetings with my clinical and academic 
supervisors. The implemented changes were fed back to the oncology and 
haematology teams. The acceptance of the study protocol and the involvement 
of a number of regional oncology and haematology teams was widely discussed 
over a 10 month period Appendix 2 (study protocol version 5).  
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3.3 NHS Research Ethics Committee approval 
At the time of my application for ethical approval, the Integrated Research 
Application System on line (IRAS) had recently been introduced (IRAS project 
ID 12828). The on-line application form completed by myself included questions 
on the research and its design, ethical issues, research procedures, risks and 
benefits, details of recruitment, management and informed consent. 
The project was evaluated by Warwickshire Research Ethics Committee, and 
its view was that cancer patients should not be given the results of their AMH 
tests because the assay was not validated for this particular group of patients. 
Additionally, an abnormal result following chemotherapy could cause stress in 
cancer patients. Additionally, a drop in AMH levels during or immediately after 
chemotherapy may be transient and could recover with time.  
Pending minor changes in the Oncology Team Form and consent form, 
conditional approval was granted by the Ethics Committee. Final confirmation 
was received on 01/12/2009. 
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3.4 R&D approval and UKCRN Portfolio approval 
Once ethical approval had been granted, R&D approval was sought for each 
research site. This process proved to be time consuming because of recent 
centralisation of R&D approvals. As a result, many research nurses and/or 
Principal Investigators (PIs) were not familiar with IRAS site-specific information 
(SSI) forms. In order to expedite the R&D approval process, I completed draft 
SSI forms for each R&D site.  
I approached and met the PIs on each of 13 sites and discussed details of 
recruitment as well as the protocol. The sites and PIs were as follows:  
 Dr Fiona Clarke, Dr Andrea Stevens (Good Hope Hospital, The Heart of 
England NHS Foundation Trust and Queen Elizabeth Hospital, 
University Hospitals Birmingham NHS Foundation Trust),  
 Dr Guy Pratt (Heartlands Hospital, The Heart of England NHS 
Foundation Trust),  
 Professor Christopher Poole (University Hospital, University Hospitals 
Coventry and Warwickshire NHS Trust),  
 Dr Rozenn Allerton (New Cross Hospital, The Royal Wolverhampton 
NHS Trust and Russells Hall Hospital, The Dudley Group NHS 
Foundation Trust),  
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 Miss Raghavan Vidya (Stafford Hospital, Mid Staffordshire Foundation 
Trust),  
 Dr Jane Worlding (George Elliot Hospital NHS Trust),  
 Dr Shazza Rehman (Airedale General Hospital, Airedale NHS 
Foundation Trust),  
 Mrs Lynda Wagstaff (Walsall Manor Hospital, Walsall Hospitals NHS 
Trust),  
 Mrs Jan Dodge (The Great Western Hospital, The Great Western 
Hospitals NHS Foundation Trust),  
 Mrs Rebecca Foster (Pinderfields Hospital, Mid Yorkshire Hospitals NHS 
Trust), 
 Dr Fiona Clark (Worcestershire Royal Hospital, Worcestershire Acute 
Hospitals NHS Trust),  
 Dr Gillian Lockwood (Midland Fertility, Tamworth). 
At the same time, I started the process of including my study into the UK Clinical 
Research Network Study Portfolio (UKCRN). As mentioned before, malignant 
conditions are relatively rare in young women. Therefore, it was important to 
recruit across several centres. NHS Portfolio approval was essential to obtain 
support from research nurses and help with recruitment. The NCRI Breast 
Cancer Studies Group supported the project and subsequently my study was 
included in the UK Clinical Research Network (UKCRN) Portfolio. An NIHR 
Clinical Research Network Portfolio account was set up for details to be viewed 
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by the public or other research teams under number UKCRN: 8445. The study 
trial registration number is: International Standard Randomised Controlled Trial 
Number Register: ISRCTN28988709 
I attended a course on Good Clinical Practice for Chief Investigators (CI) at the 
University of Warwick. Since all students are registered as Masters Students for 
their first year, I could not become a CI (University of Warwick regulations). My 
supervisor, Professor Geraldine Hartshorne assumed the role of CI, allowing 
me to be relatively independent in coordination and administration of the project.  
3.5  Training of trial centre staff 
When all approvals were in place, I conducted training sessions for all the 
research nurses on AMH and ovarian reserve. I also discussed the details of 
recruitment. The main points included, for example, log books, transport of 
samples in a timely manner and the need for completion of the medical 
questionnaire at the time of the blood test. I provided folders including flow 
charts, recruitment charts, the study protocol and general information on AMH. 
The research teams on each site were provided with research packs which 
included an instruction letter, medical questionnaire, MFS blood analysis 
request form, blood tube, plastic bag (DGP PATHOSEAL), boxes for safe 
transport of biological substances (biological substance category B, UN3373), 
pre-paid envelopes and oncology team forms.  
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I discussed the need for timely follow-ups with each research nurse and PI. It 
was agreed that breast cancer patients would have routine follow-ups at 6, 9 
and 12 months in most centres, which was why these intervals were selected 
for my protocol. In general, haematology teams tended to see patients more 
frequently for their follow-ups and the exact dates are decided on an individual 
basis. The haematology teams agreed to follow the same protocol for follow-
ups as the breast cancer teams. I encouraged each team to have a system in 
place to remind them about follow-ups. 
To minimize any burden of additional appointments for participants, 6 weeks 
leeway for appointments was accepted.  
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3.6 Study design 
A prospective cohort study design was used to measure the effect of 
chemotherapy on ovarian function over 5 years. However, for this thesis, the 
assays and analysis of AMH have been performed over a shorter period (1 
year), in keeping with an MD time scale. I plan to follow up the research 
participants for at least 5 years, to assess their post-chemotherapy fertility, using 
pregnancy, live birth and early menopause as end points for the whole project. 
Serum AMH was measured in patients before starting the treatment with 
potentially gonadotoxic chemotherapy and at follow-up intervals of 6, 9 months 
and 1 year. The results were compared with an age-matched group of healthy 
control women without known fertility problems. 
The following eligibility criteria were applied:  
 Patients aged 18-43 with newly diagnosed cancer, prior to any 
chemotherapy/radiotherapy  
 For the control group, volunteer women of the same ages were recruited, 
without known significant medical problems or previous exposure to 
chemotherapy/radiotherapy 
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The following exclusion criteria were applied: 
 Previous chemotherapy/radiotherapy 
 Age below 18 
 Age above 43 
 End stage cancer patients with very poor prognosis 
 Known significant ovarian pathology 
Patients over the age of 43 were excluded because they were reaching the end 
of their reproductive life and had reduced prospects of pregnancy (less than 5%). 
Patients with a poor prognosis (less than 10% chance of 1 year survival) might 
find it inappropriate to be asked to take part in a project which assesses their 
potential future fertility. The oncology teams had flexibility (based on their 
experience and clinical judgement) to decide when to approach patients. Women 
with known significant ovarian pathology were excluded because it might prove 
difficult to distinguish the effects of chemotherapy from the natural progression of 
ovarian pathology. Women with known PCOS (or PCOS diagnosed as a result of 
participation in our study) or oophorectomy were not included in the analysis. 
Information on any additional medical conditions was collected via medical 
questionnaire and the oncology team form. The latter was completed by PIs or 
research nurses directly from the patients’ medical records. 
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3.7 Recruitment  
3.7.1 Multicentre recruitment of cancer patients 
Female patients meeting the eligibility criteria, who were about to proceed with 
chemotherapy, (mainly with breast Ca and lymphoma) were identified by 
participating oncology and haematology research teams within the West 
Midlands and Yorkshire. An information leaflet describing the study and its 
objectives was circulated to all prospective patients by oncology teams 
Appendix 3 (Patient/volunteer information leaflet and consent form). A 
consent form and a medical questionnaire including obstetric and 
gynaecological history, were completed in the oncology clinic together with a 
research nurse. Alternatively, patients were requested to complete the forms at 
home and return them using pre-paid envelopes.  
Data collected from the medical questionnaire included: age, regularity of 
menstrual cycles, parity, history of gynaecological or fertility problems, family 
history of early menopause, body mass index (BMI), smoking habits, hormonal 
contraception and medications Appendix 4 (Medical questionnaire/Follow-
up medical questionnaire). An additional question was asked about patients’ 
wishes for pregnancy. Patients described their desire for pregnancy on a scale 
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from 1-4 (1–no, 2-neutral, 3-maybe, 4-strong). Patients were given the option to 
write comments. 
All site PIs and research nurses who were direct patients’ clinicians, provided 
written information on the number of patients who were referred to a specialist 
for discussion about fertility preservation options. Additional information on the 
type and stage of cancer, dose, duration, and the number of courses of 
chemotherapy and radiotherapy was provided by the oncology teams from the 
medical records. All participants had a blood sample taken together with a 
detailed questionnaire before starting any chemotherapy. 
Recruitment of the first patients began in UHCW and QE in the last week of May 
2010, while the R&D approval process continued in other centres. The last R&D 
approval was obtained on 20th August 2011 for Pinderfields Hospital (Mid 
Yorkshire). 
3.7.2 Recruitment of volunteers 
An age-matched control group was recruited into the study in order to compare 
the changes in AMH levels between patients undergoing chemotherapy and 
those receiving no gonadotoxic treatment over the same period.  
The control group consisted of healthy, reproductive age women, aged 18-43 
years, who responded to an advertisement at UHCW. The advertisement was 
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conducted via intranet following approval from Trust R&D and Medical Director. 
More detailed information about the study was given verbally by research 
nurses at UHCW and by providing a written information leaflet. Volunteers 
wishing to proceed were asked to complete a consent form.  
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3.7.3 Provision of results to volunteers 
Following the initial submission to NHS REC, a new, second generation AMH 
assay was for the first time registered for diagnostic use. The previous, first 
generation assay had been registered for research use only. Following 
discussion with my supervisors, I submitted an amendment, approved on 
05/03/2011, allowing the AMH results to be disclosed to healthy volunteers only. 
As agreed earlier at the ethics committee meeting, AMH results were not 
provided to cancer patients because the assay was not validated for that 
particular group.  
The results letter for volunteers was approved by the UHCW R&D department, 
following discussion with the local research nurses, specialists in Reproductive 
Medicine, and Consultant Obstetrician and Gynaecologist, Mr Tarek Ghobara. 
In order to support the volunteers in dealing with abnormal AMH results, the 
following protocol was agreed with UHCW R&D: 
 Volunteers wishing to discuss their results contacted the research nurse,
who passed their details to the CI, Professor Hartshorne.
 Professor Hartshorne contacted those in receipt of an abnormal result to
discuss their concerns and to offer them the opportunity to be referred to
an Infertility Specialist, for further investigations.
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 If required, an appointment with Mr Tarek Ghobara, Consultant
Obstetrician and Gynaecologist, was arranged at the Centre for
Reproductive Medicine at UHCW, after prior agreement by the
volunteer’s GP. During that consultation, the woman had the opportunity
to discuss the implications of the abnormal AMH results and if necessary,
additional blood tests and a transvaginal ultrasound scan were offered,
to further investigate the ovarian reserve. Reassurance was provided,
and a course of action was discussed and documented. Where
appropriate, the GP was provided with guidance on further management.
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3.8  Data and record management 
Upon arrival at the MF Laboratory, identifiable data about the participants 
(name, date of birth, address, and contact telephone number) were recorded on 
a separate (paper based) database and a unique research reference number 
was applied to each blood sample. Identifiable data were stored in the MF 
medical records area and were accessible only by responsible persons in 
connection with the research. Anonymised clinical data were analysed and 
stored on a University of Warwick database. A log book at each research site 
was completed by the PI and dedicated research nurse. 
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3.9 Blood sample handling and assay methodology 
All participants underwent venepuncture at an unspecified time of the menstrual 
cycle. Cancer patients had their samples obtained before the first dose of 
chemotherapy. Whole blood was collected in serum tubes and sent to MFS by 
first class post. Samples that arrived more than 48 hours after collection were 
not used, and venepuncture was repeated if possible. Samples were processed 
on the day of receipt, rendered acellular by centrifugation and then the serum 
was stored in 3-4 aliquots at -20°C. The cellular fraction was discarded. Serum 
aliquots were thawed on the day of analysis. AMH was measured according to 
MFS protocol LO77 using the AMH Gen II assay. MF is an approved laboratory 
for AMH assay, and regular quality checks were performed. Each assay 
procedure included both AMH Gen II ELISA (enzyme-linked immunosorbent 
assay) controls and independent external controls provided by the Assay and 
Control Company Ltd. Controls were used across the plate to assure quality for 
all samples measured with each kit. Researchers and laboratory personnel 
were blinded to either patient clinical progress or AMH concentration. The 
results were not used to manage the patients. 
Blood samples (biological substance, category B) sent by first class post from 
any of the 13 centres, were normally received at MFS within 24 hours. In rare 
cases of delay (more than 48 hours), the research nurse was contacted to 
request a repeat sample. 
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During the initial phase of recruitment, I was actively involved in handling the 
samples and performing AMH assay at the MF laboratory. In the later stages of 
my study, I concentrated on coordinating sample arrival, administrative tasks 
related to blinding, filing of patients’ consent forms, medical questionnaires and 
oncology team forms and transferring data to electronic database. During this 
period, assays were performed by Jo Milner and Lynne Harrison (Biomedical 
Scientists at MF Laboratory). For each assay, a full calibration curve, high and 
low level controls were documented, and a summary results form completed. 
3.10 Changes in AMH assay methodology 
For the purposes of this study, all participants’ samples were analysed using 
Beckman Coulter Active AMH Gen II ELISA assay. At the initiation of the study, 
this assay had replaced the discontinued DSL Active AMH ELISA assay (first 
generation). The second generation assay used the same antibodies but was 
CE marked and intended for in vitro diagnostic use. Second generation assay 
values were 40% higher than the DSL assay as confirmed in a multicentre study 
(Wallace et al., 2011). 
Sometime later, a field safety notice, FSN 17971, was issued by Beckman 
Coulter (November 2011), recommending a change from linear to cubic 
regression curve fit protocol for reporting AMH values. In response, 74 study 
samples were re-analysed using both regression plots. The results for cubic 
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regression were found to be 12% lower than linear regression. Therefore, all 
ranges were recalculated Appendix 5 (Linear versus cubic regression 
models). 
A second safety field notice was issued in June 2013 when all the study samples 
were already analysed, and statistical analysis was being undertaken. The 
report suggested that results using the second generation assay may be lower 
than expected due to complement interference. The company provided 
instructions for a modification of the protocol including an initial ‘dilution’ step.   
Following this safety notice, I conducted a pilot study assessing the correlation 
between the new ‘diluted protocol’ (adding 300 µl of assay buffer prior to sample 
analysis) and old method using selected study serum samples (ensuring that 
the samples of serum analysed had not previously been thawed). It showed that 
the new method of analysis gave consistently higher AMH results than the 
previous method but fixed corrective additive adjustment would be sufficient 
Appendix 6 (Comparison of two methods of AMH assay). Eventually, 
following discussion with a representative of Beckman Coulter, my supervisors 
and a statistician, all the study samples were re-analysed in duplicate using the 
new diluted protocol to assure reliability of the study results.  
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3.11 Assay methodology 
Below, I have described the final assay methodology used in this dissertation. 
The AMH assay was a sandwich enzyme linked immunoassay. The 
microtitration wells were coated with anti AMH antibody which bound the AMH. 
A second biotin labelled antibody bound to the AMH at a different site. 
Streptavidin enzyme conjugate attached to the biotin which acted as a catalyst 
when the tetramethylbenzidine (TMB) substrate was added. The addition of 
stopping solution terminated the reaction due to acidification. Dual wavelength 
absorbance measured at 450 nm and 600-630 nm was proportional to the AMH 
concentration. The calibration curve of absorbance was plotted against AMH 
concentrations. 
The first step was to allow the contents of the reagent kit, calibrators, controls 
and samples to reach room temperature. Following preparation of the 
worksheet recording batch numbers and conducting the necessary checks, 
dilution of 60 µl of calibrators, controls and samples with 300 µl of assay buffer 
into labelled centrifuge tubes took place (pre-dilution was the new step added 
following safety notice REF 79765). In the next step 120 µl of diluted standards, 
controls and samples were added and incubated on the plate shaker at 600rpm 
at room temperature for 1 hour. The procedure was repeated a total of 5 times. 
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Subsequently, 100 µl of the antibody-biotin conjugate was added to each well 
and incubated on the shaker for 1 hour, as before. After that, 100 µl streptavidin-
enzyme conjugate was used, following incubation on the shaker for 30 min 
before the next wash. Final steps included adding 100 µl of TMB chromogen 
solution and incubating as before for no longer than 7 min and using forward 
pipetting to improve mixing of 100 µl of stopping solution. After stopping the 
reaction with sulphuric acid, the degree of enzymatic turnover of the substrate 
was evaluated using a spectrophotometer. All steps and timings were recorded. 
3.12 Assay Characteristics 
The characteristics outlined below are based on work by Kumar et al., 2010 on 
the development of the second generation AMH assay. 
The limit of detection, described as the lowest amount of AMH in a serum 
sample, which could be detected with a 95% probability, was 0.08 ng/mL (0.57 
pmol/L). The limit of quantification (also called the functional sensitivity) i.e. the 
lowest dose that could be measured quantitatively, was 0.16 ng/mL (1.14 
pmol/L) (Kumar et al., 2010). 
There was no evidence of cross reactivity between AMH and FSH, LH, inhibin 
A, activin A found in an experimental pilot study (Kumar et al., 2010). 
Interestingly, human antispecies antibodies have been reported to interfere with 
first generation immunoassays, by generating false positive results. This could 
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be particularly important in patients with breast cancer taking Herceptin 
(monoclonal antibodies) and could generate unusually high results in this group 
of patients. To avoid the problem, in the second generation assay heterophilic 
blockers were used (Kumar et al., 2010).  
When I was setting up the study, there was little information published on the 
optimal handling of samples to ensure the stability of AMH measurements. 
Therefore, I conducted a pilot study on sample handling which is presented in 
Chapter 4, Results.  
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3.13 Statistical methods 
Initial statistical support for the study design and power calculation was provided 
by Prof Nigel Stallard, Professor of Statistics, Warwick Medical School. 
3.13.1 Power calculation 
The power calculation was performed based on the sample size and previously 
reported mean AMH levels (±SD). The calculation was performed using the 
online power calculator http://www.quantitativeskills.com recommended by the 
University of Warwick. The calculation was based on the estimated study 
sample (50 cancer patients, 100 volunteers). The sample mean was derived 
from published papers (Anderson et al., 2006b; Steiner et al., 2011). Based on 
the study sample size, with 80% power and alpha error of 0.05, the study was 
powered to detect a difference in AMH levels of 0.14ng/ml and to detect a 
difference of 0.16ng/ml with 90% power. 
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3.13.2 Statistical Analysis 
Final analysis of the AMH assay results was performed with assistance from Dr 
Nick Parsons from the Statistics and Epidemiology Group at Warwick Medical 
School. Statistical analysis was conducted using R freeware by Dr Parsons. I 
have performed the more basic statistical analysis using SPSS. 
The mean ages of the control and cancer groups were calculated. As some 
cases did not have exactly age-matched controls, following discussion with Dr 
Parsons, the decision was made to analyse data as an unmatched case control 
study and adjust for age imbalance during the statistical analysis.  
The AMH levels were log transformed to normalise a right skewed distribution. 
Continuous variables were compared using the Tukey multiple comparisons of 
means while categorical variables were presented as a proportion and 
compared using Pearson’s Chi-squared test.  
A logistic regression model was built where the outcome (dependant variable) 
was used as an indicator for the groups: cases and controls. The univariate 
analysis allowed the selection of statistically significant variables (p<0.05) and 
construction of multiple logistic regression models adjusting for any confounding 
factors. The decline in AMH concentration with age in three subgroups: 
volunteers, breast cancer and lymphoma patients, was presented using fitted 
regression models. Boxplots were used to present log transformed AMH 
concentrations in relation to the stage of breast cancer. 
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A prediction model was built to estimate differences in serum AMH 
concentrations between the healthy volunteer group and the cancer patients 
according to their age at the point of recruitment.  
For the longitudinal part of the study, a paired t-test was used to compare values 
between baseline AMH concentrations and follow-ups in both groups. The 
recovery of ovarian function post chemotherapy was presented as a percentage 
of detectable serum AMH in each group. A Pearson correlation coefficient was 
used to examine if pre-chemotherapy levels of AMH were associated with levels 
post-chemotherapy.  
Assessment of cancer patients’ desire at different stages of treatment to have 
children was analysed descriptively and presented as percentages.  
McNemar test was used to test whether the level of desire to have children had 
changed during the follow-up period amongst cancer patients. 
For the final part of the analysis, serum AMH concentrations in the healthy 
volunteer group were examined in the context of stages of the menstrual cycle, 
contraception use, BMI and smoking status by using linear regression model. 
Reliability of AMH assay was tested by using the coefficient of variation.  
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Chapter 4 
4 Results: assay validation and sample handling 
4.1 Introduction 
Sample handling and storage for AMH were not described in detail in the assay 
manufacturer’s instructions. Setting up a multicentre study, which required 
transportation of samples between sites, raised the question of reliability of 
results if blood samples were not processed immediately. Therefore, the first 
step of my study was to conduct a pilot study for assay validation and sample 
handling. Further, I provide details of patient and volunteer demographics 
including past gynaecological history, menstrual cycles, contraception, smoking 
status, BMI and family history of early menopause. The first part of my data 
analysis was focused on serum AMH concentration in the healthy population 
and those with a diagnosis of cancer at point 0. Next, longitudinal data on AMH 
was examined to assess its potential value as an ovarian reserve marker in 
young female cancer patients. Finally, I analysed changes in AMH levels in 
association with menstrual cycles, parity, hormonal contraception, BMI and 
smoking status. 
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4.2 Assay validation 
I personally performed a pilot study in order to optimise and validate the planned 
procedures for serum assay after collection of blood samples at each site. This 
validation was performed using the DSL assay which was the only AMH assay 
available at the time. The ultrasensitive AMH/MIS ELISA was performed as per 
manufacturer instructions (Active MIS AMH ELISA, PCL-10-14400A-Beckam 
Coulter, Inc performing a DSL 10-14400 AMH assay). The lowest detectable 
level of MIS/AMH distinguishable from zero with 95% confidence was 0.06 
ng/ml as determined by the manufacturer.  
The intra-assay precision of active AMH/MIS ELISA has been calculated from 
two different AMH concentrations by assaying two serum samples 8 times 
(duplicate 4 times) within the same assay. 
Table 6 The intra-assay precision of active AMH/MIS ELISA in MF Laboratory 
Serum sample 
(low and high in 
house controls) 
N=times 
tested 
Mean 
(ng/ml) 
Standard 
deviation 
(ng/ml) 
Coefficient of 
variation (%) 
1 8 0.5 0.01 2 
2 8 7.2 0.07 0.97 
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The inter-assay coefficient of variation was also determined for two different 
AMH concentrations by assaying two serum samples in duplicate in 15 
independent assays  
Table 7 The intra-assay precision of active AMH/MIS Elisa in MF Laboratory 
Serum 
sample 
N=times 
tested 
Mean(ng/ml) Standard 
deviation(ng/
ml) 
Coefficient of 
variation (%) 
1 15 1.27 0.12 9.4 
2 15 4.89 0.45 9.2 
Following the introduction of the new assay the intra and inter-assay precision 
was determined for AMH second generation Elisa with a detection level of >1.2 
pmol/L.  
The intra-assay precision of active AMH second generation Elisa has been 
calculated from two different AMH concentrations (low and high) by assaying 
two serum samples 8 times (duplicate four times) within the same assay. The 
inter-assay coefficient of variation was also determined for two different AMH 
concentrations by assaying two serum samples in duplicate in 11 independent 
assays run on different days. 
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Table 8 The intra-assay precision of AMH second generation ELISA in MF 
Laboratory. 
Serum sample 
(low and high in 
house controls) 
Number of 
times tested 
Mean 
(ng/ml) 
Standard 
deviation 
(ng/ml) 
Coefficient of 
Variation (%) 
1 (low) 8 2.635 0.05 2 
2 (high) 8 6.689 0.228 3.4 
Table 9 The inter-assay coefficient of variation of AMH second generation 
ELISA in MF Laboratory. 
Serum sample Number of 
times tested 
(in duplicates) 
Mean 
(ng/ml) 
Standard 
deviation 
(ng/ml) 
Coefficient of 
Variation (%) 
1 11 2.673 0.15 5.6 
2 11 7.068 0.408 5.7 
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4.3 Conclusion 
The intra and inter-assay precision was found to be within recommended 
values. The second generation assay had higher intra and inter-assay precision 
as compared with DSL assay. Ongoing monitoring of inter-person, intra assay 
and inter-assay precision have been conducted during the duration of the study. 
The external quality assurance scheme is performed by UK NEQAS.  
4.4 Pilot study on sample handling 
4.4.1 Introduction 
AMH is a known marker for ovarian reserve, frequently assayed as part of sub-
fertility investigation and treatment using commercial assay with a standardised 
assay technique. It is not clear how the initial sample handling, storage 
temperature, delay in processing can affect final results. There is no agreed 
standard methodology for AMH sample storage, and there are no guidelines 
which hinders the comparison of results between different clinical and research 
laboratories. The assay manufacturer recommends storage of samples in a 
tightly stoppered container for no longer than 24 hours. In some situations, this 
may not be practical e.g. when there is not a batch of samples be analysed or if 
transferred to a laboratory some distance away from the clinics where samples 
were obtained. If equivalent results were observed, e.g. after thawing freshly 
frozen serum samples, this shortcoming could be overcome. To address those 
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uncertainties, I performed a pilot study comparing serum AMH measurements 
in different storage condition of blood samples obtained from 15 volunteers. 
4.4.2 Methods 
Institutional review board agreement was obtained for this pilot study. Fifteen 
consecutive healthy volunteers provided blood specimens via venepuncture for 
AMH assay. Two identical blood samples were obtained from each volunteer 
on one occasion, without consideration of the individual’s menstrual cycle. One 
fraction of serum was stored at room temperature (20°C) only and the second 
was frozen at-20°C in three different time frames: immediately after 
venepuncture, 24 hours after venepuncture and 48 hours after venepuncture. 
The frozen specimen was thawed gradually at room temperature, and AMH 
assay was performed when the specimen had completely defrosted and been 
thoroughly mixed as per manufacturer instructions. In summary, the samples 
were analysed under 5 different storage conditions for each participant: within 
2 hours from venepuncture as per manufacturer instructions (storage at room 
temperature only); after 24 hours (storage at room temperature only); following 
immediate freezing after venepuncture; following freezing after 24 hour storage 
at room temperature; following freezing after 48 hour storage at room 
temperature.  
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The mean serum concentrations of AMH in blood samples processed 
immediately and after 24 hours storage at room temperature were compared 
using paired t-test (STATA 8.2). 
4.4.3 Results 
The mean age of women who provided the samples was 37.8 (range 20.6 - 
45.2), and their mean parity was 1.2 (range 0 - 3). All of them were Caucasian, 
Mean BMI was 24.6 (range 19 – 32). 33% (5/15) of them were smokers, and 
60% (9/15) of them use combined hormonal contraception.  
The changes in AMH serum concentration in 5 different storage conditions for 
each participant were plotted on the graph below (Figure 8). The mean 
concentration of AMH in freshly frozen serum was 1.48 ng/ml (immediately after 
venepuncture) and at 24 hours of whole blood storage AMH was 1.719 ng/ml. 
Paired t-test did not show a statistically significant difference (p=0.82) between 
the concentrations of AMH for samples stored using either method (Figure 9).  
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Figure 7 Repeated AMH concentrations in different samples storage conditions 
 (axis y–serum AMH measurements in ng/ml, axis x–sample storage 
conditions).
Figure 8 Comparison of serum AMH concentrations under five different storage 
conditions. 
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1. within 2 hours from venepuncture as per manufacturer instructions
2. after 24 hours storage in room temperature only
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Figure 9 Comparison of AMH concentrations (ng/ml) measured in 2 different 
storage conditions: serum frozen immediately after venepuncture (sample 
frozen immediately) and whole blood stored for 24 hours at room temperature 
before processing (storage at room temperature for 24 hours). Paired t-test did 
not show a statistically significant difference (p=0.82) between the mean 
concentrations of AMH for samples stored using either method. Boxes 
represent the interquartile ranges (IQR), horizontal bars within the boxes 
represent the medians, and whiskers represent the lowest / highest data points 
within 1.5 IQR of the lower/upper quartiles. 
S
e
ru
m
 A
M
H
 c
o
n
c
e
n
tr
a
ti
o
n
s
 i
n
 n
g
/m
l 
      Samples frozen immediately  Samples stored in room temperature for 24 
h
141 
4.4.4 Conclusion 
The two analysed methods of storage including freezing the serum samples 
immediately after venepuncture and after 24 hour storage of full blood at room 
temperature were broadly comparable. Small differences in actual results would 
not affect AMH-guided clinical decisions in the assisted conception setting and 
would indicate that transfer of samples from distant Laboratory for AMH testing 
should be an acceptable method in my research setting. Additional 
measurement of samples frozen after 48 hours from venepuncture, have been 
higher but did not reach statistical significance. Further validation studies using 
a larger population at a variety of temperatures would be valuable unless an 
agreed storage procedure for samples transferred from distant Laboratories or 
IVF units is established by a relevant national or international body. 
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Chapter 5 
5 Results: Demographics in cancer patients and 
healthy volunteers 
5.1 Introduction 
A total of 68 patients between the ages of 18 and 43, recently diagnosed with 
malignancy, were recruited into the study. The majority of participants, 54/68 
(79.4%) were diagnosed with breast cancer. The second large group, 12/68 
(17.6%) were women with haematological conditions, namely Hodgkin 
Lymphoma (HL) and non- Hodgkin Lymphoma (NHL). Two patients: one with 
adenocarcinoma of the caecum and one with Ig kappa myeloma were not 
included in the main analysis 2/68 (2.9%).  
The volunteer group comprised 130 healthy women aged between 18 and 43 
years, with no previous history of exposure to chemotherapy. Women with a 
confirmed history of polycystic ovarian syndrome (PCOS) or diagnosed with 
PCOS as a result of this study were not included in the analysis. Thus, 6/130 
(4.6%) volunteers were excluded.  
Overview of participants’ demographics and past medical history is presented 
below. Overall, a group of women diagnosed with cancer had higher parity as 
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compared with controls (Table 10). A similar percentage of women in both 
groups reported a family history of early menopause (‘first line relative’). In the 
cancer group, only 4.4% of women were using combined oral contraceptive pill 
while in the control group nearly 18% (Table 11). No data were available on the 
duration of contraception. In the group of women recently diagnosed with cancer 
the preferred form of contraception was Mirena coil. While combined oral 
contraceptive pill was the most commonly used form of hormonal contraception 
in healthy volunteers. Obesity (BMI >30) was noted in 13.4% of cancer patients 
and 14.4% of control group respectively. A higher percentage of active smokers 
was noticed in the cancer group (Table 12). 
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5.2 Overview of participants’ demographics 
Table 10 Past obstetric and gynaecological history in volunteers and cancer 
patients including age at menarche, family history of early menopause, parity. 
Age of menarche Case n (%) Control n (%) 
Below age of 9 0/68 0/130 
Below 11 2/68 (2.9%) 6/130 (4.6%) 
11-15 62/68 (91.1%) 118/130 (90.7%) 
16 and above 2/68 (2.9%) 5/130 (3.8 %) 
Not stated 2/68 (2.9%) 1/130 (0.7 %) 
FH of early menopause (first 
line relative) 
Case n (%) Control n (%) 
Yes 5/68 (7.3%) 7/130 (5.3 %) 
No 61/68 (89.7%) 119/130 (91.5 %) 
Not stated 2/68 (2.9 %) 4/130 (3 %) 
Parity Case n (%) Control (%) 
Nulliparous 21/68 (30.8%) 71/130 (54.6%) 
Para 1 14/68 (20.5%) 22/130 (16.9%) 
Para 2 20/68 (29.4%) 30/130 (23%) 
Para ≥3 13/68 (19%) 7/130 (5.3%) 
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Table 11 Type of contraception used and timing of the natural menstrual cycle 
at the time of the blood test in non-users in both volunteers and cancer patients. 
Type of contraception Case n (%) Control n (%) 
Mini-pill 3/68 (4.4%) 3/130 (2.3%) 
Combined oral contraceptive pill 3/68 (4.4%) 23/130 (17.6%) 
Mirena coil 8/68 (11.7%) 14/130 (10.7%) 
Implanon 2/68 (2.9%) 10/130 (7.7%) 
Depo-Provera injections 2/68 (2.9%) 2/130 (1.5%) 
Unknown 1/68 (1.5%) 6/130 (4.6%) 
No hormonal contraception 49/68 (72%) 72/130 (55.3%) 
Time of natural menstrual cycle    
Follicular phase 19/68 (27.9%) 32/130 (24.6%) 
Mid-menstrual cycle 11/68 (26.2%) 6/130 (4.6%) 
Luteal phase 18/68 (26.2%) 30/130 (23%) 
Not known 1/68 (1.5%) 4/130 (3.0%) 
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Table 12 Body mass index and smoking status at time 0 in volunteers and 
cancer patients. 
Body mass index Case n (%) Control n (%) 
Below 18.5 3/68 (4.4%) 3/130 (2.3%) 
18.5-24.9 34/68 (50%) 61/130 (46.9%) 
25-29.9 18/68 (26.4%) 46/130 (35.3%) 
30-34.9 3/68 (4.4%) 10/130 (7.6%) 
35-39.9 5/68 (7.3%) 8/130 (6.1%) 
Above 40 1/58 (1.7%) 1/130 (0.7%) 
Not stated 4/68 (5.8%) 1/130 (0.7%) 
Exposure to nicotine Case n (%) Control n (%) 
Smoker 8/68 (11.7%) 8/130 (6.1%) 
Non smoker 48/68 (70.5%) 102/130 (78.4%) 
Ex-smoker 8/68 (11.7%) 20/130 (15.3%) 
Passive smoker 4/68 (5.8%) 0/130 
Not stated 0/68 0/130 
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5.3 Type of malignancy and cancer therapy 
Invasive ductal carcinoma accounted for 70.5% of all breast cancer cases 
(n=48), ductal carcinoma in situ for 1.4%. Only one patient was diagnosed with 
invasive lobular carcinoma. Rare types of cancer were represented by 
inflammatory breast cancer (n=3) and medullary breast cancer (n=1). 
In the group of patients with haematological malignancies, there were nine 
women diagnosed with Hodgkin lymphoma, 9/68 (13.2%) and three with non-
Hodgkin lymphoma, 3/68 (4.4%): namely mediastinal large B-cell lymphoma 
(n=2) and MALT Lymphoma also called extranodal marginal zone B-cell 
lymphoma (n=1). Additionally, there was one participant suffering from IgG 
kappa myeloma. One patient was recruited with adenocarcinoma of the 
caecum, as she expressed great interest in taking part in the study. The latter 
two participants were not included in the analysis. 
 Detailed information on the type of cancer, staging, and treatment are 
presented below (Table 13-16). In breast cancer group, only one patient was 
known to have BRCA mutation. Nearly 60% of patients had oestrogen positive 
breast cancer. In breast cancer group, more than 50% of patients had treatment 
with FEC and Docetaxel. In lymphoma group, the most commonly used regimen 
was ABVD only (58.3%). 
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Table 13 Type of diagnosed malignancy in patients. 
Type of cancer Number of 
cases  
Percentage ( %) 
Invasive ductal carcinoma 48/68 70.5% 
Ductal carcinoma in situ 1/68 1.4% 
Invasive lobular carcinoma 1/68 1.4% 
Inflammatory breast cancer 3/68 4.4% 
Medullary carcinoma of breast 1/68 1.4% 
Hodgkin lymphoma 9/68 13.2% 
Non-Hogdkin lymphoma NHL 3/68 4.4% 
 MALT lymphoma (NHL) 1/68 1.4% 
 Mediastinal large B cell lymphoma 
(NHL) 
2/68 2.9% 
IgG kappa myeloma 1/68 1.4% 
Carcinoma of caecum 1/68 1.4% 
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Table 14 Staging and other characteristics in breast cancer patients. 
Stage of breast cancer (n= 54) Number of cases n (%) 
In-situ 1/54 (1.8%) 
I 14/54 (25.9%) 
II 32/54 (59.2%) 
III 6/54 (11.1%) 
IV 1/54 (1.8%) 
Estrogen receptor positive 31/54 (57.4%) 
Known BRCA mutation 1/54 (1.8%) 
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Table 15 Chemotherapy regimen and hormonal therapy used in breast cancer 
patients. 
Chemotherapy regimen  N (%) 
*FEC 9/54 (16.6%) 
FEC+Docetaxel 29/54 (53.7%) 
**EC  2/54 (3.7%) 
EC +Docetaxel 9/54 (16.6%) 
CMF***+Epirubicin  3/54 (5.5%) 
CMF, Epirubicin, Docetaxel 2/54 (3.7%) 
Additional Paclitaxel or Carboplatin 8/54 (14.8%) 
Use of hormonal therapy 
Tamoxifen 
GnRH agonist 
 
30/54 (55.5%) 
2/54 (3.7%) 
*FEC (Fluorouracil(5FU), Epirubicin, Cyclophoshamide) 
**EC (Epirubicin, Cyclophoshamide) 
***CMF (Cyclophosphamide, Methotrexate, Fluorouracil) 
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Table 16 Staging and chemotherapy regimen in haematology group.  
Haematological malignancies (n=13) Stage (I-IV) Cases (n=) 
Hodgkin lymphoma I 0 
Hodgkin lymphoma II 5/12 (41.6%) 
Hodgkin lymphoma III 1/12 (8.3%) 
Hodgkin lymphoma IV 3/12 (25%) 
Mediastinal large B-cell lymphoma I 1/12 (8.3%) 
Mediastinal large B-cell lymphoma IV 1/12 (8.3%) 
MALT lymphoma IV 1/12 (7.6%) 
Type of lymphoma Treatment N (%) 
Hodgkin lymphoma (HL) *ABVD/**AVD  7/12 (58.3%) 
Hodgkin lymphoma (HL) ABVD+***BEACOPP 2/12 (16.6%) 
MALT lymphoma (NHL) Chlorambucil 1/12 (8.3%) 
Mediastinal large B cell lymphoma (NHL) ****R-CHOP 2/12 (16.6%) 
*ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) **AVD (Adriamycin, 
Vinblastine, Dacarbazine) 
***BEACOPP (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, 
Procarbazine, Prednisolone) 
****RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone) 
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Table 17 Patients with other malignancies and chemotherapy regimen. 
Type of cancer Chemotherapy 
regimen 
Percentage of 
patients 
Ig kappa myeloma *CTD+Mephalan 1/68 (1.4%) 
Adenocarcinoma of caecum Oxaliplatin 
Capecitabine 
1/68 (1.4%) 
*CTD (Cyclophosphomide, Thalidomide, Dexamethazone) 
 
In the haematology group, none of the patients received total body radiotherapy 
during the 12 month period of follow-up. Some of the patients had localised 
radiotherapy, but none had pelvic radiation. Therefore, information about 
radiotherapy was not included in the analysis. The patient with IgG kappa 
myeloma had Mephalan based autograft, followed by a maintenance dose of 
Lenalidomide (immunomodulator), but she was not included in the main 
analysis. 
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Chapter 6 
6 Results: Analysis of pre-treatment serum AMH 
concentrations in women with malignancy 
compared with healthy controls 
6.1 Introduction 
It is debatable whether women who develop a malignancy have the same 
ovarian reserve as a general population before they begin cancer treatment. It 
is not clear if malignancy itself or systematic illness has a significant impact on 
results of ovarian reserve tests. In previous studies, 38 lymphoma patients had 
significantly lower serum AMH concentrations prior to chemotherapy compared 
to a healthy population (Lawrenz et al., 2012) while the same was not confirmed 
in young (aged <37) women with breast cancer (Su et al., 2013).  
Knowing pre-chemotherapy ovarian reserve would be particularly useful for 
counselling patients regarding: their individual risk of subfertility; fertility 
preservation options and doses of stimulation drugs needed in ovarian 
stimulation cycles. At present, only limited data are available to guide clinicians 
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about individuals’ likelihood of early menopause before starting cancer therapy 
(Kim et al., 2012). 
Additionally, it is important to assess patients’ views and expectations about 
future fertility prospectively, at the time of cancer diagnosis and after treatment. 
Previous reports from the USA have shown dissatisfaction with fertility 
counselling and significant concerns for future fertility among young female 
cancer survivors, reported retrospectively (Partridge et al., 2004). Therefore, I 
assessed the desire for pregnancy at the time of cancer diagnosis as well as 
the number of referrals to fertility specialists in young cancer patients in this 
multicentre UK based study. 
6.2 Statistical analysis 
The analysis of serum AMH concentration at time of recruitment is presented 
below. Serum concentrations of AMH were compared between the cancer 
population (breast cancer and lymphoma) and healthy volunteers before any 
gonadotoxic treatment was commenced. Measured results for AMH were log 
transformed to normalize the right skewed distribution. A linear regression 
model was built with log transformed values of AMH concentrations as the 
response variable and age as the explanatory variable. A logistic regression 
model was used to assess if the outcome (log transformed AMH value) is an 
indicator for cases or controls. Univariate analysis was used to indicate if factors 
such as smoking status, previous live births, type of contraception used, time of 
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the menstrual cycle (in non-users) and BMI are predictive of group membership 
(cases versus controls). The multiple logistic regression model was built by Dr 
Nick Parsons to confirm whether AMH was significantly different in cancer 
patients and volunteers after adjusting for all of the confounding factors. 
Assessment of the patient’s wishes for pregnancy at the time of cancer 
diagnosis was analysed descriptively and presented as percentage (scale 1-4). 
The percentage of patients being referred to a fertility specialist for consultation 
regarding fertility preservation was calculated.  
6.3 Results 
Overall, a total of 66 patients and 124 volunteers were included in this analysis 
with a mean age of 35.9 (SD±5.9) and 33.8 (SD±6.4) years respectively. Overall 
mean serum AMH concentration of patients in the cancer group was 13.6 
(SEM±2.1) pmol/L. The mean AMH of the breast cancer subgroup (n=54) was 
12.8 pmol/L while haematology subgroup (n=12), 16.8 pmol/L (SEM±2.1). The 
control group consisted of 124 healthy volunteers with a mean AMH of 20.6 
pmol/L (SEM±1.6).  
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Table 18 Demographic factors, obstetric and gynaecological history in 
volunteers and cancer patients (p value calculated using Tukey comparison of 
means/Pearson's Chi-squared test. 
Parameter Breast cancer 
group (n=54) 
Lymphoma 
group(n=12) 
Volunteer group 
(n=124) 
(p value) 
Mean age 37.8 (SD±4.2) 27.6 (SD±5.5) 33.8 (SD±6.4) p<0.001 
Age at menarche 12.7 (SD±1.6) 13.1 (SD±1.6) 12.7 (SD±1.5) p=0.71 
Family hx of 
menopause<45 
5/52 (9.6%) 0/12  7/119 (5.8%) p=0.32 
Parity 
0 
1 
2 
≥3 
 
12/54 (22.2%) 
12/54 (22.2%) 
17/54 (31.4%) 
13/53 (24.1%) 
 
8/12 (66.6%) 
2/12 (16.6%) 
1/12 (8.3%) 
1/12 (8.3%) 
 
67/124 (54%) 
21/124 (16.9%) 
29/124 (23.2%) 
7/124 (5.6%) 
p<0.001 
Time of cycle 
Follicular 
Mid-cycle 
Luteal 
 
16/40 (40%) 
8/40 (20%) 
16/40 (40%) 
 
3/9 (33.3%) 
3/9 (33.3%) 
3/9 (33.3%) 
 
30/64 (46.8%) 
5/64 (7.8%) 
29/64 (45.3%) 
p=0.2 
Type of 
hormonal 
contraception 
Combined oral 
Progestin based 
No contraception 
 
 
0/54 
14/54 (25.9%) 
40/54 (74%) 
 
 
2/12 (16.6%) 
1/12 (8.3%) 
9/12 (75%) 
 
 
23/124 (18.5%) 
29/124 (23.2%) 
72/124 (58%) 
p=0.01 
 
 
 
 
 
 
Smoking 
Active smokers 
Ex-smokers 
No smokers 
 
8/54 (14.8%) 
5/54 (9.2%) 
41/54 (75.9%) 
 
0 
1/12 (8.3%) 
11/12 (91.6%) 
 
7/124 (5.6%) 
19/124 (15.3%) 
98/124 (79%) 
p=0.15 
BMI 26.2 (SD±5.6) 23.2 (SD±5.9) 25.7 (SD±4.8) p=0.83 
 157 
 
 
AMH data was extremely right –skewed. Distributional properties of AMH were 
improved significantly by log transformation. 
 
Figure 10 Log transformed AMH values in 3 groups: breast cancer, lymphoma 
and control. Boxplot: black dots represent means, boxes represent the 
interquartile ranges (IQR), horizontal bars within the boxes represent the 
medians, and whiskers represent the lowest / highest data points within 1.5 IQR 
of the lower/upper quartiles. 
Tukey multiple comparisons of means in 3 groups, shown that patients with 
breast cancer had significantly lower serum AMH concentrations than the 
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control group (95% CI -0.41. -0.01, p<0.006). Lymphoma group had serum AMH 
concentrations that appeared lower but were not found to be significantly 
different to the volunteer group (95% CI -0.23, 0.47, p=0.57). 
Based on the linear regression model, after adjusting for age, cancer patients 
as a whole had significantly lower serum AMH concentrations as compared to 
same age volunteers (F 2,175=21.3, p=0.01). AMH declined with age in both 
cancer and volunteer groups.  
 
Figure 11 Correlation between log10 transformed serum AMH concentrations 
(y-axis) and age (x-axis) in the control group and cancer patients. A linear 
correlation was found to be the line of best fit. There was no evidence that the 
slope of the line was different between the two groups (p=0.135).  
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After adding cancer type to the regression model and adjusting for age, AMH 
was found to be statistically different in all three subgroups: breast cancer, 
lymphoma and volunteers (F 5,174=14.5, p=0.01).  
 
Figure 12 Linear correlation between log10 transformed serum AMH 
concentrations (y-axis) and age (x-axis) in breast cancer, lymphoma and control 
groups.  
After adjusting for age, serum AMH concentrations differed significantly 
between 3 groups: breast cancer, lymphoma (Hodgkin and non-Hodgkin) and 
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healthy volunteers. The prediction model built by Dr Nick Parsons which was 
based on AMH values in age-matched volunteers and cancer patients, 
estimated that a cancer patient had AMH level equivalent to a 6 years older 
volunteer, prior to chemotherapy. There was no evidence that the extent of the 
difference changed with age (interaction term was not significant). 
Univariate analysis was used to indicate if factors such as smoking, previous 
live births, number of pregnancies, type of contraception used, time of the 
menstrual cycle, BMI, etc. were predictive of group membership (cases versus 
controls).  
Table 19 Univariate analysis indicates whether the dependent variable is an 
indicator for volunteers and cancer. Variables: log transformed AMH, age, age 
at menarche, length of menstrual cycle, number of pregnancies, number of life 
births, body mass index (BMI), time of menstrual cycle in non-users of hormonal 
contraception, regularity of menstrual cycles (1-regular 2-no regular), gynae 
problems* (gynaecological history: ovarian cystectomy or endometriosis), 
hormonal therapy other than hormonal contraception, desire for children, 
smoking status. Df* degrees of freedom. 
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Dependent Variable Df* Deviance P value Rank 
Age 1 5.166 0.023 5 
log10(AMH) at baseline 1 9.256 0.002 3 
Cycle length 1 0.454 0.501 11 
Age menarche 1 0.087 0.768 14 
No pregnancies  1 13.966 <0.001 2 
LB at baseline 1 15.096 <0.001 1 
BMI 1 0.041 0.839 15 
Time of cycle 1 9.793 0.002 4 
Regularity of cycles 2 0.671 0.7155 12 
Gynae problems 1 0.014 0.905 16 
Other medical problems 1 1.68 0.195 7 
Family early menopause 1 0.567 0.452 10 
Contraception type 5 11.959 0.021 6 
Hormonal Therapy 1 0.180 0.671 13 
Desire for children 3 4.506 0.212 8 
Smoking 1 0.946 0.331 9 
Based on multiple logistic regression models (built by Dr Nick Parsons), AMH 
was significantly different between cancer patients and volunteers after 
adjusting for the variables ranked above (p=0.01). 
Baseline serum AMH concentration was not found to be significantly different 
between groups with negative and positive estrogen receptor breast cancer 
(p=0.61). The trend suggestive of lower serum AMH concentrations in more 
advanced stages of breast cancer was observed, but no significant difference 
was found in between patients with breast cancer stage I, II and III (p=0.57). 
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Figure 13 Differences in log transformed AMH levels (y-axis) by stage of breast 
cancer (x-axis). Boxplot: black dots represent means, boxes represent the 
interquartile ranges (IQR), horizontal bars within the boxes represent the 
medians, and whiskers represent the lowest / highest data points within 1.5 IQR 
of the lower/upper quartiles. No statistically significant difference was found in 
log transformed AMH levels between patients with breast cancer stage I, II and 
III (p=0.57). 
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Of the total group of women newly diagnosed with cancer, 35% still expressed 
some desire to have children. When considering a younger subgroup of women 
(those aged ≤39), 48.8% (21/43) desired children in future. In total, 9% of 
women had been seen by a fertility specialist for discussion about fertility 
preservation options. 
Table 20 Assessment of women’s desire to have children at the time of cancer 
diagnosis before commencing chemotherapy in the age group 18-43. 
Desire to have children 
(marked as strong or maybe 
on medical questionnaire at 
the time of cancer 
diagnosis) 
All patients 
N (%) 
Breast cancer 
group 
N (%) 
Lymphoma 
group 
N (%) 
Age range 18-43 24/68 (35.3%) 14/54 (25.9%) 10/12 (83.3%) 
Age ≤39 21/43 (48.8%) 11/31 (35.5%) 10/12 (83.3%) 
6.4 Summary of results 
 Serum AMH concentrations decrease with female age.
 AMH levels were found to be lower in the cancer group as a whole, prior
to any gonadotoxic treatment, compared to healthy volunteers. Based
upon a multiple logistic regression model, after adjusting for
confounders: i.e. age, smoking status, BMI, parity, use of contraception,
time of the cycle; AMH levels were still found to be significantly lower in
the cancer group.
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 A prediction model estimated a 6 year difference in ‘fertility age’ between
groups. In other words, on average a 25 year old cancer patient was
found to have a serum AMH concentration equivalent to that of a 31 year
old healthy volunteer.
 There was no significant difference in baseline AMH concentrations,
according to the stage of breast cancer. The trend was suggestive of
lower AMH in patients with more advanced stages of breast cancer, but
a larger study would be needed to provide conclusive results.
 Nearly 50% of women, newly diagnosed with cancer at an age ≤ 39
years, expressed some desire (either ‘strong’ or ‘maybe’) to have
children.
 Less than 10% of women recruited into the study had had a consultation
with a fertility specialist.
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Chapter 7 
7 Results: Longitudinal data analysis 
7.1 Introduction 
An accurate assessment of remaining ovarian function and fertility potential 
after chemotherapy is not straightforward. Women who regain menses may 
appear fertile but are still at risk of premature menopause and have reduced 
window of potential fertility (Bath et al., 2003; Larsen et al., 2003a; Reh et al., 
2008). 
The exact long-term effects of the different types of chemotherapeutic agents 
and regimens upon ovarian reserve in a woman of reproductive age are still 
difficult to determine on an individual basis. The degree of chemotherapy-
induced ovarian follicle loss depends on the type of chemotherapy, its dosage, 
duration and the age of the patients i.e. how large their ovarian reserve is before 
treatment begins (Lower et al., 1999; Meirow & Nugent, 2001). 
Additionally, information on the menopausal status of women with breast cancer 
is very valuable for oncologists. Post chemotherapy, it helps to determine what 
type and duration of adjuvant hormonal therapy would be most suited for the 
group of young women with breast cancer (Henry et al., 2014). At present, an 
accurate determination of menopausal status in patients around the age of 40 
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who have completed chemotherapy is not straightforward. A number of studies 
have used as an indicator, the recurrence of menses at 6 or 12 months follow-
ups post chemotherapy, but amenorrhea was not found to be a reliable indicator 
of menopause (Smith et al., 2006). Biochemical markers, such as FSH and 
estradiol, were not found to be reliable markers of ovarian reserve in patients 
post chemotherapy, especially in breast cancer patients taking hormonal 
therapy e.g. Tamoxifen (Hadji et al., 2012; Lum et al., 1997). 
Currently, measurement of serum AMH is considered the best biomarker of 
ovarian reserve (Broekmans et al., 2006). AMH was previously found to be an 
accurate indicator of ovarian function even amongst women without regular 
menstrual cycles and was found not to be strictly dependent of the menstrual 
cycle (La Marca et al., 2006a). Interestingly, in a small pilot study, in patients 
with breast cancer using Tamoxifen, no significant impact of Tamoxifen on AMH 
levels was observed during 8 months of follow-up (Oktay et al., 2013). 
These characteristics make an AMH a good candidate for ovarian reserve 
assessment and measurements of the degree of changes in ovarian reserve in 
childbearing age women with cancer. Those women who may not have regular 
menstrual cycles following chemotherapy for months. Additionally, in 
premenopausal women with estrogen positive breast cancer information about 
definitive menopausal status following chemotherapy, is crucial for planning any 
hormonal therapy. 
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7.2 Statistical analysis 
In the initial analysis, serum AMH concentrations were measured at the time of 
recruitment (Time 0). For the longitudinal analysis, additional samples were 
obtained at 6, 9 and 12 months later in both groups: cancer patients (who had 
been undergoing treatment for their condition) and healthy volunteers over the 
same period. These samples were analysed simultaneously using the same 
assay protocols as the Time 0 samples. 
Statistical analysis was performed using log transformed AMH values in 
volunteer and cancer groups using 4 repeated values. Paired t-test was used to 
compare values between baseline AMH and follow-ups in both groups. A 
Pearson correlation coefficient was used to asses if pre-chemotherapy levels of 
AMH were correlated with levels post-chemotherapy. Logistic regression 
analysis was used to check if serum concentrations of AMH at the time of cancer 
diagnosis (explanatory variable) were predictive of return of menstrual cycle 
(binary variable) at 12 month follow-up. 
Mc Nemar test was used to test whether the desire to have children before and 
12 months after completing chemotherapy had changed significantly in cancer 
patients. 
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7.3 Results 
AMH concentrations reduced with the onset of chemotherapy, as was expected 
since growing follicles in the ovary would become atretic. However, after 9 or 12 
months, some recovery was expected unless the patient was still undergoing 
chemotherapy at this time. Considering the age group 18-43 years of recruited 
patients, the degree of recovery of AMH concentrations with time was lower 
than anticipated. 
Overall, in the cancer group, at 6 months follow-up, significant fall in serum AMH 
was observed. Only 7.4% of women had detectable serum AMH concentrations 
at that point while at 9 months this proportion increased to 18%. Recovery of 
ovarian function increased slightly at the time of final follow-up when 21.8% 
(12/55) of women had detectable AMH concentrations in serum samples. Five 
of these were in the Hodgkin lymphoma group, in which 62.5% (5/8) of patients 
who completed 12 month follow-ups had a noticeable recovery of ovarian 
function. It was observed that all of them (5/8) had received ABVD regimen only 
and were aged ≤32. Additionally one patient with same characteristics had 
detectable AMH at the 9 month follow-up but did not complete the final 12 month 
follow-up. Interestingly, some recovery of ovarian function was observed even 
in cases in which AMH at point 0 was as low as 3.6 pmol/L if standard ABVD 
regimen was used. In all patients (5/8) with detectable AMH concentrations at 
the time of 12 month follow-up, the concentration was similar to or higher than 
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that measured at time 0. Two patients in Hodgkin lymphoma group (2/8) were 
given Cyclophosphamide (non ABVD regimen), and both of them had 
undetectable AMH in the follow-up period. Overall, in the haematology group, 
the return of menses, either regular or irregular, was reported in 88.8% of 
patients at the time of final follow-up appointment. At the time of final follow-up, 
only 16.6% (2/12) of patients were on combined oral contraceptive pill. 
Interestingly, two young patients diagnosed with Hodgkin lymphoma, aged 21 
and 31, conceived within three months from their 12 month follow-up. The final 
serum AMH measurement was low (3.6 pmol/L) in one patient and undetectable 
in the other.  
Among breast cancer patients, 12 months from starting chemotherapy, in 15.5% 
(7/45) of them, some degree of recovery of ovarian function was noted. All 
patients with measurable AMH concentrations at 12 months were aged ≤40 with 
a baseline serum AMH concentration ≥18 pmol/L and had received regimen 
FEC/EC with or without Docetaxel. Overall, in the breast cancer group, 58.1% 
(25/43) of patients were amenorrheic at 12 months from commencing 
chemotherapy. A further 23.2% (10/43) had irregular bleeding, and 18.6% (8/43) 
reported regular menstrual cycles. Women who were taking hormonal 
contraception or were known to have a non-hormonal coil have been excluded 
from this final sub-analysis. 
Overall, based on logistic regression analysis, after adjusting for age, pre-
chemotherapy serum concentrations of AMH in reproductive age women with 
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malignancy were not found to be associated with presence or absence of 
menstrual bleeding at the 12 month follow-up (p=0.219). Same was confirmed 
for a subgroup of patients with breast cancer (p=0.108). 
A younger age of the patient was confirmed to be statistically significant in 
predicting return of menses at 12 months after initiation of chemotherapy (EXP 
(B) =0.86, 95% CI 0.76, 0.98, p=0.033).
Based on formula (build by Dr Richard Crossman) for any age and pre-
chemotherapy AMH for a patient, one can calculate the probability of return of 
menses at 12-month follow-up: 
p = ( exp (4.407 -0.144A+1.020L) )/(1+exp(4.407 -0.144A+1.1020L) ) 
where p is the probability of menses returning at 12 months from first dose of 
chemotherapy, A is equal to the age of a patient, L is equal to the log-
transformed pre-treatment AMH concentration: 
e.g. patient aged 30 with pre-chemotherapy AMH of 9 pmol/L would have 74%
chance of menstruation by 12 months. 
Exp (4.407 – 0.144*30 + 1.020*LOG(9)) =74.3% 
Using a Pearson correlation coefficient, no association between pre-treatment 
and 12-month follow-up serum concentrations of AMH in cancer patients as a 
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whole group was found (p=0.18). Same was confirmed in the group of women 
with breast cancer (p=0.408). In Hodgkin lymphoma, higher pre-treatment 
levels were correlated with better recovery of ovarian function (p=0.02). 
However, the group size is small, and those results need to be interpreted with 
caution.  
In the volunteer group, serum concentrations of AMH at point 0 were not found 
to be significantly different from AMH at 6, 9, and 12-month follow–ups. This 
finding was in contrast to the cancer group where pre-chemotherapy AMH 
concentrations were significantly higher than at 9-month and 12-month follow-
ups (p=0.01, p=0.014 respectively). 
172 
Figure 14 Boxplot for temporal tends in serum AMH concentrations (y-axis) in 
control group and cancer patients (cases) at different time points (x-axis): point 
0 (base), 6 months (6m), 9 months (9m) and 12 months (12m). Black dots next 
to the boxes represent means, boxes represent the interquartile ranges (IQR), 
horizontal bars within the boxes represent the medians, whiskers represent the 
lowest/ highest data points within 1.5 IQR of the lower/upper quartiles and dots 
represent outside the boxes represent outliers. 
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Table 21 Changes in serum AMH concentrations (on log transformed scale) 
over a 12 month period using paired t-test in the control group. AMH 
concentrations at time 0 (baseline) compared with measurements at 6, 9 and 
12 month follow-up. No evidence for significant temporal changes in serum 
AMH concentrations in the control group. Df*- degrees of freedom. U.CI** upper 
limit of the confidence interval, L.CI*** lower limit of the confidence interval. 
 
Log transformed AMH at time 0 and 6, 9 and 12 month follow-up in volunteers 
Time of the 
samples 
Mean 
Difference 
U.CI95%** L.CI95%*** t.statistic Df* p value 
Baseline 
versus 6 month 
0.023 -0.014 0.061 1.23 102 0.221 
Baseline 
versus 9 month 
0.045 -0.002 0.092 1.88 98 0.063 
Baseline 
versus  12 
month 
0.046 -0.001 0.094 1.95 98 0.054 
6 month versus 
9 months 
0.011 -0.026 0.048 0.6 93 0.551 
6 month versus 
12 month 
0.02 -0.024 0.063 0.9 89 0.371 
9 month versus 
12 month 
0.016 -0.029 0.061 0.71 90 0.479 
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Table 22 Changes in serum AMH concentrations (on log transformed scale) 
over a 12 month period using paired t-test in cancer patients. AMH 
concentrations at time 0 (baseline) compared with measurements post-
chemotherapy at 6, 9 and 12 month follow-up. Evidence of statistically 
significant differences between pre and post-chemotherapy AMH was 
observed. P value of 0.014 and 0.001 is considered statistically significant, Df*- 
degrees of freedom. U.CI** upper limit of the confidence interval, L.CI*** lower 
limit of the confidence interval. 
Log transformed AMH at time 0 and post-chemotherapy in cancer patients 
Time of the 
samples 
Mean 
Difference 
U.CI95%** L.CI95%*** t-
statistic 
Df** p value 
Baseline versus 
6 month 
0.433 -0.326 1.191 1.81 3 0.167 
Baseline versus 
9 month 
0.525 0.288 0.762 5.11 8 0.001 
 Baseline versus 
12 month 
0.447 0.108 0.786 2.9 11 0.014 
6 month versus 
9 month 
-0.435 -1.274 0.403 -6.6 1 0.096 
6 month versus 
12 month 
-0.286 -0.942 0.369 -1.39 3 0.258 
9 month versus 
12 month 
0.059 -0.214 0.333 0.56 5 0.602 
After adjusting for age, no significant difference was found between mean AMH 
concentrations in breast cancer patients using Tamoxifen versus non-users of 
Tamoxifen (p=0.053) at 12 month follow-up. 
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The comparison of patients’ wishes before and after chemotherapy regarding 
future pregnancy is presented. In the haematology group, all but 2 women 
provided the same answers to the question about wishes for future pregnancy 
(scale 1-4) both before commencing chemotherapy and at the 12-month follow-
ups.  
In the breast cancer group, 20% of patients marked a higher score (1-4 scale) 
in comparison to their pre-treatment answers, suggesting a trend of increasing 
desire to have children after completion of chemotherapy. However, this result 
was not statistically significant (p=0.291). Those views were not analysed in the 
context of the progression of the disease and need for repeated doses of 
chemotherapy. 
7.4 Summary of results 
 Twelve months after starting chemotherapy nearly 80% of women still
had undetectable AMH levels. Therefore, measurement of serum AMH
at 12 month follow-up could not be reliably used to assess the degree of
damage to ovarian function caused by specific chemotherapy regimen
and dosage.
 In comparison, in the same age group of healthy volunteers, AMH
concentrations were found to be stable over 12 months.
 In a young group of patients aged ≤ 32, with Hodgkin lymphoma on
ABVD protocol, over 60% had a noticeable degree of recovery of ovarian
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reserve at 12 months. Nearly 90% of those women reported the return 
of menstrual bleedings. 
 In breast cancer group, only a small number of women had detectable
AMH at 12 month follow-up – those women were overall younger (age
≤40) and had ‘good ovarian reserve’ before chemotherapy.
 During the follow-up period, in the haematology group, desire to have
children remained as high as prior to chemotherapy. In the breast cancer
group, 20% of women reported a greater wish for future pregnancy at 12
month follow-up than at the time of cancer diagnosis.
 Pre-chemotherapy concentrations of AMH were not found to be
correlated with the recurrence of menses at 12 month follow-up.
However, a prediction model was built, using age and pre-chemotherapy
AMH which allowed the chances of return of menstrual periods at 12
months from starting chemotherapy to be estimated.
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Chapter 8 
8 Results: AMH as a marker of ovarian reserve in a 
healthy population 
8.1 Introduction 
Anti-Müllerian hormone (AMH) testing has been widely investigated for its use 
in a range of fertility applications. However, it remains controversial due to 
issues with the reliability of the assay, including changes in methodology, 
different thresholds, interference caused by complement in serum samples 
causing artificially low AMH measurements. These problems are compounded 
by the prevalence of small published studies, mainly addressing the subfertile 
population. All of these issues have resulted in contradictory evidence regarding 
the clinical uses of serum AMH assays (Dewailly et al., 2014). 
Among the controversial aspects are, for example, impact of the use of 
hormonal contraception, smoking and BMI on serum concentrations of AMH. 
Some research groups have reported a negative relationship between high 
body mass index and AMH in women age 35-47 (Freeman et al., 2007), but this 
finding was not confirmed by others (Halawaty et al., 2010). Similarly, the AMH 
concentration was found to be lower in active smokers (Plante et al., 2010) but 
a different study showed that smoking status had no impact (Dafopoulos et al., 
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2010). As described in my introduction chapter, serum concentrations of AMH 
are generally considered to be relatively independent of the menstrual cycle 
(Hehenkamp et al., 2006; La Marca et al., 2006b; Tsepelidis et al., 2007), 
however, some studies have reported statistically significant inter- and intra-
cycle fluctuations in AMH concentrations (Cook et al., 2000b; Streuli et al., 
2009). Additionally, the reproducibility of AMH measurements using the second 
generation assay has been questioned (Rustamov et al., 2012). Consequently, 
a new method of testing including pre-dilution step was recommended to 
improve stability of the assay (described in methodology chapter) 
In order to address these problems, I have analysed in detail the results of AMH 
assays in the group of healthy controls. I have conducted an analysis of the 
stability of AMH concentrations measured at four specified points in time, 
including an assessment of cycle dependence, the impact of hormonal 
contraception, smoking and BMI on the measured AMH concentrations. The 
most recently recommended ‘pre-dilution’ method for the assay was employed. 
8.2 Statistical analysis 
For this part of the analysis, previously recruited 124 volunteers, without any 
significant medical illness, were selected 
Four repeated AMH measurements were used to calculate within-subject 
variability using the coefficient of variation. Correlation between AMH changes 
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during stages of the menstrual cycle, contraception use, BMI and smoking 
status were assessed using a linear regression model with AMH as the 
response variable. 
8.3 Results 
Overall 124 volunteers with a median age of 34 were included in this analysis. 
Mean AMH for the group was 20.6 pmol/L (SD±18.9) at time 0, 20.5 pmol/L 
(SD±18.7) at 6 months follow-up, 19.1 (SD±16.4) at 9 months and 20.7 
(SD±20.7) at final blood test. Amongst healthy volunteers, 18.5% (23/124) have 
been on combined oral contraceptive pill while 23.3% (29/124) were using 
progestin based contraceptives. Assessment of past obstetric history showed 
that 45% (57/124) of women were para≥1. Less than 5% of patients reported a 
family history of early menopause at age <45 in a first line relative. Mean BMI 
was 25.7 (SD±4.8). In the volunteer group, 5.6% (7/124) were active smokers. 
Mean CV (coefficient of variation) in the group of volunteers on 4 repeated 
measurements of AMH at time 0, 6, 9 and 12 months was 15% which confirms 
acceptable within-subject (sample to sample) variability of second generation 
assay using new method of testing (including pre-dilution step).  
Univariate analysis of relationship between the time of natural menstrual cycle 
and serum measures of AMH showed no statistically significant correlation at 
the time of recruitment (p=0.868) and at repeated analysis at time of 6 month 
180 
follow-up (p=0.638), 9 moth-follow-up (p=0.531) and at final follow-up (p=0.960). 
After adjusting for other confounding factors: time of the menstrual cycle, type 
of contraception used, parity, smoking status, and BMI were not found to be 
significantly correlated with serum AMH concentrations in healthy volunteers.  
Table 23 Linear regression model: the relationship between log transformed 
AMH values (dependent variable) and explanatory variables listed below. R 
representing correlation coefficient, R square showing the amount of variation 
in AMH value that can be explained by age. 
Model Summary 
Model R R Square 
Adjusted R 
Square 
Std. Error of the 
Estimate 
1 0.470 0.221 0.184 0.33725 
ANOVA 
Model Sum of Squares 
Degrees of 
freedom 
Mean 
Square Sig. 
1 Regression 3.422 5 0.684 p=0.001 
Residual 12.056 106 0.114 
Total 15.478 111 
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Table 24 Linear regression model- the relationship between AMH and 
explanatory variables. AMH log transformed values which is dependent variable 
and explanatory variables: age at the time of recruitment, time of the menstrual 
cycle (1-follicular, 2-mid-cycle, 3-luteal), type of contraception used (1-none 
hormonal, 2-combined oral contraceptive pill, 3-progestin based 
contraceptives), BMI (calculated as  body mass divided by the square of height), 
smoking status (1-smoker, 2-non-smoker, 3-ex-smoker) and number of life 
births >24 weeks (parity). After adjusting for other confounding factors, only age 
was found to be correlated with serum AMH concentrations (p=0.001). AMH 
concentrations decrease with age (β=-0.453, 95% CI -0.38, -0.18, p=0.001). 
Model Unstandardized 
Coefficients 
Standardized 
Coefficients 
Tscore P value 
Β Standard 
error 
Beta 
Constant 2.341 0.308 7.596 p=0.001 
Age -0.027 0.006 -0.0460 -4.148 p=0.001 
Day of 
natural cycle 
-0.006 0.036 -0.21 -0.172 p=0.864 
Type of 
contraception 
-0.012 0.031 -0.048 -0.397 p=0.692 
Parity 0.011 0.040 0.029 0.268 p=0.789 
BMI -0.008 0.007 -0.098 -1.111 p=0.269 
Smoking 
status 
-0.029 0.075 -0.033 -0.382 p=0.703 
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After adjusting for age, serum AMH concentrations were not found to be 
significantly correlated with the type of hormonal contraception used by healthy 
volunteers. Additional analysis on two subgroups, users of combined oral 
contraception versus non users found no correlation between AMH and use of 
combined contraceptives (p=0.545). 
Table 25 Multivariate model-correlation between different types of hormonal 
contraception and log transformed values of serum AMH concentrations. 
Model Estimate (log 
odds ratio) 
Standard 
error 
T value P value 
Intercept 0.770554 0.348293     0.0296 
Age -0.026576 0.005413 -4.910 4.35e-06 
Combined 
oral 
contraception 
-0.130497 0.082616 1.400      0.1179 
Mini pill 0.447458 0.319669 -1.580      0.1652 
Mirena coil -0.426522 0.172015 -2.480      0.151 
Implanon 0.026186 0.324170 0.081      0.9358 
Depo-provera 
injection 
-0.244766 0.321456 -0.761      0.4485 
Residual standard error: 0.3171 on 85 degrees of freedom, multiple R-squared: 
0.4049, adjusted R-squared: 0.3558 , F-statistic:  8.26 on 7 and 85 DF,  p-value: 
1.174e-07 
8.4 Summary of results 
 The study confirmed acceptable, within-subject (sample to sample)
variability of the second generation assay using a new method of testing
(including pre-dilution step).
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 Smoking status, BMI, timing of menstrual cycle and type of contraception
used were not found to be correlated with serum AMH concentrations in
the healthy population.
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CHAPTER 9 
9 Conclusions and Discussion 
There are now, considerable data in support of ovarian reserve testing using 
AMH in a cancer population (Anders et al., 2008; Lie Fong et al., 2009; Decanter 
et al., 2010, Partridge et al., 2010b; Anderson & Cameron, 2011; Dillon et al., 
2013, Su et al., 2013, Su et al., 2014, Hamy et al., 2014, Peigne et al., 2014, 
Bozza et al., 2014). By contrast, there are fewer studies that have data on AMH 
in reproductive age women at the time just before they initiate cancer therapy 
(Lawrenz et al., 2012; Su et al., 2013). This dissertation provides good evidence 
of diminished ovarian reserve in women with malignancy even before any 
gonadotoxic treatment is commenced. AMH levels were lower in the cancer 
group as a whole, prior to any gonadotoxic treatment being commenced, as 
compared with the same age group of healthy volunteers. After adjusting for 
other confounders: smoking status; BMI; parity; use of contraception; time of the 
cycle; AMH was still found to be significantly lower in the cancer group and 
differed between breast cancer, lymphoma and control groups.  
This finding is similar to that of the FertiPROTEKT Network report (Lawrenz et 
al., 2012) who studied ovarian reserve in 38 female patients with Lymphoma 
prior to cancer treatment and compared it with age-matched healthy controls. In 
combined Hodgkin and non-Hodgkin lymphoma groups, the mean AMH was 
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2.06 ng/mL while a significantly higher mean concentration of 3.20 ng/mL was 
reported in volunteers. The study population of 38 patients is considered to be 
relatively small, and the authors do not mention if they adjusted their analysis 
for any confounding factors. Strict selection criteria for the control group have 
been described, but it was not stated whether the same was applied to the 
cancer group. Nearly 60% of controls were on hormonal contraception while the 
same information was not reported for the cancer population. This is one of the 
first studies presenting results in the context of age-matched healthy volunteers 
as opposed to previous reports including subfertile patients as controls (Yu et 
al., 2010). 
The only other study presenting results of pre-chemotherapy ovarian reserve in 
reproductive age women diagnosed with cancer, provided opposing results (Su 
et al., 2013). A total of 108 patients with a breast cancer and a median age of 
40.2 years were found to have similar serum concentrations of AMH in 
comparison with healthy controls with a median age of 33.9 years. In contrast 
to this dissertation, the research group did not exclude women with PCOS who 
are known to have significantly higher serum AMH concentrations. Additionally, 
in their analysis, they have not adjusted for confounding factors including usage 
of hormonal contraception, time of the menstrual cycle and previous history of 
infertility. The multiple logistic regression models built for this dissertation 
population has included all of the above. Su et al. (2013) also provided only a 
limited description of how the blood samples were handled moreover, it is not 
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clear whether a pre-mixing step for assaying the serum using the second 
generation assay was included, as currently recommended by manufacturer. If 
the old methodology was used, this might have affected their AMH results.  
In summary, this dissertation is the first one to confirm lowered ovarian reserve 
in women with malignancy prior to any gonadotoxic treatment using a new, more 
reliable AMH assay method and adjusting for any confounding factors in 
statistical analysis.  
A biological explanation of diminished ovarian reserve in cancer sufferers, even 
before gonadotoxic therapy, is difficult. At present, it is unclear whether there is 
a cause and effect relationship, for example, does the lower ovarian reserve in 
some way predispose to breast cancer initiation, or does it arise as a response 
to the malignant disease? Titus et al., reported that women with BRCA1 
mutation may have lower levels of serum AMH as a result of impaired DNA 
repair mechanisms in oocytes. This idea may imply that loss of more oocytes 
might be expected due to a deficit of DNA repair. Expression of BRCA1 gene in 
oocytes was found to be important in the process of ovarian aging related to 
DNA double–strand break repair (Titus et al., 2013). Others have reported that 
BRCA mutation may be associated with a lower age at natural menopause that 
would support the finding of reduced ovarian reserve in this group (Finch et al., 
2013; Lin et al., 2013). By contrast, others have recently found similar serum 
AMH concentrations in healthy BRCA1/2 mutation carriers age 26-40, as 
compared with the general population (Michaelson-Cohen et al., 2014). 
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Apart from widespread metastatic disease, the mechanisms that may be 
responsible for decreased fertility potential in women with other malignancy are 
uncertain. The consumptive character of systemic illness, increased catabolism, 
and elevated levels of stress hormones causing an increase in prolactin levels, 
which may impact on ovulation have all been proposed as possible pathways 
affecting ovarian reserve (Agarwal & Said, 2004). Additionally, poor health at 
the time of cancer diagnosis measured using serum markers e.g. increased C-
Reactive Protein (CRP), high body temperature and low haemoglobin have 
been shown to correlate with low serum AMH concentration in girls age 0-18 
years newly diagnosed with cancer (van Dorp et al., 2014). The nature of this 
relationship is unclear, but the author has hypothesised that factors other than 
the size of the pool of follicles in the ovary might be contributing to low serum 
AMH in cancer patients. 
In basic science research, it has been suggested that AMH is one of the 
mediators of growth regulatory signals in breast tissue (Hoshiya et al., 2003). 
Exposure of breast cancer cells to AMH was found to inhibit growth and induce 
apoptosis. These authors suggested that lowered circulating AMH 
concentrations may be one of the predisposing factors for developing breast 
cancer (Hoshiya et al., 2003). To explore this hypothesis further, the author has 
tested to find if there is a significant difference in pre-treatment serum AMH 
concentrations according to the stage of breast cancer at the time of diagnosis. 
The slight trend was suggestive of lower AMH in patients with more advanced 
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stages of breast cancer, but a larger study would be needed to provide 
conclusive results. 
The data in this dissertation confirmed previous reports that AMH 
concentrations in serum decrease with female age (Wallace & Kelsey, 2010) in 
both healthy volunteers and the cancer group. Interestingly, a prediction model 
estimated a six year difference in ‘fertility age’ between groups. In other words, 
on average, a 25 year old cancer patient was found to have a serum AMH 
concentration equivalent to that of a 31 year old healthy volunteer. There was 
no evidence that the extent of the AMH difference between groups changed 
with age. At present, this is the first dissertation to report such a prediction model 
that can be used in clinical practice. 
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The longitudinal results of this dissertation show that, within 12 months from the 
first dose of chemotherapy, in nearly 80% of patients, serum AMH 
concentrations remained undetectable.  
Measurements of AMH, 12 months from first dose of chemotherapy, may not 
provide a valuable clinical indication of the risk of early menopause. 
Undetectable AMH at this point cannot confirm the diagnosis of early 
menopause unless proved by long term studies with end points including 
pregnancy and permanent amenorrhea. Until today there has been insufficient 
data to define clearly the time needed for recovery of ovarian function post-
chemotherapy and the best time for AMH measurements to be undertaken (Lie 
Fong et al., 2008, Decanter et al., 2010; Dillon et al., 2013; Anderson et al., 
2013; Behringer et al., 2013a).  
 The few studies that describe the recovery of ovarian function, based on pre- 
and post-chemotherapy AMH levels have some limitations. Dillon et al., (2013) 
included a heterogeneous patient population comprising 46 women with many 
different types of cancers including breast cancer, brain tumour, sarcoma, 
leukaemia etc., requiring different treatment types and dosages and followed 
them up every three months. The rate of post-chemotherapy recovery of ovarian 
function was based on the estimated monthly recovery of AMH in two adjusted 
group of patients with pre-chemotherapy AMH of ≤2 ng/ml and ≥ 2 ng/ml. This 
statistical model is based on assumptions and, due to the heterogeneity of the 
population, might not be relevant for a given subgroup of patients. In opposition, 
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Anderson et al., (2013), recruited only women with breast cancer and followed 
them up to two years. The authors compared mean AMH in women with the 
return of menses (nine patients) versus women with no menses (30 patients) at 
two year follow-up. Women with the presence of menses at follow-up had 
statistically higher mean AMH pre-chemotherapy versus women with no 
menses. It is worth noting that the mean age of the participants was 42.6 years, 
and all cancer patients had undetectable AMH at one year of follow-up. 
In this dissertation, in the breast cancer group, only a small number of women 
had detectable AMH at 12 months of follow-up. Overall, those women were 
younger (age ≤40) and had higher average AMH concentrations before 
chemotherapy. The results show that in the group of patients with breast cancer, 
pre-treatment levels of AMH were not predictive of post-treatment levels of 
AMH, however, such a correlation was found in the small sub-group of patients 
with Hodgkin lymphoma. Additionally, pre-chemotherapy serum concentrations 
of AMH were not predictive of return of menses at 12 month follow-up. 
Interestingly, the age of patients at the time of first dose of chemotherapy was 
associated with their risk of amenorrhea within 12 months and was found to be 
a better indicator than AMH alone.  
In the Hodgkin lymphoma group, better recovery of ovarian function was 
observed in patients who received the ABVD regimen only and were aged ≤32. 
Although, some recovery of ovarian function was observed even in cases where 
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the first AMH measurements were as low as 3.6 pmol/L if ABVD regimen only 
was used.  
The same was not found in patients using the non-ABVD regimens including 
alkylating agents. Analysis of the results in for this dissertation was performed 
on a small subgroup of haematology patients but is consistent with results from 
a large cross sectional study on Hodgkin lymphoma survivors (Behringer et al., 
2013b). The authors observed statistically higher mean AMH concentrations in 
women who were younger (30 year old) and who received the ABVD regimen. 
Use of a cyclophosphamide-based protocol resulted in undetectable serum 
AMH concentrations. In the same study, 90% of participants experienced a 
recurrence of menses which is high and similar to the results in this dissertation 
(88%). As confirmation, another prospective study on 30 patients diagnosed 
with lymphoma reported good recovery of ovarian function in the group of 
patients on the ABVD regimen, which was observed to be significantly better 
than in patients on the non-ABVD protocol (Decanter et al., 2010) 
Interestingly, in this dissertation, two cancer patients with very low or 
undetectable levels of AMH conceived with three months of the final blood test. 
It shows that, despite an undetectable or low serum AMH concentration at 12 
months, conception can still take place. The occurrence of pregnancy despite 
undetectable serum AMH levels has been previously presented in a case report 
(Fraisse et al., 2008). Similar findings were reported from a large cross sectional 
study where some cancer survivors with undetectable AMH concentrations in 
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serum reported pregnancy (Behringer et al., 2013a), although the authors 
provided no clinical details nor time between pregnancy occurrence and testing 
for AMH. 
All the results presented above raise questions about the time needed for 
recovery of ovarian function post-chemotherapy and the findings also challenge 
the sensitivity of the currently available second generation AMH assay. A new 
ultrasensitive AMH assay (Ansh) with a lower limit of detection of 0.2 pmol/L has 
been developed. Some pilot studies have provided evidence supporting its use 
in certain circumstances, e.g. reduced ovarian reserve post-chemotherapy 
(Fleming et al., 2013b). It is unclear how many non-growing follicles are still 
remaining in the ovary when serum AMH concentrations become undetectable 
(using detection limits of the currently available assay) post-chemotherapy 
because AMH is produced mainly by small, growing follicles. However, this 
population is believed to be lost first when chemotherapy is applied. It is 
estimated that the postmenopausal ovary would, on average, contain fewer than 
1000 non-growing follicles that are considered too few to initiate recruitment and 
growth that could lead to pregnancy (Kelsey et al., 2012). One research group 
estimated that serum AMH concentrations below 0.39 ng/mL (2.7 pmol/L) are 
predictive of menopause in the next six years following serum measurements 
(Tehrani et al., 2013).  
This dissertation shows that, in breast cancer patients taking Tamoxifen as 
compared to non-users of Tamoxifen, after adjusting for age, no difference was 
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found in serum AMH concentrations at 12 months follow-up. In contrast to a 
report from a small study of 20 patients, which suggested lowered levels of AMH 
in Tamoxifen users (Partridge et al., 2010a).The sample size of Partridge’s 
study was small, and the authors did not adjust their results according to the 
age of the patients. However, the results of this dissertation are consistent with 
a report from Oktay et al., (Oktay et al., 2013). Their study recruited 210 
menstruating women and measured AMH prior to the use of Tamoxifen at 4 and 
eight months follow-up that showed unchanged levels during the follow-up 
period. 
This dissertation has provided important data on patients’ wishes to become a 
biological mother assessed at the time of cancer diagnosis and 12 months later 
after completion of cancer therapy. In women aged up to 43 years, facing a 
cancer diagnosis, overall 35% still expressed desire (either ‘strong’ or 
‘possibly/maybe’) to have children, while this was true for nearly 50% in the 
group aged ≤ 39 years. In the group of patients with lymphoma, more than 80% 
of them expressed wishes for pregnancy. As reported by the oncology group 
recruiting into this study, less than 10% of participants had had a consultation 
with a fertility specialist. This finding is reported prospectively for the first time in 
this multicentre, UK based study. The results indicate that the often forgotten 
aspect of fertility is important for cancer patients. An effort should be made to 
build protocols that would help to refer young women of reproductive age for 
fertility counselling before commencing chemotherapy. 
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In this study, during the follow-up period, the desire to have children remained 
the same in the haematology patients while in the breast cancer group 20% of 
women reported a more favourable view on future motherhood at 12 month 
follow-up as compared with initial assessment prior to chemotherapy at the time 
of diagnosis. Overall, in the whole group of cancer patients, wishes for future 
pregnancy had not changed as a result of treatment burden. 
Serum AMH concentration was undetectable at 12 months of follow-up in the 
majority of patients. Consequently, assessment of the impact on fertility in 
subgroups of patients receiving different types and dosages of chemotherapy 
was suboptimal. The time frame of this MD study was too short to correlate 
changes in ovarian reserve with clinical outcomes such as pregnancy rate and 
early or premature menopause. It was, therefore, aimed to complete a 5 year 
follow-up (as per protocol) to describe the longer term impact of chemotherapy 
and the value of AMH measurements in this group of women. 
There is ongoing support for using AMH as a marker of ovarian reserve (Fleming 
et al., 2015, Iliodromiti et al., 2015), however most of publications present data 
on AMH results obtained from subfertile population (La Marca et al., 2007, Broer 
et al., 2009; Nelson et al., 2009 Anderson et al., 2012). Among the published 
studies, there is conflicting evidence on the degree of cycle dependence of 
serum AMH concentrations and also disagreement regarding the effects of 
other factors such as hormonal contraception, BMI or smoking status on its 
levels (Dewailly et al., 2014).  
 195 
 
In this study, a sub-analysis of serum AMH measurements was conducted in a 
population of healthy women. It was found that, in healthy volunteers aged 18-
43 without hormonal contraception, AMH was not correlated to the stage of the 
menstrual cycle (categorised as follicular, mid-cycle and luteal phase). Blood 
samples for this study were obtained at unspecified times of the cycle and AMH 
results were analysed according to the self-reported time of the cycle at 
venepuncture. To assess the intra-cycle variability of AMH, a different design, 
with repeated measures of blood samples within the same menstrual cycle 
would be more appropriate. Some researchers have found fluctuations in the 
mean AMH increasing up to 20% in the late follicular phase and decreasing 20% 
after ovulation and in early luteal phase (Cook et al., 2000a; Wunder et al., 
2008a, Sowers et al., 2010a;) in contrast to others (La Marca et al., 2006b; 
Tsepelidis et al., 2007). Some authors have suggested that changes in AMH 
concentrations were more prominent in younger women, while only minimal 
changes were observed in the older population, which the authors explained in 
terms of changes related to ovarian aging (Sowers et al., 2010b; Wunder et al., 
2008a). 
The first two well-designed, prospective studies assessing intra-individual 
variation of AMH were conducted in the subfertile population (Fanchin et al., 
2005; van Disseldorp et al., 2010). The author has assessed intra-subject 
fluctuation of AMH on 4 repeated measures and found that the mean coefficient 
of variation for the groups was 15% which is consistent with a previous report 
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from Van Disseldorp et al., (2010). Overall, as previously recommended ( La 
Marca et al., 2009, Dewailly et al., 2014;) by a group of experts, AMH 
measurements at unspecified times of the menstrual cycle are acceptable. This 
dissertation confirmed those findings in a group of healthy volunteers using the 
most up to date and accurate method of assaying AMH, which included a pre-
dilution step. It is a very important finding for clinicians working in the field of 
Reproductive Medicine, who may have decided to stop using AMH in their 
clinical practice as a result of recent questions about reproducibility and 
reliability of AMH results.  
The impact of the use of hormonal contraception on AMH levels was debated 
(Somunkiran et al., 2007; Streuli et al., 2008; van den Berg et al., 2010, Li et al., 
2011) until a large, prospective study on nearly 900 participants reported 
significantly lowered AMH concentrations (by 29%) in combined contraception 
users (Bentzen et al., 2012) in comparison with non-users. In contrast, this 
study, after adjusting for other confounding factors, found no significant 
correlation between the use of combined contraception and AMH 
concentrations, although, only a small number of participants (18%) was using 
combined contraception which might have contributed to lack of statistical 
power to detect significant differences. The theory behind decreasing levels of 
AMH during the use of hormonal contraception is that the number of small antral 
follicles responsive to FSH, which are known to have a relatively large mass of 
granulosa cells responsible for AMH production, is decreased. Additionally 
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estradiol may play a role in AMH production which may be altered by use of 
combined hormonal contraception (Kallio et al., 2013). Therefore, the duration 
and type of hormonal contraception and the timing of the blood tests, potentially, 
have had an impact on the degree of changes in AMH serum concentrations. 
This study design did not allow to look into all those aspects. 
After adjusting for age, in the group of healthy childbearing age women, this 
dissertation found no association between BMI and serum AMH measurements. 
By contrast, one study (Freeman et al., 2007), reported lowered AMH levels in 
obese women in late reproductive age. This study’s group had a wider age 
range which could provide different results because AMH declines throughout 
the reproductive life span and some AMH changes provoked by lifestyle factors 
could be more prominent in late reproductive age. In agreement with this 
dissertation’s results, another research group found no correlation between 
AMH and obesity, however, the mean age in their examined population was 46 
(Halawaty et al., 2010). Also, a large study on 461 healthy women, after 
adjusting for age found no correlation between serum AMH concentrations and 
BMI (La Marca et al., 2012). Others found negative correlation between AMH 
and high BMI in group of Caucasian women only (Moy et al., 2015) but not in 
Asian and African-American. 
In a cross sectional study on 284 women, active smoking was found to be 
correlated with lowered serum AMH concentrations in late reproductive age 
women, aged 38-42 (Plante et al., 2010). This is consistent with studies 
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suggesting an impact of smoking on the age at natural menopause (Sun et al., 
2012), although the authors did not observe the same correlation in women who 
were ex-smokers. In this dissertation, which included a younger population of 
patients with median age of 34, no relationship between smoking status and 
AMH concentrations was found. The findings are similar, however, to a large 
study on a healthy population with a similar age range (La Marca et al., 2012). 
As mentioned earlier, selection of an older age group for analysis could have an 
impact on AMH results in the light of lifestyle factors. 
Overall, measuring serum AMH concentrations at unspecified times of the 
menstrual cycle was found to be reliable. This dissertation adds conclusive 
results to improve upon a large number of small studies with contradictory 
results regarding the relationship of serum AMH concentrations with different 
lifestyle factors. 
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10 Recommendations for clinical practice and 
limitations of the study 
10.1 Recommendations for clinical practice 
The AMH assay has historically had a number of concerns. However, the results 
of this dissertation are among the first to utilise the manufacturer’s most recent 
instructions of applying a pre-mix step and, thus, are more reliable than most of 
the previous studies. These results have verified the adequate intra-subject 
(sample to sample) reproducibility of the second generation AMH assay. It has 
confirmed that serum AMH measurements can be reliably measured at 
unspecified times of the menstrual cycle, which is in concordance with current 
recommendations ( La Marca et al., 2009, Dewailly et al., 2014). It gives a very 
useful information for clinicians who may have questioned the practical use of 
AMH test following recently published data (Rustamov et al., 2012).     
Measurement of AMH concentrations at 12 months from starting chemotherapy 
in pre-menopausal patients with breast cancer, as a means of determining the 
patient’s future reproductive function, cannot be supported at present as there 
is not enough evidence that undetectable levels of AMH would confirm 
menopause. Pre-treatment AMH measurements in this group were not 
predictive of post-treatment AMH or amenorrhea at the 12 month follow-up. A 
longer period of follow-up may be needed to find such a correlation.  
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This study has resulted in a predictive model where, based on pre-treatment 
AMH and age of the patient, the chance of return of menses can be calculated. 
Using this model, one can calculate, for example, an average 30 year old with 
pre-treatment AMH of 9 pmol/L would have a 74% probability of return of 
menses within the 12 months after the first dose of chemotherapy. It can be 
used as a tool in counselling young, reproductive age women with cancer who 
may ask for more tailored and detailed information about gonoadotoxity of 
chemotherapy and its impact on menstrual cycle prior commencing treatment. 
In contrast to the breast cancer group, in patients with lymphoma, recovery of 
ovarian function was good in patients with Hodgkin lymphoma who received 
only the ABVD regimen. It is, once again, reassuring for Haematology 
Consultants that the ABVD protocol is relatively ‘gonadal-sparing’ if used in 
young women. This study showed that the impact of the ABVD protocol on the 
ovarian reserve is less pronounced in women aged ≤32. Interestingly, in this 
particular subgroup of patients, pre-treatment AMH was predictive of higher 
chances of a return of menses and correlated with post-treatment AMH 
concentrations. However, this analysis included only a small number of patients 
and should, therefore, be interpreted with caution.   
This study showed that in reproductive age women (18-43 years) diagnosed 
with cancer, the serum AMH concentration is already diminished prior to 
commencing chemotherapy, if adjusted for age, parity, type of contraception, 
BMI and smoking status. It is one of the first studies providing evidence of 
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reduced ovarian function in this group of patients, where the statistical analysis 
was corrected for all confounding factors. Additionally, derived from my results’ 
prediction model estimated a 6 year difference in ‘fertility age’ between healthy 
volunteers and women newly diagnosed with cancer, which may be used in 
clinical practice as ‘numbers to quote’ while counselling patients about fertility 
preservation. Interestingly, that correlation was stable throughout the whole age 
span.  
From previously published papers, it is known that, among women diagnosed 
with breast cancer under the age of 40, less than 10% subsequently have 
children after treatment (Kim et al., 2011). Simultaneously, some studies 
suggest that 60% of breast cancer survivors express concerns about fertility and 
early menopause, some 40% strongly wished to have the option of becoming a 
biological mother still available to them. Only half of those women felt that their 
concerns about future fertility had been adequately addressed (Partridge et al., 
2004).  
In my study, more than 35% of women newly diagnosed with cancer still 
expressed some desire to have children. In a younger subgroup of women 
below the age of 40, nearly 50% of them still wished to have children even 
though they were facing a cancer diagnosis. Despite that, amongst all cancer 
patients recruited into the study, only 9% had been referred to discuss their 
options with a fertility special fertility prior to chemotherapy.  
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The implications of my findings are important for both oncologists and fertility 
specialists. In my opinion, oncologists may need to take into consideration 
referral of all young women newly diagnosed with cancer to a fertility specialist, 
especially those wishing for a future pregnancy. One of the first tests that they 
may receive is a serum AMH assay which would provide information about their 
remaining ovarian reserve. Together with knowledge of their chemotherapy 
regimen, this could provide some assessment of their likely chances of 
subfertility or sterility ensuing after their therapy and inform their decisions 
regarding fertility preservation. Patients should be aware that they may have a 
potentially diminished ovarian reserve and that this may be relevant to their 
stimulation protocol if fertility preservation is offered in the form of egg or embryo 
freezing. Better coordination between oncology and fertility clinics will be 
needed if patients are ever to receive a full assessment of their needs and 
comprehensive information on their prospects.   
Additionally, nearly two-thirds of women diagnosed with breast cancer have an 
oestrogen receptor-positive tumour and would be advised to have adjuvant 
therapy with Tamoxifen (partial agonist of oestrogen) and/or a GnRH agonist 
which would further delay and impact their chances of achieving pregnancy 
(Kim et al., 2011). It would be advisable for women to be advised of this in the 
light of knowledge about their prospective fertility. 
An integrated approach to the wellbeing of reproductive age women diagnosed 
with cancer should include a fertility consultation. Referral to a Reproductive 
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Medicine Consultant prior to chemotherapy is still not a routine practice in the 
UK although, in some Trusts there are already protocols in place (e.g. in Queen 
Elizabeth Hospital in Birmingham where all newly diagnosed female patients 
with lymphoma are referred for fertility discussions with a specialist (if patient 
agrees). Alternatively, regular training or up-dating sessions on fertility 
preservation could be organised for Oncologists or it could become a regularly 
discussed topic at oncology conferences to make sure that up-to-date 
knowledge is being used while discussing these sensitive issues before 
commencing chemotherapy.  
10.2 Limitations of the study design 
I planned to recruit exact age matched controls in the ratio of two controls per 
cancer patient, as advised by Prof. Dunn (Professor of Clinical Trials and Head 
of Cancer Trials). The final stage of the recruitment process targeted age groups 
previously underrepresented by controls. Despite that, some cases did not have 
exact age-matched controls. Given the overall availability of control data, Dr 
Nick Parsons, Statistician, advised that the data should be analysed as an 
unmatched case-control study with adjustment for the age imbalance between 
groups in all analyses. 
The breast cancer group was, therefore, significantly older than the group of 
healthy controls. Of the cancer patients, 42/54 (77%) already had offspring prior 
to diagnosis, although the risk of early menopause, its consequences and the 
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need for long term adjuvant hormonal therapy with Tamoxifen in premenopausal 
patients still makes the question of remaining ovarian function very relevant. 
Only a small group of patients with lymphoma was recruited. In addition, the 
statistical analysis was not sufficiently well powered to detect differences in 
AMH concentrations in sub-groups of patients (e.g. based upon staging of the 
disease, the dosage of chemotherapy). The extent of analysis possible was not, 
therefore, as great as anticipated. 
Women taking hormonal contraception were not excluded from the study. At the 
time of recruitment into the study, some of the patients newly diagnosed with 
breast cancer may have recently stopped hormonal contraception at the request 
of the oncologist and some residual suppression of AMH was possible. In the 
control group around 20% of women had taken the combined oral contraception 
which has been shown to have some effect on AMH concentrations (Bentzen 
et al., 2012). This study was not published when I devised my protocol. Papers 
published previously had provided conflicting results (Somunkiran et al., 2007; 
Streuli et al., 2008; van den Berg et al., 2010; Li et al., 2011). However, all the 
statistical analyses have been corrected for confounding factors including the 
use of contraception.  
Some of the volunteers opting to take part in the study may have done so 
because they had concerns about their fertility, or they had, perhaps, been 
actively trying for a pregnancy. Seven women in the volunteer group became 
pregnant during the 12 months follow-up period. They have been included in 
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the final analysis. The overall number of patients who became pregnant during 
the study remained small and statistical advice indicated that this factor is 
unlikely to have affected the final analysis. There is conflicting evidence on AMH 
concentrations in maternal blood samples during pregnancy (La Marca et al., 
2005b, Koninger et al., 2013, Koninger et al., 2015). One of the first studies, 
conducted on 84 participants aged 18-37 examined in the first, second and third 
trimesters of pregnancy, showed no significant changes in AMH measurements 
compared with a volunteer group (La Marca et al., 2005b). A larger cross-
sectional study presented the results of serum AMH measurements in 450 
healthy pregnant women at any gestational age (Koninger et al., 2013). In the 
first part of this study, AMH results from 15 women were carried out through the 
first, second and third trimester of pregnancy. The authors observed a 
statistically significant decline in AMH concentrations during pregnancy, the 
lowest being in the third trimester. Similarly, during the first 4 days of the 
postpartum period, levels of AMH remained low. The authors discussed 
possible causes for lowered AMH including inhibition of folliculogenesis in 
pregnancy. It can be related to decreased number of growing follicules which 
are known to be hugly responsible for the production of AMH. Another possible 
explanation is that high oestrogen levels during pregnancy may suppress AMH 
promoter activity and decrease AMH concentrations (Chen et al., 2003). 
Additionally, it is still unclear whether there is any placental production of AMH 
in humans (La Marca et al., 2005b). 
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Considering the design of my study, known issues with the AMH assay 
technology, beyond the control of this study, may indicate that having another 
reliable test of ovarian reserve, such as AFC, would have been ideal to provide 
additional validation of my findings but this was never a realistic option for the 
cancer patient group or a multicentre study such as this.  
Finally, this study aims to follow patients up for at least five years, which is 
beyond the standard duration of an MD degree. I have, therefore, not yet been 
able to complete the analysis to correlate serum AMH concentrations pre- and 
post-chemotherapy with clinical end points of early menopause, infertility and 
live birth at 5 year follow-up. 
10.3 Limitations arising from using second generation AMH 
assay as a marker of ovarian reserve 
The company producing the AMH assay kits (Beckman Coulter) issued two field 
safety notices during the duration of this study. Initially, the methodology was 
changed from linear to cubic regression. Then, following a publication on the 
poor reproducibility of AMH results using the second generation assay 
(Rustamov et al., 2012), in June 2013, another field safety notice was issued 
 207 
 
informing users about possible interference of complement in serum samples, 
lowering the AMH results. This led to the decision to re-analyse all my study 
samples using the new assay method including a pre-mixing step to assure 
reliability and consistency of all the results presented in my thesis. The pilot 
study which I conducted on storage of blood samples for AMH assay and strict 
protocol on sample storage and transport provided the basis for reliable analysis 
of the results. Additionally, proper preparation and storage of 3-4 aliquots of 
each collected sample, allowed me to performed unbiased analyses of two 
different methods of assaying (with and without the pre-dilution step). Statistical 
analysis, performed by Dr Nick Parsons, showed a consistent difference 
between old and new data, which would support the view that my research 
samples were handled appropriately Appendix 6. Since then the new method 
has been shown to give consistent AMH concentrations under different storage 
conditions (Han et al., 2014).  
There is still a lack of international standards for AMH assay measurements, 
only a limited number of laboratories offer AMH testing and, finally, different 
methods of blood sample handling and storage may have impacted on all 
previously reported results (Nelson & La Marca, 2011), especially, if the 
samples were being sent from distant centres (Fleming et al., 2013a). This 
situation has exacerbated the amount of conflicting data being published 
regarding AMH.  
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The newest, first automated platforms for AMH measurement offer hope for a 
more robust establishment of this useful test of ovarian reserve (Gassner & 
Jung, 2014). Such a development would allow availability of this test to be 
extended beyond the infertile population. Offering it more routinely to cancer 
patients could help with pre-treatment counselling, fertility preservation 
discussion and in making decisions about adjuvant hormonal therapy in older 
reproductive age women with breast cancer (Henry et al., 2014; Lawrenz et al., 
2012). 
10.4 Recommendations for future research 
This study has shown that serum AMH measurement recovers in a minority of 
patients within one year of initiation of chemotherapy. This study will continue 
with a view to identifying clinical outcomes in patients. However, there remain 
several areas of study where further information is needed.   
1. The reliability of ovarian reserve tests in predicting early menopause, chances
of pregnancy and live birth following cancer therapy needs to be determined in 
a large cohort longitudinal study with follow-up at 5 -10 years. 
2. The best timing for ovarian reserve testing (AMH measurement, AFC)
following chemotherapy in order to provide reliable clinically relevant 
information. This would entail following patients to an end point such as 
menopause or chemotherapy-induced infertility. 
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3. Further study is needed to provide a biological explanation for the lowered 
serum levels of AMH prior to chemotherapy in cancer patients. 
5. The stability of AMH assay measurements following storage of samples in 
different conditions and the potential benefits of using an ultrasensitive AMH 
assay in the cancer population require further investigation. 
6. The desires of cancer patients for greater knowledge of the impacts of 
chemotherapy upon their fertility and means to avoid infertility where 
appropriate should be analysed and responded to by both oncologists and 
fertility specialists. 
7. The place of AMH testing in the general population, for example, as means 
of educating young women regarding declining fertility, diagnosing premature 
ovarian decline, predicting menopause and advising regarding family planning 
remain to be explored.  
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Abbreviation 
ABVD- doxorubicin, bleomycin, vinblastine and darcarbacine 
AC- cyclophosphamide, doxorubicin 
AFC- antral follicle count 
AMH- anti-Müllerian Hormone 
BEACOPP- bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, 
procarbazine and prednisolone 
BMI-body mass index 
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BRCA mutation- mutation of gene BRCA1 or BRCA2 
Ca- cancer 
ChlVPP-chlorambucil, vinblastine, procarbazine and prednisolone 
CI- Chief Investigator 
CMF- cyclophosphamide, methotrexate and fluorouracil 
DNA- deoxyribonucleic acid 
EC-epirubicin and cyclophosphamide 
ELISA- The enzyme-linked immunosorbent assay 
E2-Estradiol 
FAC- 5-fluorouracil, doxorubicin, cyclophosphamide 
FEC- 5-fluorouracil, epirubicin and cyclophosphamide 
FSH-F Follicle stimulating hormone 
GnRH-Gonadotropin-releasing hormone 
GnRHa- GnRH agonist 
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HCG-human chorionic gonadotropin 
HRT-hormone replacement therapy 
IVF- In vitro fertilisation 
LH- Luteinizing hormone 
MALT lymphoma- form of lymphoma involving the mucosa-associated lymphoid 
tissue 
MFS/MF- Midland Fertility Services/Midland Fertility from end of 2014 
MIS-Müllerian inhibiting substance 
NIHR- The National Institute for Health Research 
ORT- ovarian reserve test 
PCOS- Polycystic ovary syndrome 
PI-Principle Investigator 
POI-premature ovarian failure 
REC-research ethics committee 
R&D- Research and Development 
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TGF-transforming growth factor 
TMB- tetramethylbenzidine 
UKCRN-UK Clinical Research Network 
USS –ultrasound 
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Appendices 
Appendix 1 Proforma- data extraction- literature review 
Proforma for study inclusion and data extraction 
Date Reviewer 
Paper number  1st author  Language 
Selection criteria 
Population: reproductive age women (adult) with cancer who received 
chemotherapy  
YES    NO 
Ref standard ovarian reserve test including AMH 
Select this diagnostic test study  YES  NO 
If no reject ad specify reason 
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…………………………………………………………………………………………
…………………………………………………………………………………………
…………………………………………………………………………………………
………… 
Data retrieval 
Population: 
N= 
Mean age 
Study design……………………………………………..Cohort/Cross-
sectional/Case control/other 
Data collection…….Prospective/Retrospective/Can’t tell/Other 
Patient enrolment…………Consectutive/Arbitary/Can’t tell/Other 
Blind comparison with ref standard  Yes/No/Can’t tell 
Differential use of ref standard…………………. Yes/No/Can’t tell 
Inclusion criteria clearly stated  Yes/No/Can’t tell 
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    1 
    2 
    3 
    4 
    5 
Exclusion…………………………………………………… YES/NO/Can’t  tell 
Sample population:  infertility  menstrual disorder  regular menses 
Type of cancer: 
Stage of cancer        YES/NO/Can’t tell  what stage: 
A prior calculation of sample size  YES/NO/Can’t tell 
Intervention 
Type of intervention  CT   RT   CTplus RT 
Regimen described         YES/NO/Can’t tell 
    Criterion: 
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Dosage given  YES/NO/Can’t tell 
Duration of therapy  YES/NO/Can’t tell 
Relapse………………………. YES/NO/Can’t tell 
Follow-up 
Duration of follow up 
Loss to follow up: 
    Cancer group N= 
    Control group N= 
Recruitment 
Original population 
Pre-enrolment exclusion 
Post enrolment exclusion 
Analysed data 
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Ovarian reserve test characteristics 
Test performed: 
…………………………………………………………………………………………
………………………………………………… 
What was measured at baseline? 
………………………………………………………………………………………. 
Reference  standard 
………………………………………………………………………………
……………………………… 
Type of AMH assay used (1st, 2nd generation/other) 
Time interval between first and second measurments 
……………………………………………………… 
Time interval between second and third measurments 
……………………………………………………… 
Time between the last dose of chemotherapy and ORT 
…………………………………………………… 
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Blinding of the test results 
Results: 
-comparison of mean/median
-ROC
-LR
Sensitivity/Specificity 
-NPV
-PPV
Others: 
Outcome measures 
Changes in hormone levels 
Amenorrhea 
Pregnancy 
Live birth 
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Recurrence of menses 
Early menopause 
Other…………… 
Completeness of follow up ……% 
Bias: 
selection bias – if same selection criteria have been used for all participants 
 loss to follow-up –if it differs between exposed and not exposed group 
information bias –if same quality and extent of information is available from 
exposed and not exposed groups  
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Appendix 2 Study protocol 
Full title: Effects of chemotherapy upon fertility amongst women of reproductive 
age, using AMH as a marker of ovarian reserve 
Short title: Measuring effects of cancer therapy upon female fertility 
Version 5, 29th of September 2010 
Title 
Effects of chemotherapy upon fertility amongst women of reproductive age, 
using AMH as a marker of ovarian reserve. 
Introduction 
Reproductive function in women after cancer treatment is increasing in 
importance because improvements in the survival rates mean that many more 
women live longer after cancer (Sonmezer and Oktay, 2004; Wallace et al., 
2005). Some of the newer, more effective therapies are also more aggressive 
and impact substantially upon fertility. In parallel, new methods of fertility 
preservation have been developed, such as oocyte and embryo 
cryopreservation. Women may wish to access these, and to understand the 
impact of their treatment upon their future chances of fertility. For many women, 
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fertility, or the prospect of it, is a major factor influencing self-esteem, personal 
identity and wellbeing. 
 
Chemotherapy frequently leads to subfertility, principally through direct effects 
that reduce the number of oocytes remaining in the ovary. Oocytes are laid 
down before birth and then enclosed into small follicles that persist into adult 
life. This supply of follicles, which is finite and pre-determined at birth, is called 
the ‘ovarian reserve’. The follicles are gradually used up over the woman’s 
reproductive life. Once used (growth towards ‘ovulation’) or damaged, they are 
irreplaceable. Total or near complete loss of oocytes results in menopause and 
sterility, while partial loss has a correspondingly lesser impact. 
The exact, long-term effect of the different types of chemotherapeutic agent and 
regimens upon ovarian reserve amongst women of reproductive age is still 
unknown. The degree of chemotherapy-induced ovarian follicle loss depends 
on the type of chemotherapy, its dosage, duration and the age of patients, ie 
how large their ovarian reserve is before treatment begins (Whitehead et al., 
1983; Meirow and Nugent, 2001, Lower et al., 1999). An accurate assessment 
of remaining ovarian function and therefore fertility potential after chemotherapy 
is not straightforward. Women who regain spontaneous menstrual cycles 
following chemotherapy may yet have evidence of occult ovarian dysfunction 
and be at risk of subsequent premature menopause (Bath et al., 2003; Larsen 
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et al., 2003). These effects may be particularly dependent upon the 
chemotherapy regimens. 
Counselling prior to chemotherapy should include discussion regarding family 
planning, potential for and implications of premature menopause and options of 
fertility preservation treatments, all of which should be considered as an 
important, integral part of care for young women with cancer. Yet, it is clear that 
many women do not have the opportunity for detailed assessment of their 
fertility potential or to avail themselves of cryopreservation measures, since 
there is often little time between diagnosis and the initiation of treatment. 
Additionally, in this tumultuous period, they may be unable to assimilate the 
complex issues that may result from fertility-related interventions. Therefore, an 
accurate and rapid method of testing ovarian reserve would be extremely useful 
to both clinicians and to women to inform subsequent fertility management in 
such situations. 
Recent studies have shown that anti-mullerian hormone (AMH) is a valuable 
marker of ovarian reserve. It is produced by granulosa cells of the growing 
follicles (Baarends et al., 1995; Durlinger et al., 2002b; Weenenet al., 2004) with 
expression initiated in the smallest growing primary follicles and only declining 
in the early antral stages or as follicles become atretic. AMH concentration thus 
is independent of the menstrual cycle (Cook et al., 2000) (cycle dependence 
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was a problem with all previous markers) and accurate even amongst women 
with irregular menstrual cycles. It is promising as a useful routine marker for 
potential reproductive capacity in women of childbearing age pre- and post- 
chemotherapy (Bath et al., 2003), however its application to this situation has 
not been fully assessed in a prospective study. 
We therefore aim to undertake a prospective study to evaluate the adverse 
effects upon fertility of some of the chemotherapeutic regimens used for cancers 
affecting young women, and the accuracy of serum AMH measurement in 
predicting women’s potential reproductive capacity following chemotherapy 
treatments. The results of this study would be crucial in informing decision-
makers and various stakeholders regarding fertility treatment prognosis, and in 
informing oncologists’ and women’s choices about chemotherapeutic options. 
Objectives 
The objectives of this prospective study are (i) to assess the effect of different 
types, dosage, and duration of chemotherapy and/or radiotherapy regimens on 
ovarian reserve using AMH as a marker, (ii) to assess the accuracy of AMH in 
predicting future reproductive capacity, and (iii) to achieve a reliable marker of 
ovarian function for women undergoing chemotherapy, which would not be 
menstrual cycle dependent. 
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Methods 
We plan to recruit between 50-100 reproductive age women newly diagnosed 
with cancers, prior to chemotherapy/radiotherapy within the West Midlands 
Cancer Network. A prospective cohort study design will allow us to assess the 
effect of exposure to chemotherapy agents on ovarian function over time. 
Serum AMH levels will be measured in a group of patients undergoing treatment 
with potentially gonadotoxic drugs before commencing chemotherapy and with 
a follow up at 6, 9 months and 1 year and will be compared with an age-matched 
control group cohort without known fertility problems. 
A 5-year follow-up questionnaire including a detailed history of number of 
pregnancies and live births is planned to assess the accuracy of AMH 
measurement in predicting longer-term fertility. 
Women aged 18-43 with newly diagnosed cancer, prior to 
chemotherapy/radiotherapy would be eligible. Women will be excluded if they 
have a history of previous exposure to gonadotoxic agents and/or radiotherapy; 
been diagnosed with end stage cancer having a very poor prognosis (less than 
10% chances of 1 year survival); or significant ovarian pathology. Usage of 
hormonal contraception methods will not be an exclusion criterion.  
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An age-matched control group will be recruited to compare the changes in AMH 
in women receiving no cancer treatment. 
AMH in blood samples will be measured using a newly developed AMH 
Immunoassay. This assay has been established in a research setting at the PI’s 
clinic by Al-Qahtani A (Al-Qahtani, 2005b). Patients, clinicians and laboratory 
personnel would be blinded to either patient clinical progress or the AMH 
concentration, which will not be used to manage the patient. 
Recruitment and data collection: 
Cancer patients: 
Female patients meeting our criteria who are about to proceed with 
chemotherapy will be identified through the direct healthcare team - oncology 
teams within PAN Birmingham Cancer Network, Wolverhampton and Coventry 
Hospitals and will be recruited consecutively where possible. 
An information leaflet describing the study and its objectives will be circulated to 
all prospective patients (inviting them to participate) by oncology teams. 
Having received the leaflet, any patient considering joining the study will be 
informed by an oncology team member about the research program and the 
blood tests involved. The researchers will provide further details direct to 
patients, if necessary. 
273 
Blood samples will be obtained in the oncology clinic together with a medical 
questionnaire including obstetric and gynaecological history (e.g. menstrual 
history) and consent form. 
Additional information will be provided to the researchers by oncology teams 
from the medical records (regarding the type of cancer and chemotherapy 
regimen). 
All forms together with the blood sample will be sent to the MFS laboratory to 
be tested. 
Healthy volunteers: 
Healthy, reproductive age volunteers (aged 18-43) will be recruited by two 
methods: advertisement in local newspapers, locally displayed posters and local 
GP surgeries, near to MFS. These volunteers will be invited to attend MFS for 
procedures associated with the study. 
Notices displayed at hospitals participating in the study (specifically UHCW), 
aimed at recruiting female staff to participate as volunteer members of the 
control group. These volunteers will be able to take part in the study from their 
workplace, subject to local PI agreement.  
Volunteers will be given a telephone number and an email address to contact 
the study coordinator (Dr Karolina Palinska-Rudzka) and local PI/research 
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nurse. More information about the study and the risks involved will be given 
verbally and/or via email or post.  The information sheet and consent form will 
be made available to the prospective volunteer.  
Volunteers will have time to decide if they want to participate (up to 12 months- 
see study time table).  
In the case of a positive reply, a suitable date and time will be arranged at the 
most appropriate location for the volunteer. During the appointment, written 
consent will be sought, and if consent is forthcoming, a blood sample will be 
taken and the medical questionnaire will be completed.  
The volunteer will be given a copy of the information sheet and consent form to 
keep. This provides the contact details of the researchers and the opportunity 
for follow up in the event of any concerns.   
Both groups: 
Identifiable data (name, DOB, address, contact telephone number) will be 
recorded on a separate (paper based) database and a unique research 
reference number applied. Identifiable data will be stored in lockable filling 
system in medical record area at Midlands Fertility Services with limited access 
to documentation by researchers only. At the time of processing a serum 
sample unidentifiable data will be saved on excel file to provide a point of central 
references for research. A label with the same unique reference number will be 
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applied on each blood sample on its arrival at the Laboratory.The computer 
database will only contain the unique research reference number without any 
personal details. Any information stored electronically will be encrypted. 
Data analysis 
Anonymised clinical data will be stored in a Warwick University database and 
statistical support from statistician at Warwick University is available. 
In consultation with our statistical colleagues, we will use the appropriate 
statistical tools to perform our data analysis. Changes in hormone 
concentrations with time will be analysed by analysis of variance for repeated 
measures; to investigate at what time points significant treatment effects are 
evident. The impact of the chemotherapy will be measured by testing the 
deviation of the cohort from the age-matched control group. 
All statistical analysis will be carried out using SPSS or similar software. 
Project management 
This project will be undertaken by Dr Karolina Palinska-Rudzka, an MD 
candidate at the University of Warwick, under the academic supervision of Prof 
Geraldine Hartshorne. Progress of the study and its compliance with protocol 
will be assessed on a regular basis during meetings with the academic 
supervisor. 
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The University of Warwick will act as sponsor of this study. 
Expert opinion on clinical implications and understanding of ovarian reserve test 
will be provided by Dr Gill Lockwood- Fertility Specialist. 
The funding for the project has been secured from Midland Fertility Services. 
Cancer patients: 
The oncology teams agreeing to take part in our project will be offered an initial 
1-hour training session in obtaining research consents including presentation 
on effect of chemotherapy on ovarian reserve and AMH marker. All the consent 
forms, medical questionnaire, information leaflets, pre-paid envelopes, blood 
bottles will be distributed by the Study Coordinator on a regular basis to all 
oncology clinics involved in the project. 
A member of the NHS healthcare team will make the initial approach to potential 
participants. During the treatment planning appointment in oncology clinics all 
women aged 18-43 will be given verbal information and/or leaflets on ovarian 
reserve tests and details of our project. 
Patients will have time to decide if they want to participate until their next 
appointment, when a written consent will be requested. 
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Initially, all information will be given to patients by the oncology teams, but 
patients may also seek further information from the researchers by telephone 
or email. 
Whole blood samples will be obtained by adequately trained oncology teams 
(handled according to standard hospital practice when sending samples for 
analysis off site) and send via post to be processed at MFS within 24 hours. 
Detailed instruction on blood samples transport and equipment required for 
packing will be provided according to UK Transport Legislation 602 and/or 
605/UN Packaging Instruction P650.  Accompanying forms will be send together 
with blood samples in previously pre-paid (first class) envelope. 
Whole blood in serum tubes, received at MFS will be separated on the day of 
delivery. Serum samples will be rendered acellular by centrifugation and 
removal of supernatant. The resulting serum samples will be stored frozen at 
MFS. The cellular fraction will be disposed of immediately the serum has been 
removed. 
On arrival to Midlands Fertility Laboratory unique reference number will be 
applied and sample process according to MFS protocol L077 AMH. 
Volunteers: 
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Once volunteers have been recruited to the study, after the first visit, 
appointments for follow up blood samples will be given in advance or sent via 
email/txt or letter, according to the volunteer’s preference.   
Information about publication arrangements are included in the participant 
information sheet. 
Volunteers, in contrast to cancer patients, will be sent a letter with their own 
AMH results and its interpretation. On request, verbal explanation of the results 
and its implications will be given by fertility specialist appointed locally and/or by 
Dr Karolina Palinska-Rudzka and Dr Gillian Lockwood (contact details will be 
provided with result letter).A thank you letter with the full study results will be 
sent to participants (if they wish to receive it). 
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Appendix 3 Patient/volunteers information leaflets and consent 
Version 4, 29th September 2010 
Study number: 09/H1211/87 
VOLUNTEER INFORMATION SHEET 
Measuring effects of cancer therapy upon female fertility 
Dear Volunteer, 
You are being invited to take part in a research study. 
Before you decide, it is important for you to understand why the research is 
being done and what it will involve. Please take time to read the following 
information carefully and discuss it with others if you wish. Ask us if there is 
anything that is not clear or if you would like more information. Take time to 
decide whether you wish to take part. If you do choose to participate in the 
research, you remain free to withdraw your consent at any time before your 
material has been used in the research. Such withdrawal of consent will have 
no effect on any aspect of how you are treated by us. 
Thank you for reading this. 
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WHAT IS THE PURPOSE OF THE STUDY? 
We would like you to take part in our research to enable us to compare the 
results obtained for patients treated for cancer with those of a healthy 
population, the ‘control’ group. We are asking if you would be willing to be a 
member of the ‘control’ group for this study.   
Treatment of cancer, and some related conditions, produces many side effects. 
In particular, we are interested in the effects upon fertility in young women 
undergoing chemotherapy. For many women, the possible effects of cancer 
treatments upon their future chances of having children are a very important 
issue. Unfortunately, there is currently no easy way to assess ovarian function 
and predict future fertility. 
The exact, long-term effects of different types of cancer treatment upon the 
ovaries of women of reproductive age are still uncertain. A reliable and quick 
method of testing the ovaries would be extremely useful. Such a test would help 
women to know their fertility potential, and likely reproductive time-span, 
allowing them to plan for their future. It would also help doctors to choose the 
most appropriate therapies for their patients, by providing new information on 
the likely impact on fertility. 
Recent studies have shown that anti-mullerian hormone (AMH) is a valuable 
marker of ovarian reserve; however, it has not been used clinically for patients 
undergoing chemotherapy. Further information is essential before this can take 
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place. We therefore aim to conduct a prospective study to assess the effect of 
chemotherapy, used for cancers affecting young women, upon ovarian reserve, 
as measured using AMH. We shall also determine the accuracy of AMH 
measurement in blood samples, in predicting women’s potential reproductive 
capacity following chemotherapy treatments. In order for us to analyse the data 
properly, we need to be able to compare the results with those in a control group 
of women of similar ages, who do not have cancer and who are not known to 
have any particular problems with fertility.  
Why have I been chosen? 
We are aiming to recruit around 50-100 volunteer women of age 18-43. We 
would like to ask if you would be willing to donate blood samples taken 4 times 
during a year, to measure your AMH levels for comparison with the group of 
cancer patients.  
Do I have to take part? 
Participation is voluntary. 
What will happen to me if I take part? 
If you agree to participate, you are requested to provide four blood samples 
within a one-year period - the first at the start of your involvement in the study 
and the others approximately 6 months, 9 months and 1 year later. AMH will be 
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measured in the blood samples provided by you. You are also requested to fill 
in a medical questionnaire at the time of your blood tests and another similar 
one after about 5 years. The questionnaires will take around 5-10 minutes to 
complete and you are asked to return them at the time of the blood tests, or post 
them back in the prepaid envelope supplied.  The first questionnaire is attached 
herewith.   
If you wish to participate, we will take blood samples at a time convenient for 
you. Please call us or send an email and we will make the arrangements. All 
dates of the appointment will be given in advance and a reminder will be send 
to you via email, txt message or a letter, according to your preference.    
What do I have to do? 
Please take time to read the information and discuss any questions that you 
may have with a member of the research team (our contact details are provided 
in this information). If you wish to take part, please complete and sign three 
copies of the consent form.   
What are the possible benefits and risks of taking part? 
You will receive no direct benefit from participating in this study. In the future, 
we hope that this research may bring benefits to young women going through 
cancer treatment. There are no risks of this study over and above those of taking 
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the blood samples. There is a very small (less than 1 in 100) risk of skin infection 
following any blood test.  
Psychological discomfort is possible for the following reasons: you may feel 
uncomfortable with some questions in the medical questionnaire, which will 
include your past medical history, questions about your periods, fertility, and 
surrounding issues. None of those questions will be asked directly (no face- to- 
face interview). 
Please note, AMH is commonly measured in women commencing fertility 
treatment because it helps to predict response of the ovaries to stimulation 
medicines. For you, the AMH test will assess the ‘biological age’ of your ovaries 
and the four measurements together could perhaps show the natural decline of 
your ovarian function over time. However, please be aware that AMH 
measurements cannot predict pregnancies because many other factors are 
involved, as well as AMH.   
It is up to you whether you want to be told about the results of your tests.  If you 
wish to know your AMH result, please be aware that the occurrence of an 
abnormal result might cause you anxiety.  If you decide that you do want to 
know, we will provide you with the results and a full explanation.  If your results 
cause you particular anxiety, we can offer the possibility to discuss further with 
a fertility doctor.   
What happens when the research study stops? 
At the end of this study, any blood samples that have been used for research 
are normally disposed. However, if you agree, it is possible that they can be 
kept in case they could be useful for other research projects in future. We would 
like to keep them for this purpose; however, you are under to obligation to agree 
to this, regardless of whether you agree to participate in the present study. 
Please would you indicate on the consent form whether you agree for this to be 
done. Rest assured that a Research Ethics Committee would have approved 
any such future research in advance. 
What happens if I lose the capacity to consent during the project? 
In the unlikely event of your losing capacity to consent during the course of the 
project, we propose that any samples and data that had already been collected 
would continue to be used confidentially for the study, but no further samples or 
data would be taken from you. This could also include further research after the 
current project has ended.  You are asked to indicate your consent to this on 
the consent form. 
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What if something goes wrong? 
If you experience any concerns about the research, you are very welcome 
to contact the researchers in the first instance.  We do not envisage any 
problems arising during the course of this research. However, if an untoward 
event were to occur, please be assured that we will do everything we can 
to put matters right.  
Will my taking part in this study be kept confidential? 
Yes, your participation will be confidential. Any samples you provide and 
non-identifying information about your medical history will be stored 
in an anonymous form. Please note that such anonymised information may 
be stored on a computer database. Your personal details would only be 
accessible under strictly controlled conditions and then only to the 
researchers involved in the study. 
What will happen to the results of the research study? 
We understand that your AMH results could be of personal interest to you. It 
is important for you to know that AMH is a new marker of ovarian reserve, 
only recently been registered for diagnostic use and has mostly been 
validated in patients undergoing IVF treatment. Since you are not 
undergoing such treatment, and are a normal healthy volunteer, the 
results may not be particularly useful or relevant to you. However, we are 
happy to let you know the results if you are interested in them. 
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If you wish to know your results, please show this on your consent form. The 
letter with explanations of the results will be sent to the address given by you. If 
you have any queries arising from the results, please contact us and we will 
make arrangements to discuss the results further with you.   
The collected results from all participants will be published in a medical journal 
and presented to learned societies at conferences, but you would not be 
identified in any publication. If you would like a copy of the final publication, 
please write to Professor Hartshorne at the address below. Please note, it 
usually takes several years for results to be fully analysed and published.  
Who is organising and funding the research? 
This study is receiving funding from the Midlands Fertility Services, Third Floor, 
Centre House, Aldridge, WS9 8LT, which employs Dr Karolina Palinska-
Rudzka, and provides the facilities and funds needed to run the specialised 
AMH assay. Through this research, Dr Palinska Rudzka is studying for a Doctor 
of Medicine degree at the University of Warwick, under the academic 
supervision of Professor Hartshorne. Staff involved in NHS treatment, who 
agree to provide information about the study or take blood samples, are not 
remunerated for their involvement. No inducement or financial reward will be 
given to any of the staff involved in this study. If you would like to take part, 
please complete all three copies of the consent form. You will be given the 
information sheet and a signed consent form to keep. If you have any questions 
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or queries, please ask one of the staff, or contact (provided). Thank you for your 
consideration. 
PATIENT/VOLUNTEER CONSENT FORM, Study Number:  09/H1211/87 
Measuring effects of cancer therapy upon female fertility (Name of 
Researchers: Dr Karolina Palinska-Rudzka, Prof Geraldine Hartshorne) 
Please, write yes or no and initial each box. 
1. I confirm that I have read and understand the Information
Sheet dated 29th September 2010 (version 4) for the above study and 
have had the opportunity to ask questions. 
2. I understand that my participation is voluntary and that I am free to withdraw
at any time until any samples are used, without giving any reason. My care or
legal rights will not be affected.
3. I agree to have blood samples taken for this research and to be contacted to
make arrangements for this.
I am willing to fill in a medical questionnaire now and I am happyto be contacted 
again in 5 year time. 
4. I understand that responsible individuals involved in the research may look at
my medical questionnaire. I give permission for them to use anonymised
medical history data from my medical questionnaire for analysis of this study.
5. At the end of the study, I agree that my anonymised blood sample can be
kept.
6. In the event of my losing the capacity to consent during research, I agreethat
any samples or data already collected will be retained for use in the study and
in any future research.
7. I wish to receive a letter with explanation about my AMH results at the address
given by me overleaf
Name of Person taking consent Date Signature 
Researcher    Date Signature 
Appendix 4 Medical questionnaire 
Version 2, 23rd of September 2009 
Study number: 09/H1211/87 
MEDICAL QUESTIONNAIRE 
MEASURING EFFECTS OF CANCER THERAPY UPON FEMALE 
FERTILITY 
This is your first medical questionnaire for purpose of this study. It should 
take no longer than 5 to 10 minutes to fill it in. The questions are mainly 
about your age and past medical history including previous pregnancies. 
All this information is important for our study in order to provide the 
most accurate results. Please do your best to provide full information. If 
you are unsure, you are welcome to contact us to ask, or to provide any 
additional information that you feel is relevant. You will be asked in the 
future to fill in a similar questionnaire called the follow-up medical 
questionnaire. A prepaid addressed envelope is enclosed for your 
convenience. Thank you for taking the time to do this.
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Please fill in the gaps and/or circle your answers 
Which day of your menstrual cycle are you today?(day one of menstrual 
cycle=1first day of bleeding)   
for example last bleeding started around 10 days ago 
...................................................................................................................... 
Are your periods normally regular/irregular? 
Normal length of your menstrual cycles (for example every 28 days) 
every................days 
How old were you when you had your first period.............. years 
Have your periods recently become more irregular or have they stopped 
for a long time?  
No/Yes    If yes, please provide details? 
...................................................................................................................... 
Have you ever been investigated or treated for problems with getting 
pregnant? 
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No/Yes  If yes, please provide details 
Number of pregnancies......... 
Number of births.......... 
Age of children…………………………........................................................... 
Do you have any known gynaecological problems (e.g polycystic ovaries, 
endometriosis)?  
No/Yes  If yes, please provide details or give name of your condition 
...................................................................................................................... 
Do you have any other significant medical problems? 
No/Yes  If yes, please provide details or give name of your condition 
...................................................................................................................... 
Do you have a family history of early menopause (menopause starting 
before age of 45)? 
No/Yes    If yes please give details (e.g my mum/sister/cousin had menopause 
at age of 40) 
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...................................................................................................................... 
Are you on any medications (not including chemotherapy)? 
No/Yes  If yes, please write the name of any medications that you take or 
state what it is for (e.g I am taking some tablets for my blood pressure) 
...................................................................................................................... 
Are you currently taking the contraceptive pill or any other hormonal 
treatment? 
No/Yes    If yes please give details 
.............................................................................................................................. 
How would you describe your desire to have children? 
None/Neutral/Maybe/Strong 
Others/comments:........................................................................................ 
Your height   ……………… metres/feet 
Your weight  ………………. Kg/stone 
Are you a smoker/ non-smoker/ ex-smoker/ passive smoker? 
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Any other comments you may wish to make. 
Version 3, 8 October 2010 
Study number: 09/H1211/87 
10.4.1 MEDICAL QUESTIONNAIRE 
MEASURING EFFECTS OF CANCER THERAPY UPON FEMALE 
FERTILITY 
This is your follow-up medical questionnaire. It should take no longer than 
5 to 10 minutes to fill it in. 
The questions are mainly about your age and past medical history 
including previous pregnancies. 
All this information is important for our study in order to provide the most 
accurate results. Please do your best to provide full information. If you are 
unsure, you are welcome to contact us to ask, or to provide any additional 
information that you feel is relevant (see contact details on your consent 
form). 
Thank you for taking the time to do this. 
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A prepaid addressed envelope is enclosed for your convenience. 
Please fill in the gaps and/or circle your answers 
Which day of your menstrual cycle are you today?(day one of menstrual 
cycle=1first day of bleeding) for example last bleeding started 
around 10 days ago 
............................................................................................................................. 
............................................................................................................................. 
Are your periods regular/irregular? 
Have your periods recently become more irregular or have they stopped 
for a long time?  No/Yes    If yes, please provide details? 
............................................................................................................................. 
............................................................................................................................. 
Do you have any significant medical 
problems? 
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No/Yes If yes, please provide details or give name of your 
condition
Are you on any medications? 
No/
Yes 
 If yes, please write the name of any medications that you 
 
.................................................................................................................... 
Are you currently taking the contraceptive pill or any other 
hormonal treatment? 
No/Yes    If yes please give details 
.................................................................................................................... 
How would you describe your desire to have children? 
None/Neutral/Maybe/Strong 
Others/comments:..................................................................................... 
 Your weight  ………………. Kg/stone 
Are you a smoker/non-smoker/ex-smoker/passive smoker? 
Any other comments you may wish to make. 
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Appendix 5 Linear versus cubic regression model (second 
generation AMH assay). 
y = 0.8745x + 0.3805
R² = 0.9991
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Appendix 6 Comparison of two methods of second generation assay AMH 
assay. 
Bland-Altman plot suggests small but consistent difference 
between old and new data. Supports view that fixed additive 
corrective adjustment is sufficient. 
